The regulation of the serum response network by the RGS RHOGEFS is critical for YAP1 activity and cell fate decisions by Lane, Brandon S.
 
 
 
 
THE REGULATION OF THE SERUM RESPONSE NETWORK BY THE RGS-
RHOGEFS IS CRITICAL FOR YAP1 ACTIVITY AND CELL FATE DECISIONS 
 
 
 
 
 
 
 
 
 
 
 
 
Brandon S. Lane 
 
 
 
 
 
 
 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School 
in partial fulfillment of the requirements 
for the degree 
Doctor of Philosophy 
in the Department of Biochemistry and Molecular Biology, 
Indiana University 
July 2017
 ii 
 
 
Accepted by the Graduate Faculty, of Indiana University, in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
 
                                                         
          Clark D. Wells, Ph.D., Chair 
 
Doctoral Committee 
 
                                                         
          Theresa Guise, M.D. 
 
 
 
                                                         
          Lindsey D. Mayo, Ph.D. 
 
November 17, 2016 
 
                                                         
          Lawrence Quilliam, Ph.D. 
 
 
 
 
 
 
 
 
 
 iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 
Brandon S. Lane 
 
 
 iv 
DEDICATION 
I dedicate this dissertation to my family, especially my parents, Susan R. Lane 
and Randal S. Lane, as they valued my education and pushed me to strive for perfection 
during my academic career. I would also like to dedicate this dissertation to my close 
friends, Tim Rayne, Kate Ruddell, Michael Vinci, Mikal Coppage, Kristen Holcomb, 
Brittany Cardinal, Lauren Bringman, Nick Renier and Jessica Vogel. None of this would 
have been possible without their support, adventurous spirits, companionship, and the 
dedication they showed in their own line of work. They are all truly inspirational in their 
own right and I thank them for being supportive through the good, the bad and the ugly. 
However to be frank, they also contributed to prolonging my stay, by my estimation, for 
an extra year or two. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
ACKNOWLEDGMENTS 
I would first and foremost like to thank my mentor Dr. Clark D. Wells. He 
allowed me to pursue my own independent project, and pushed me to ask the necessary 
and tough questions to see it through. He further instilled in me a scientific acumen that 
was second to none. His dedication to my success over the past 6 years was paramount to 
my success in this program and to all my future endeavors. For that I am forever grateful. 
I would also like to thank my committee members Dr. Lindsey Mayo, Dr. Theresa 
Guise, and Dr. Lawrence Quilliam, as they all provided valuable feedback both 
scientifically and professionally, and unwavering support throughout this entire process. I 
would especially like to thank Dr. Lawrence Quilliam, for being our lab neighbor, and 
always engaging in strong scientific discussions both experimentally and conceptually. 
His scientific knowledge was extremely valuable to my success as I often consulted with 
him about new ideas and he always provided insightful feedback. 
 When I first began in the lab of Dr. Clark Wells, Dr. Lauren Bringman also began 
at the same time. Through our struggles becoming accustomed to the rigors of graduate 
school, we developed a life-long bond of friendship. She has seen me at my highs and 
lows throughout this process, as I have with her. It is that shared struggle that pushed me 
to finish this project, and for that I thank her. 
 I would also like to thank my close friends Dr. Tom Baird, Dr. Sara Young, and 
Dr. Aarti Chawla. They also shared in my struggles and achievements, and were 
invaluable sources to bounce scientific ideas off of over occasional beers. To all of you I 
would like to say one final THANK YOU! 
 vi 
 And finally I would like to say thank you to the entire office staff of the 
Department of Biochemistry and Molecular Biology. They were always helpful in 
circumventing our IT problems, scheduling classes, and ordering reagents. Without them 
much of the nuisances of graduate school would not be possible. Thank you all for your 
time and patience. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
Brandon S. Lane 
 
THE REGULATION OF THE SERUM RESPONSE NETWORK BY THE RGS-
RHOGEFS IS CRITICAL FOR YAP1 ACTIVITY AND CELL FATE DECISIONS 
 
 The growth of mammary epithelial cells is regulated by interactions with 
neighboring cells and by exposure to soluble factors including hormones and growth 
factors. These cues are integrated within the cell, perpetuating changes onto the 
organization of the actin cytoskeleton, resulting in altered transcriptional programs. Rho 
family GTPases regulates actin dynamics that facilitate transcriptional reprogramming. In 
particular, RhoA induces the formation of actin stress fibers to promote the 
transcriptional co-activator YAP1 to translocate from the cytosol into the nucleus. There, 
it co-activates TEAD family transcription factors to drive the expression of pro-growth 
and survival genes. Rho family members are activated by guanine exchange factors 
(GEF) and inhibited by GTPase activating proteins (GAP). Here, we determined the 
relative effects of expression of 67 RhoGEFs and RhoGAPs on the activation of TEAD. 
This revealed that regulator of G-protein signaling (RGS) domain containing ArhGEF1, 
ArhGEF11 and ArhGEF12 all promoted YAP1 dependent activation of TEAD. These 
RhoGEFs mediate signaling from heptahelical receptors that are stimulated by lipid 
mitogens to activate the heterotrimeric G-proteins Gα12 and Gα13. Consistently, loss of 
expression of ArhGEF12 and to a lesser degree ArhGEF11 prevented actin stress fiber 
accumulation and activation of YAP1 mediated signaling by serum. Conversely, several 
complementary experiments revealed that ArhGEF1 dominantly limits Gα13 selective 
activation of YAP1 and the mitogen activated protein kinase (MAPK) cascades. 
Furthermore excessive Gα13 activity results in both high levels of filamentous actin and  
 viii 
arrest cells in the G1/0 phase of the cell cycle. This is likely due to the systemic inhibition 
of cell cycle promoting signaling and a loss of protein translation. Further, YAP1 was 
found to be essential for the survival of ArhGEF1 silenced cells. Together, these studies 
define a circuit whereby the rgRhoGEFs regulate Gα 12/13-RhoA signaling flux to regulate 
cellular growth that is promoted by serum factors. 
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CHAPTER 1. INTRODUCTION 
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1.1 Organization of the Mammary Organ and the Origins of Breast Cancer 
The growth of living organisms is dictated by the availability of nutrients as well 
as interactions with the surrounding environment. The responses to these factors exists 
along a continuum from the macroscopic level, the world with which we live, down to 
the microscopic level, the world with which our cells are maintained in the human body. 
The human body maintains inherent growth control via mechanisms that are both 
biochemical or biophysical in nature (1). Malfunctions in the ability to sense alterations 
in biochemical cues or changes in tissue architecture, is a major contributor to the 
development of diseases such as cancer (1). The mammary gland is prime example of 
how biochemical and biophysical signals dictate tissue homeostasis. The structure of the 
mammary organ changes throughout the life cycle of a female and is mediated by 
remodeling events that are induced by temporal hormonal activity (2). These continued 
alterations in growth control mechanism make this organ highly susceptible to the 
development of hyperplastic growth. This makes studying normal and cancerous 
mammary cell lines an ideal model for studying signaling mechanisms that regulate 
cellular growth control.  
The mammary organ remains relatively naïve in structure and function during 
prepubescent growth, whereas it undergoes drastic remodeling events during puberty, 
pregnancy, lactation, and menopause (3). These events require the reorganization of the 
tissue, which is orchestrated by changes in cellular size, location and growth patterns (4). 
The mature mammary organ is composed of support tissues and glandular epithelium. 
The supporting material is comprised of adipose tissue, blood vessels, and underlying 
pectoral muscles. The glandular tissue secretes and transports milk to support the growth 
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of a mother’s offspring. The development of glandular tissue begins during puberty and 
becomes fully functional during lactation. The continued remodeling of the glandular 
tissue and its composition makes it susceptible to perturbations that may result in 
unwarranted hyperplasia (4). 
 Post pubescent but pre menopausal mammary glandular tissue contains a network 
of hollow tubes that facilitate the secretion and movement of milk during lactation. These 
tubes are organized into 10-20 lobules that are comprised of 10-100 alveoli structures (5). 
Each lobule has a hollow duct; termed the lactiferous duct that drains the secreted milk 
into the opening of the nipple. The ducts and lobules are surrounded by a layer of 
myoepithelial cells, which upon stimulation by the hormone oxytocin, contract. The 
consequent squeezing of the epithelial cell layer promotes milk flow through the lumens 
of the lobules and lactiferous ducts (6). The structural component of lactiferous ducts and 
lobule trees are the mammary cuboidal epithelial cells. Mammary cuboidal epithelial 
cells are asymmetrically organized into a baso-lateral domain and an apical domain. The 
baso-lateral domain facilitates attachment to the basement membrane and neighboring 
cells (2). The apical domain facilitates milk secretion consistent with it facing the hollow 
lumen of the ducts and lobules. The asymmetric organization of mammary epithelial cells 
is not only essential to maintain proper structure and function of both the ducts and 
lobules, it also fundamentally acts to prevent unwanted growth (2). Ductal epithelial cells 
are overwhelming the origin of breast cancers as perturbations in the organization of this 
cell type elicits pro-growth effects (Figure 1-1A). 
Hyperplasia’s that arise from the epithelial cells that line the lactiferous ductal 
structure can be either invasive or non-invasive. Non-invasive hyperplasia and its more 
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advanced form, diagnosed as ductal carcinoma in situ (DCIS) are considered pre-
cancerous due to the lack of cells that have infiltrated the surrounding supporting tissue 
(7). DCIS is characteristic of the mammary epithelial cells severing attachments with the 
basement membrane and actively proliferating into the hollow lumen of the lactiferous 
duct. Once the cells break through the underlying basement membrane, they are 
considered cancerous, as they invade into the surrounding supporting stroma. This 
phenotype is diagnosed as invasive ductal carcinoma (IDC) (7). These cells can then 
infiltrate supporting blood and lymph vessels to metastasize throughout the body (Figure 
1-2A).  Such spreading is the primary cause of patient mortality.  
Breast cancer is the second leading cause of cancer related deaths among women. 
According to the American Cancer Society. In the United States it is expected that 
roughly 300,000 new cases of breast cancer will be diagnosed in 2016. Of these cases, 
60,000 will be classified as pre-cancerous DCIS, while 240,000 will be classified as IDC. 
DCIS is considered the lowest malignant type of tumor (Stage I) with an expected 5-year 
relative survival rate of nearly 100%. As the disease progresses to Stages II-IV, it is 
based upon acquiring an IDC phenotype. The expected five year relative survival rate 
declines with each successive stage: 93%, 72%, and 22%, respectively. It is therefore 
essential to understand the mechanisms by which mammary epithelial cells transition into 
growth activating states of DCIS and then through increasing grades of IDC.  
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Figure 1-1: Structure of the Mammary Organ.  
A. The breast is composed of supporting and functional tissue. The supporting tissue is comprised 
of adipose tissue, stroma and a network of connective tissue. The lactiferous duct and lobules 
comprise the functional tissue that facilitates the secretion and transportation of milk. The subset 
(lower left) is a cross-sectional view of a lactiferous duct. The lactiferous duct is made up of 
cuboidal mammary epithelial cells and surrounded by supporting myoepithelial cells and 
underlying stroma. These cells give rise to the structure and secretory function of lactiferous duct. 
(Figure Adapted from J. Adler). 
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Figure 1-2: Progression of Invasive Ductal Carcinoma in Breast.  
Representation of a “normal” mammary duct and the supporting cells and stroma (above). Below 
is a cross-sectional reference that highlights the progression of cancer within the ductal system. In 
normal mammary ducts, epithelial cells are growth arrested through contact-dependent growth 
inhibition providing a barrier between the hollow lumen and surround stromal tissue. The 
development of ductal carcinoma in situ (DCIS) results in the loss of contact inhibition of growth 
and the proliferation of cells into the hollow lumen. Advancement of this precancerous state to a 
cancerous state involves the proliferating epithelial cells penetrating the basement membrane; this 
is termed invasive ductal carcinoma (IDC). (Figure Adapted from W.Ranahan). 
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1.2 Cell Cycle Regulation in Epithelial Cells is Dependent on Biochemical and 
Biophysical Stimuli  
 Normal mammalian epithelial cells can either be actively proliferating, held in a 
non-proliferative state that is readily induced to proliferate (quiescence), or terminally 
differentiated. Mammalian cells actively grow when nutrients and space to grow are 
plentiful, otherwise they arrest at the “restriction point (8).” Studies of a variety of cell 
types, highlight the lack of nutrients causes cells to enter a quiescent state, and the 
subsequent re-introduction to those nutrients, enhances DNA synthesis (9-12) and 
induces synchronized growth, as measured by thymidine incorporation, and cell division 
(10). If cells experience prolonged stress, such as extended periods without essential 
nutrients, they are unable to exit the restriction point through an unidirectional extension 
of quiescence known as senescence (13). Differentiated epithelial cells also, typically, do 
not exit the restriction point as long as interactions with the surrounding environment 
reinforce this state. Cancers cells, by circumventing these mechanisms for growth 
control, are able to exit a normal restriction point and progress through the cell cycle (8).  
The “cell cycle” describes the process whereby eukaryotic cells duplicate their 
genomes  and separate into two daughter cells (14). In eukaryotes, the cell cycle is a 
product of three temporal periods: interphase, mitosis, and cytokinesis. During early 
interphase the cell actively acquires nutrients and carries out protein synthesis to grow in 
size while concurrently facilitating normal functions. This also prepares it for duplication 
of its genome during late interphase. Interphase is comprised of three unidirectional 
stages that are monitored by checkpoints to ensure their integrity. The initial stage of 
interphase is called Gap 1 (G1). During G1 the cell acquires nutrients and produces the 
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protein machinery necessary for undertaking DNA replication (9-12). The second stage 
of interphase is Synthesis (S), during which the cell duplicates its entire genome. The 
final stage of interphase is Gap 2 (G2). During G2 the cell checks the integrity of the 
replicated genome and produces lipids and proteins that are necessary for mitosis. During 
mitosis the duplicated cellular genome condenses into sister chromatids, which following 
their separation into sister chromosomes, are transported to opposite ends of the dividing 
cell. Cell division commences during cytokinesis, which creates two daughter cells with 
replicate, semi-conserved genomes. The cell then either initiates another round of the cell 
cycle or it exits the cell cycle and enters dormancy, this is considered G0. In normal cells 
improper duplication of the genome or division of the cell is sensed by specific 
checkpoints that pause mitosis and initiate corrective measures (15, 16). If these measures 
cannot restore integrity, cell clearing is initiated through various forms of cell death. 
Cancer cells often acquire mutations that override integrity checkpoints to evade cell 
death and to facilitate cell growth (16). 
 Cell cycle activity is regulated by a variety of proteins that monitor the integrity 
of the duplicating genome (14). Principle amongst these are the cyclins whose expression 
and subsequent degradation oscillate with the stages of the cell cycle (Figure 1-3A) (17). 
In mammals 16 cyclins either control the progression through the cell cycle or have 
independent roles in regulating transcription, DNA repair, promoting differentiation or 
apoptosis. Cyclins contain a cyclin box domain that signals their destruction upon 
phosphorylation by members of the cyclin-dependent kinases (Cdk) family. Exit from G0 
requires at least one of the three D-type cyclins (18) to be stabilized in response to  the 
presence of nutrients (14). This allows D-type cyclins to associate with the cyclin-
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dependent kinases (Cdk) 4 or 6 to couple them to hyper-phosphorylate Retinoblastoma 
tumor suppressive protein (Rb) (19). This prevents Rb from interacting and inhibiting 
members of the E2F family of transcription factors. This further allows E2F proteins to 
activate genes involved in DNA synthesis and cell cycle progression, including E, and A-
type cyclins. The inhibition of Rb by cyclin D-Cdk4/6 protein complexes is essential for 
cells to by-pass multiple restriction points and thereby progress into S, G2, and M phase. 
E-type cyclins are required for G1 to S phase transition (20), where their transcription in 
response to  E2F activity  increases at mid G1 phase and is maintained through the middle 
of S phase (21). E2F activity also promotes the transcription of A-type cyclins (21), when 
associated with Cdk2 and mediates the entry of the cell into S-phase. During latter stages 
of S phase, A-type cyclins associate with Cdk1 to facilitate S phase completion (22, 23) 
and the transition into mitosis. Finally, B-type cyclins associate with Cdk1 and are 
required for G2 exit (Figure 1-3B) (24). The regulation of these cyclin complexes by both 
biochemical and biophysical stimuli thereby controls the growth of normal mammary 
epithelial cells.  
 The activity of the cell cycle of mammary epithelial cells is highly impacted by 
the relative level of attachment of a cell to neighboring cells versus  the basement 
membrane. Many lines of evidence conclusively show that non-transformed cells 
experience growth inhibition when they contact other cells (25). This underlies the ability 
of mammary epithelial cells to form the highly organized structures in a gland. Contact-
dependent growth inhibition occurs when cells fill a space and therefore physically 
associate with other cells at all lateral points (26). Early studies on murine fibroblasts in 
culture identified this  as the “saturation point”; where DNA synthesis and cell division 
 10 
are drastically reduced (27). These cells have exited the cell cycle and remain in the G0 
phase. However, these cells can readily re-enter the cell cycle if their microenvironment 
changes in a way that unoccupied adjacent space becomes available, e.g. a confluent cell 
culture is subject to a “wound” (27). Subsequent studies have identified the molecular 
mechanism by which cell polarity proteins restrict cell growth in response to intercellular 
contact. 
The asymmetric organization of epithelial cells can fundamentally  repress cell 
cycle progression (28). Differentiated epithelial cells form a  lumen facing apical domain 
and baso-lateral domain that is attached to the basement membrane. The PAR and 
Crumbs polarity complexes localize to and establish the apical domain (29). The Scribble 
protein complex distributes to and establishes the baso-lateral domain (30). Within the 
baso-lateral domain, the Scribble complex recruits machineries that effect cell-cell and 
cell-extracellular matrix interactions, many of which directly regulate key components of 
the cell cycle (31). Several junctional complexes connect cells from the apical to basal 
axis. The  tight junction, which is composed of a belt of transmembrane strand proteins, 
is the most apical junction (32). The tight junction both acts as a fence to prevent 
diffusion between the apical and basal membranes as well as a permeability barrier 
between cells (32). The adherence junction, which lies below the tight junction, is mainly 
comprised of the cadherin-catenin protein complexes (33). The adherence junction 
provides the majority of the mechanical strength that keeps cells attached to each other 
(34). Both the tight junction and the adherence junction scaffold proteins on their 
cytosolic faces that bind the actin cytoskeleton. This produces isotension across the cell 
and tissue that is essential to maintain overall structural integrity. Furthermore the loss of 
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these junctions releases pro-growth transcription factors that are otherwise sequestered 
there. For instance, beta-catenin binds to E-Cadherin in the adherens junction. The 
breakdown of the adherens junction causes β-Catenin to release from E-Cadherin and 
enter the cytosol. If β-Catenin is not degraded, its accumulation results in its translocation 
into the nucleus where it trans-activates lymphoid enhancing factors (LEF-1-4) (35). This 
activates LEF-1 dependent transcription of many pro-growth genes including Cyclin D1 
which is a master regulator of cellular proliferation (36). Tight-junctions are mainly 
comprised of the transmembrane claudins, which form strands that encircle the cell and 
also contain other transmembrane proteins including occludins, junctional adhesion 
molecules and Nectins. These transmembrane proteins bind their counterparts on 
neighboring cells to form a seal  between cells that prevents paracellular diffusion (32). 
The zona occludin family of tight junction associated proteins, bind to the cytosolic 
domain of the claudins and to the actin cytoskeleton. The formation of tight junctions is 
well established to inhibit Cyclin D1, to prevent a G1-to-S phase cell cycle transition (37, 
38). This is only one of many known examples whereby intercellular interactions mediate 
extracellular to intracellular signaling cascades that control cell cycle progression. 
 Regulation of cell cycle progression by biophysical stimuli is likely secondary to 
biochemical stimuli. The cell needs large quantities of macronutrients to facilitate 
doubling in size. Not only does it have to duplicate its entire genome it also must 
duplicate a vast majority of cellular organelles and its lipid bilayer. This requires a spike 
in translation to facilitate protein synthesis that mediates many of these processes (11). In 
studies of cells at high density, growth restriction was released when the system was 
flooded with serum or amino acids (8). This suggests that nutrient availability is a 
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dominant regulator of cell cycle progression. In addition, potent mitogens in serum by 
activating intracellular kinase cascades promote Cyclin D1 transcription and other 
proteins that regulate progression through the cell cycle.  
 The loss of cell-cycle checkpoints that prevent the transition from G1 to S phase, 
often results in hyperplastic cell growth and eventually cancers. For instance, DNA 
translocations that activate the Cyclin D1 gene are responsible for the development of 
parathyroid adenomas (39) and B-cell lymphomas (40, 41). Furthermore amplification of 
the Cyclin D1 gene or increases in Cyclin D1 protein are found in subsets of breast (42), 
colorectal (43), and neuroblastomas (44). Identifying how biophysical and biochemical 
stimuli facilitate cell cycle regulation is essential to understanding how cancers induce 
hyperplastic growth. 
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Figure 1-3: Cyclin Activity During the Cell Cycle, Regulated by Epithelial Cell 
Differentiation.  
A. Relative levels of expression of the different families of cyclins throughout the various stages 
of the cell cycle. B. Schematic of the requirements of the different Cyclin and Cyclin Dependent 
Kinases for each stage of the cell cycle. Cyclin D1-CDK4/6 is required to initiate G0 to G1 phase 
transition as they phosphorylate and inhibit the negative regulator of the cell cycle 
Retinoblastoma (Rb). Cyclin E1-CDK complex is required for the transition from G1 to S phase. 
Cyclin A-CDK2 complex is required for S phase, and Cyclin A association with CDK1 in late 
stage S phase is required for G2 transition. PCNA is a processivity factor for polymerase. Cyclin 
B1-CDK1 complex is required for the transition from G2 to M and is positively regulated by its 
dephosphorylation by the Cdc25 phosphatase. 
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1.3 Serum Response Network and Its Role in Epithelial Cellular Growth and Cancer 
Breast cancer results from reprogramming that deregulates normal growth control 
mechanisms in differentiated growth arrested cells. Many biochemical stimuli that 
promote this transformation are transmitted through the blood or through extracellular 
fluid onto the target cells. These stimuli are often referred to as mitogens as they induce 
mitosis. Mitogens typically function by activating cell surface receptors to facilitate 
outward-inward cellular signaling that induces cell growth and proliferation (45). Lipid 
and protease mitogens in the serum fraction from blood activate G-protein coupled 
receptors. The most potent bioactive lipid mitogens are lysophosphatidic acid (LPA) and 
sphingosine-1-phosphate (S1P). Typically they are produced by platelets (46, 47) in 
response to wound healing, inflammatory responses, or by tumor-stromal interactions. 
LPA and SIP, stimulate epithelial cell growth by agonizing G-protein coupled receptors 
(GPCR) (43). In breast cancer, endothelial differentiation gene (EDG) receptors for LPA 
and S1P mediate progression and metastasis to bone (48-50). Overexpression of EDG 
receptors also induces hyperplasia in mammary murine glands (51).  
Mitogenic proteases including thrombin, tryptase and trypsin also act through 
GPCRs. Thrombin activates the protease-activated receptors (PAR) 1,3, and 4 by 
cleaving the N-terminus to expose a tethered ligand, which in-turn is free to bind and 
self-activate the second loop of the receptor. Stimulation of PAR1 promotes growth and 
invasion, and is often found in late stage breast cancers (52). PAR2 activity is stimulated 
by tryptase and trypsin to promote invasive capacity of breast cancer cells (53). Together 
bioactive lipids and cleaved peptides, explain many of the effects of serum in promoting 
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epithelial cell proliferation and the induction of hyperplasia in the mammary organ 
through their activation of GPCRs. 
GPCRs represent the largest family of cell-surface proteins and are the targets of 
an estimated 50-60% of currently used drugs (54). GPCRs function in a variety of 
signaling pathways that mediate development, differentiation, angiogenesis, cell 
proliferation and cell survival. GPCRs contain an N-terminal extracellular ligand binding 
domain, attached to 7 trans-membrane hydrophobic alpha-helices followed by a C-
terminal domain that binds to specific heterotrimeric GTPases (55, 56). GPCRs upon 
agonist dependent activation undergo internal conformational changes that result in their 
stimulation of nucleotide exchange on specific types of G-proteins. Heterotrimeric 
GTPases are comprised of a Gα, Gβ, and Gγ subunit. The  association of the Gα subunit 
with Guanine Triphosphate (GTP) causes its dissociation from the Gβ/Gγ subunits. The 
Gα-GTP and the G-βγ  subunits then activate or inhibit downstream effectors. The Gα 
subunit hydrolyzes the terminal phosphodiester bond of GTP to inorganic phosphate (57), 
which is released, forming Guanine diphosphate (GDP), that remains bound to the Gα 
subunit. This promotes Gα to rebind the Gβ/Gγ subunits.  
 There are four classes of heterotrimeric G-proteins, Gαs, Gαi, Gαq, and Gα12/13 
(58). Serum agonists including LPA, S1P, and thrombin all activate receptors that couple 
to the Gα12/13 subclass. Gα12/13, as well as Gαs, are the only subclasses to be identified as 
oncogenes based on their ability to transform fibroblast when overexpressed (59, 60). 
Gα12/13, also promote the invasion and metastasis of prostate (61), oral (62), ovarian (63) 
and breast cancer (64) cells. Gα12/13 primarily regulate actin dynamics via their activation 
of the RGS-RhoGEFs, which then activate the small GTPase RhoA (Figure 1-4A). The 
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RGS-RhoGEFs include ArhGEF1, ArhGEF11 and ArhGEF12. They are all RhoA 
specific GEFs that also contain an N-terminal GAP domain for heterotrimeric G-proteins, 
coined the Regulator of G-protein Signaling (RGS) domain. The RGS-RhoGEFs are 
recruited to the plasma membrane by activated GPCRs through an interaction of the RGS 
domain with Gα12/13 subunit (65-67). This allows their dbl homology (DH) domain, 
which is the region responsible for GEF activity for RhoA, to be activated by a secondary 
low affinity interaction with the Gα subunit (67). Conversely, their ability to GAP Gα12/13 
allows them to control the length of time over which they can be activated (68). The 
RGS-RhoGEFs along with many other Rho GEFs were identified by their ability to 
transform NIH3T3 fibroblasts when overexpressed (69-71). This activity was later 
attributed to their dbl homology (DH) domains (72, 73). Likewise, ArhGEF1 and 
ArhGEF12 are implicated in driving transformation and/or contributing to cancer 
progression, respectively. Overexpression of  a mutant of ArhGEF1 that is fused with the 
CAAX motif from RAF transforms NIH3T3 fibroblasts (74). ArhGEF12, is also known 
as Leukemia Associated RhoGEF, as its  fusion  to the MLL gene is the main driving 
mutation in  the development of acute myeloid leukemia (75, 76).  
 The RGS-RhoGEFs also mediate mitogenic lipid signaling (77, 78) onto the 
activation of RhoA induced actin dynamics that facilitates the induction of an “immediate 
early” pro-growth transcriptional program (Figure 1-4B). This specifically involves both 
the breakdown of cortical actin structures that support cell-to-cell contacts, and the 
coordinated increases in stress fiber actin. “Immediate early” gene induction is in part due 
to the reduction of globular actin (G-actin) as it assembles into filamentous actin (F-
actin). This prevents the sequestration of Myocardin Related Transcription Factor 
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(MRTF) in the cytosol, which occurs otherwise as it binds g-actin. MRTF upon its 
liberation from g-actin, translocates into the nucleus where it binds and co-activates 
Serum Response Factor (SRF) (79-83) (Figure 1-4C). SRF sits on Serum Response 
Elements (SRE) in the promoters of “immediate early” response genes (84-86), including 
cFOS, a component of the AP-1 transcription factor complex (85-88). This gene product 
when translated combines with cJUN to form the AP-1 transcription factor complex, 
which is an essential element for the transcription of cell cycle factors including Cyclin 
D1. Immediate early genes also activate transcriptional programs that promote cell 
survival, invasion and proliferation.  
 The serum response network induces transcriptional programs that facilitate cell 
growth and survival. Under normal physiological conditions the activation of this 
network is transient, however cancer cells override “fail-safe” checkpoints to allow its 
chronic activation to induce autocrine and paracrine signaling that promotes hyperplastic 
cell growth (89, 90). 
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Figure 1-4: Classical Activation of Serum Response Network.  
A. Schematic of lipid mitogen activation of the GPCR/Gα12/13/RGS-RhoGEFs/RhoA signaling 
axis. B. RhoA activation of ROCK results in the phosphorylation of downstream effectors that 
contribute to actin formation, stability and contraction. C. RhoA dependent actin filament 
formation induces MRTF translocation to the nucleus where it binds the transcriptional co-
activators SRF to drive gene transcription. 
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1.4 Regulation of the MAPK Network by Gα12 and Gα13 
Mitogen activated protein kinases (MAPK) transmit external to internal signaling 
to promote cellular growth. The activation of MAPK proteins usually occurs in a bi-
phasic manner, with an initial burst of activity that does not materially impact the cell 
cycle and a less efficacious longer-term  stimulation that strongly activates the cell cycle 
(91). However, chronic MAPK simulation can also induce cellular senescence or 
apoptosis if certain survival factors are not concomitantly activated (91). These “fail-
safe” mechanisms in nonmalignant cells are fundamentally important to prevent cancer 
(92). Malignancy occurs when cells circumvent these “fail-safe” mechanisms to  couple 
MAPK cascades to growth propagating effects that promote tumor formation (92). 
Consistent with Gα12 and Gα13 being implicated in promoting cancer, they both activate  
MAPK signaling. 
All MAPK signaling is activated by a receptor tyrosine kinase (RTK) binding to a 
growth factor peptide, stress lipopolysaccharide or inflammatory cytokines (93). Binding 
to these ligands causes RTKs to dimerize and auto-phosphorylate their c-terminal 
cytoplasmic region. This initiates the sequential activation of the MAP Kinase Kinase 
Kinase (MAP3K), MAP Kinase Kinase (MAP2K), and a MAP Kinase (MAPK) cascade. 
This results in dual phosphorylation of either serine sites on MAPKK or of a threonine 
and tyrosine near their activation loop on MAPK (93). Typically to achieve activation of 
the MAP2K or MAPK an incoming signal must be high enough to saturate both 
phosphorylation sites. MAP3Ks are less concentrated than their upstream MAP2K. 
However MAPKs and their cognate MAP2K have roughly equal concentrations within 
the cell. This allows signal amplification at each successive step within the kinase 
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cascade (94). It may also suggest why a variety of cancers harbor activating mutations in 
receptors or MAP3K proteins, as this allows signal propagation, versus a mutation in the 
downstream MAPK.  
Canonical mammalian MAPK signaling consists of three well-characterized 
pathways; the ERK1/2, JNK1/2 and p38 cascades (Figure 1-5A) (93). External stimuli 
that activate ERK1 and ERK2 generally elicit transcriptional programs that activate the 
cell cycle. Stimulation of a RTK by an agonist, such as epidermal growth factor (EGF), 
elicits the autophosphorylation of the RTK, Grb2, an adaptor protein, is then recruited to 
the membrane through binding the phosphorylated tyrosine via its SH2 domain. Grb2 
may also be recruited indirectly by phosphorylated Shc2; an  adaptor protein that binds to 
the autophosphorylated RTK. Son of Sevenless, (SOS) is then recruited by Grb2 to allow 
its GEF domain to facilitate the exchange of GDP for GTP on rat sarcoma (RAS) 
GTPases. Activated RAS binds the N-terminal domain of one of three isoforms of Raf (a, 
b, and c also known as 1) which results in their activation (95). Consequently, Raf binds 
and phosphorylates MEK1/2 at both serine/threonine (96, 97) residues near the activation 
loop. This activates the dual specificity kinase activity of MEK, resulting in its 
phosphorylation of ERK1/2 on threonine 183 and subsequently on tyrosine 185 (98). The 
dual phosphorylation of ERK1/2 increases its activity by >1000 fold (91). Initial 
mitogenic stimulation results in an early phase activation of a large fraction of ERK1/2 
within 5 minutes. Following this spike in activity, a second phase involving much lower 
levels of ERK1/2 phosphorylation can occur over several hours (91).  This sustained 
ERK1/2 activation can drive sufficient cyclin activity to promote the cell to enter S phase 
(91) while also promoting translation (99) committing the cell to growth (100). Activated 
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ERK1/2 translocates to the nucleus (101) and phosphorylates a variety of pro-growth 
transcription factors, such as Elk-1. Elk-1, contains a N-terminal ETS DNA binding 
domain (102, 103), that upon phosphorylation by ERK1/2 (104) binds to the transcription 
factor SRF to form a ternary complex factor (TCF). The TCF/SRF complex binds to 
SREs in the promoter of the proto-oncogene, cFOS, and drives its transcription (105, 
106). cFOS combined with cJUN facilitates passage through the G1 restriction point via 
the induction of Cyclin D1 transcription (107, 108). 
 JNK 1/2 signaling also occurs in a biphasic manner in which the initial phase 
promotes cell growth and survival while the secondary prolonged phase induces 
apoptosis (109). Inflammatory cytokines and biophysical stresses activate the upstream 
JNK pathway MAP3K, termed transforming growth factor-beta activated kinase-1 
(TAK1). Activated TAK1 then phosphorylates serine residues near the activation loop of 
the MAP2Ks MEKK4/7. MEKK4/7 then sequentially phosphorylate threonine and 
tyrosine residues within the activation loop of JNK. Chronic phosphorylation of these 
residues induces JNK to direct the E3 ubiquitin ligase Itch to mediate proteosomal 
degradation of the caspase-8 inhibitor cFLIPL to result in cell death (110). Furthermore, 
stress activated JNK can phosphorylate histone H2A variant, H2AX at serine 139, 
resulting in DNA fragmentation and apoptosis (111). JNK also mediates stress alleviating 
effects through its downstream target, the transcription factor cJUN. cJUN was originally 
isolated as the cellular homolog to v-Jun, the oncogene that causes Avian Sarcoma Virus 
17 (112). cJUN was first transcription factor identified to have transforming potential. 
cJUN is phosphorylated by JNK within its transactivation domain at serine 63 and serine 
73, in response to a variety of stimuli including UV-light, and receptor tyrosine kinases 
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via HRAS (113). The neutralization of cJUN by microinjected anti-cJUN antibodies 
prevents the transition of cells from G1 to S phase (114). The dominant roles cJUN and 
cFOS in cell cycle progression underlies the utilization of MAPK cascades by cancerous 
cells to mediate neoplastic growth. 
MAPK cascades are also activated by Gα12 and Gα13. Both Gα12 and Gα13 activate 
a variety of small GTPases including RAS, Rac1, Cdc42, and RhoA to stimulate the 
JNK1 cascade (Figure 1-5B). Gα12 activates JNK through MEKK7, which phosphorylates 
JNK1 at threonine 187. Conversely, Gα13 activates MEKK4, which then phosphorylates 
JNK1 at tyrosine 185. Together, phosphorylation at both sites allows the full activation of 
JNK1. Evidence for the importance of the crosstalk between the serum response network 
and MAPK signaling is highlighted by the requirement of ArhGEF1 for RhoA-dependent 
activation of JNK in P19 cells (115). Further, ectopic expression of Gα12 facilitates the 
activation or inhibition of ERK1/2 depending on cell-type (116). Because the mutations 
in proteins involved in these pathways contribute to breast cancer initiation and 
progression (117), it is essential to understand how these pathways integrate and 
contribute to normal physiological growth. 
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Figure 1-5: Classical and Non-Classical Activation of the MAPK Cascades.  
A. Classic activation of the canonical MAPK pathways. The pro-growth growth factor response 
pathway that ends in ERK1/2 phosphorylation (Left panel) and the stress response MAPK 
pathways that ends in JNK1/2 and p38 phosphorylation (Right Panel). Upstream kinases MAP2K 
(Yellow) and MAP3K (Blue). B. Role Gα12 and Gα13 play in activating the MAPK cascades in 
response to activation of G-protein coupled receptors. 
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1.5 Integration of HIPPO Signaling in Epithelial Polarity, Serum Response Network and 
MAPK 
Over the past decade the HIPPO signaling pathway has emerged as a mediator of 
growth control and stem-like features in response to biochemical and biophysical 
interactions. (118, 119). Initial discoveries elucidated the role of HIPPO signaling in 
organ size control in response to cell-to-cell contacts (Figure 1-6A) (120, 121). More 
recently, the regulation of HIPPO signaling by the Serum Response Network and MAPK 
cascades was also appreciated (122, 123). Many of these studies highlight the co-
dependencies of these pathways to drive aberrant growth in cancer cells. This 
dependency suggest that under normal physiological conditions there are a multitude of 
checks and balances integrated among various canonical signaling pathways to maintain 
cellular and tissue homeostasis. However, the mechanisms and complete functional 
relationship between the integration of the HIPPO pathway, Serum Response Network, 
and MAPK Cascades in contributing to cellular growth in epithelial cells is still largely 
not understood.  
Discovered in Drosophila melanogaster by genetic mosaic screens, mammalian 
homologues of the Drosophila HIPPO pathway have since been discovered. Mammalian 
STE-like (MST) 1/2 and Large Tumor Suppressor (LATS) 1/2 kinases are activated by 
cell-to-cell contacts . This allows them to phosphorylate and thereby inactivate the potent 
oncogenes transcriptional co-activator Yes-Associated Protein 1 (YAP1) and its homolog 
WWTR1 (TAZ). Phosphorylation of YAP1 at serine 127 or TAZ at serine 89 promotes 
their binding to 14-3-3, which results in cytosolic sequestration. If cells are not engaged 
with one another, the LATS1/2 kinases are inactive which allows  YAP1 to translocate to 
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the nucleus where it co-activates transcriptional events (120). Further regulation of YAP1 
occurs through its degradation via an Angiomotin dependent process that is initiated by 
LATS1/2 phosphorylation of serine 175 on Angiomotin in response to serum deprivation 
(124, 125). Upregulation of YAP1 occurs in a variety of cancers including  hepatocellular 
carcinoma, uveal melanoma (126), colorectal (127), pancreatic ductal adenocarcinoma 
(128), lung adenocarcinoma (129), neurofibromatosis, and malignant mesothelioma 
(130).  
YAP1 and TAZ are dynamic transcriptional co-activators that have no inherent 
DNA binding domain. They mediate their transcriptional effects by binding to a variety 
of transcription factors including RUNX2, p73 and most notable the TEA domain 
containing (TEAD) family. Mammalian TEAD family members consists of 4 highly 
conserved and ubiquitously expressed transcription factors that are conserved from yeast 
(131). All TEADs  bind YAP1 and TAZ (132-134). The N-terminal domain of YAP1 
binds the carboxyl-terminal domain of TEAD (135, 136). The transcriptional activity of 
the YAP1/TEAD complex is facilitated by the recognition of M-CAT motifs (5′-
TCATTCCT-3′) (137) in the promoter of a variety of growth inducing genes. The 
YAP1/TEAD/DNA complex is functionally activated when tethered, via the acidic 
carboxyl terminus of YAP1, to RNA Polymerase II (132). The YAP1/TEAD 
transcription factor complex drives transcription of a variety of genes, the most notable 
being the CCN family of genes (134, 138).  
The CCN family of genes are named for the first three members identified: 
Cysteine Rich, Angiogenic Inducer, 61 (Cyr1 or CCN1), Connective Tissue Growth 
Factor (CTGF or CCN2), nephroblastoma overexpressed (NOV or CCN3) and CCN4-6. 
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The CCN proteins are secreted into the stromal matrix where they activate cell growth by 
manipulating the cells interactions with the surrounding microenvironment. CTGF and 
Cyr61 activate extracellular matrix metalloprotease-2 and the integrin network to 
promote cell growth and survival signaling by activating integrin linked kinase and 
ERK1/2 (139, 140). Overall, the facilitation of autocrine and paracrine signaling by 
YAP1 is critical for cellular homeostasis and fate decisions. 
Regulation of the actin cytoskeleton network is a fundamental requirement for 
YAP1 nuclear translocation. Activation of RhoA by mitogen stimulated Gα12/13 
heterotrimeric G-proteins induces the formation of stress fibers (Figure 1-6A). Stress 
fiber formation is required for YAP1 nuclear translocation. However if this occurs in a 
LATS1/2 dependent or independent manner is still an area of controversy. The use of a 
RhoA specific inhibitor, the exoenzyme bostulum C3 toxin (141), or using latrunculin A, 
a drug that binds 1:1 with monomeric actin and inhibits polymerization prevents a mutant 
of YAP1 that is insensitive to LATS1/2 phosphorylation from localizing to the nucleus 
(142). However, activation of Gα12/13 by lipid mitogens also reduces the phosphorylation 
of LATS1/2 to promote YAP1 nuclear translocation (122). LATS1/2 phosphorylation  
and YAP1 cytosolic sequestration are also increased upon treatment of cells with C3. It is 
therefore likely that the serum response network regulates YAP1 by both LATS1/2 
dependent and independent modes depending on the context of actin dynamics.  
Activation of the MRTF/SRF and AP-1 transcription factor complexes  is 
required for many YAP1/TEAD mediated effects. For instance, in glioblastoma cells 
lines, YAP1/TEAD synergistically function with MRTF/SRF to activate the transcription 
of Cyr61, a known YAP1 target in response to activation of GPCRs by S1P (143). The 
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transcription of Cyr61 in this scenario is abrogated by the independent knockdown of 
either YAP1 or MRTF. Furthermore, in a “normal” transformed breast cancer cell line, 
MCF10A, YAP1 synergizes with AP-1 transcription factor complex to promote cell 
growth in 3D tissue culture models as well as in vivo orthotropic transplantation (144). 
Together these studies highlight how the serum response network and the HIPPO 
pathway are integrated to control cellular growth. 
MAPK cascades further regulate YAP1 activity and cell growth potential. 
Treatment of the mammary epithelial cell line MCF10As with Epidermal Growth Factor 
(EGF) causes dissociation of the HIPPO kinases  and YAP1 activation (123). Further, 
activation of the Ajuba family protein WTIP by RAS in response to the loss of cortical 
actin tension enhances its  association with LATS1/2 . This prevents LATS1/2 
phosphorylation of YAP1 to promote its nuclear localization (145, 146). A requirement 
of YAP1 and MAPK signaling is also evident in pancreatic cancers. Ninety percent of 
pancreatic cancers tumors exhibit constitutively activated KRAS mutants (147). In these 
cancers YAP1 is dispensable for initiation events, however it is required for progression 
(128). The requirement of YAP1 activity for the functionality of MAPK cascade 
signaling highlights the importance of YAP1 in dictating cellular fate decisions. 
 Further elucidation of how the serum response network, MAPK cascades, and the 
HIPPO pathway convert external biophysical and biochemical stimuli into regulated 
growth is needed. For it is the deregulation of these pathways, not in solidarity, but in the 
integrated network, that cancers can by-pass inherent fail-safe mechanism to propagate 
unwarranted growth (90, 92).  
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Figure 1-6: Integration of Serum Response Network and HIPPO Signaling. 
 
A. High HIPPO: Differentiated epithelial cells, upon cell-to-cell contact at junctions, initiate the 
sequential activation of the HIPPO kinases MST1/2 and LATS1/2, respectively. LATS1/2 then 
phosphorylates YAP1 at serine 127 and it is further sequestered from the nucleus by 14-3-3. B. A 
model of RhoA dependent actin stress fiber formation that results in the translocation of YAP1 to 
the nucleus. 
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1.6 Model Systems Justification 
 Mammary tumors are typically a heterogeneous group that utilizes a wide variety 
of hormone and growth factor signal transduction pathways to mediate cell growth (148, 
149). Tumor subtypes are classified by the presence or lack of the hormone responsive 
estrogen and progesterone receptors, and the growth factor receptor HER2 (150). 
Estrogen or progesterone receptor positive tumors are typically treated with anti-hormone 
therapy, while tumors that present with HER2 are treated with a HER2 antagonist. As 
breast cancers progress they become refractory to treatment (151). The varying receptor 
profiles of breast cancers, as they are diagnosed or as they progress, suggest that many 
cancers can re-wire internal signal transduction circuitry to adapt and mediate cell growth 
needs (90, 150).  It is therefore necessary to exploit specific breast cancers models to 
accurately represent the tumor type under investigation. Furthermore, studying signaling 
pathway in a broad range of cell lines may lead to a better understanding of how breast 
cancers develop and progress through subsequent stages.  
BT474 are estrogen (ER+), progesterone receptor (PR+) and HER2 positive. This 
cell line was derived from a 60-year-old Caucasian female. In this study, BT474 cells 
were used to initially identify RhoGEFs and RhoGAPs that modulate YAP1 dependent 
TEAD activity. MCF7 cells are estrogen receptor (ER+) and progesterone receptor (PR+) 
positive cell lines, but they lack overexpression of HER2 (HER2-). These cells represent 
an IDC luminal tumor type and are derived from a pleural effusion of a 69-year old 
Caucasian woman. MDA-MB-231 cells are derived from a metastatic site within a 51-
year-old Caucasian female. The cells are triple negative meaning they lack estrogen 
receptors (ER-), progesterone receptors (PR-), and HER2 (HER2-). Signaling regulating 
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Gα12/13 was primarily elucidated in MCF7 and MDA-MB-231 cells lines. Human 
Embryonic Kidney (HEK) 293T cells were derived from human embryonic kidneys and 
transformed with fragments of adenovirus type 3 and contain the SV40 T-antigen (152, 
153). These cells were used to produce the lentiviruses used in this study. 
 Biochemical and biophysical microenvironmental cues are major drivers of cell 
fate decisions under physiological conditions (154). Cell grown on 2D plastic surfaces 
alter cellular signaling in comparison to the connective tissue rich environment within the 
mammary organ. Therefore plastic tissue culture dishes may not be an optimal 
environment for studying cell signaling. To address these concerns, results in 2D were 
validated in a representative 3D environment. Cells were grown in a laminin rich 
extracellular matrix known as Matrigel® (155). This substance best represents the soft, 
connective tissue environment that comprises the breast tissue.  
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1.7 Rationale and Central Focus  
The overall goal of this dissertation is to understand how the integration of the 
serum response and HIPPO signaling networks facilitates cell fate decisions. Growth is a 
finite process at both the organismal and cellular level. The integration of growth 
signaling pathways inherently provides a system of checks and balances to maintain 
cellular homeostasis. In the context of epithelial cells, these checks and balances are 
mediated by biophysical interactions with surrounding cells and the basement membrane, 
as well as biochemical stimulation through serum mitogens. Recent studies have 
highlighted how these biophysical and biochemical stimuli regulate the HIPPO pathway 
and its downstream effector YAP1 to mediate cell fate decisions (122, 142). Aberrant 
regulation of this pathway leads to cell growth and tumorigenesis (156). Through cell-to-
cell contact or serum deprivation, YAP1 is phosphorylated and retained in the cytosol or 
degraded (125, 156). Conversely, the loss of cell-to-cell contacts, the activation of the 
serum response network by LPA and/or S1P, or the activation of MAPK signaling by 
EGF promotes YAP1 nuclear localization (122, 123, 145). However, even though these 
major signaling pathways are known to independently regulate YAP1 nuclear 
localization, nothing is known about how they spatially and temporally cooperate to 
regulate YAP1 and subsequent cellular fate decisions. 
Recent work has highlighted the requirement of RhoA-dependent actin stress fiber 
formation, independent of LATS1/2 for YAP1 nuclear translocation (142). RhoA is a 
small GTPase whose activity is modulated by GEFs and GAPs that respond to upstream 
extracellular signals, such as LPA and SIP (77). RhoA however, functions at various 
cellular locations, driving both stress fiber formation activating YAP1, and participating 
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in cortical actin formation (157), which is hypothesized to inhibit YAP1 activity. RhoA 
can also be active in the nucleus. These seemingly contradictory functions have muddled 
the understanding of how RhoA regulates YAP1 dependent cell fate decisions. 
A key to the selective spatial and temporal regulation of RhoA is the GEFs and 
GAPs that facilitate its GDP/GTP cycle (158-162). To date, only a handful of GEFs and 
GAPs are implicated in the regulation of YAP1, via the activation or inhibition of their 
corresponding G-protein (126, 163). It is therefore hypothesized that the regulation of 
RhoA by specific GEFs and GAPs is critical for understanding YAP1 nuclear activity.  
The central focus of this dissertation is the mechanisms for the integration of 
canonical growth regulatory signaling with HIPPO signaling to control cell growth and 
survival. The central focus was tested by: (1) the discovery of the RGS-RhoGEFs as 
major regulators of YAP1-dependent transcription. (2) The characterization of the RGS-
RhoGEFs, ArhGEF1, ArhGEF11 and ArhGEF12, in contributing to serum induced 
RhoA-dependent YAP1 activation. This characterization further highlighted that 
ArhGEF12, and to a more modest extent ArhGEF11, mainly mediates GDP/GTP 
exchange activity for RhoA, whereas ArhGEF1 is essential to GAP Gα13, which was 
further identified as the primary transducer of serum instigated YAP1 transcriptional 
activity. (3). Furthermore, all of the RGS-RhoGEFs were found to be required for cellular 
growth in 2D and 3D model systems. However, ArhGEF1 was found to be essential for 
cell growth  via a novel mechanism involving the induction of expression of proteins 
involved in cell cycle activation and protein translation (4) Finally, we describe the 
requirement of YAP1 in maintaining cell survival in hyper-activated growth signaling 
and high tensile environments. The loss of ArhGEF1 was found to sensitize cells to Gα13 
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serum signaling, however this did not initiate cellular growth. The combined knockout of 
ArhGEF1 and YAP1 results in a synthetic activation of apoptosis. These discoveries 
address a flawed presumption in the field that stress fiber induced YAP1 nuclear 
translocation always results in cell growth. This work dissects how the RGS-RhoGEFs 
fine-tune YAP1 functionality by coordinating a variety of signaling cascades that 
typically mediate cellular growth, to maintain an optimal range of cellular homeostasis 
that is defined by biochemical and biophysical interactions. However, when these 
pathways are aberrantly activated and cellular homeostasis is disrupted, YAP1 
functionality switches to promote survival.  
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CHAPTER 2. MATERIALS & METHODS 
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2.1. Methods of Cell Culture 
Cells were maintained in a 37oC incubator at 5% CO2. Cells were passaged as 
follows: Media was aspirated from the plate and cells were washed with sterile PBS. 
Upon aspiration of the PBS, 1 mL of 2.5 g/L trypsin (Sigma) supplemented with 5 mM 
EDTA (Sigma) was added and cells were placed back in the 37oC incubator. After 2-10 
minutes, varying among cell types, cells were visually inspected for cellular detachment 
from the plate. Upon detachment, 3 mLs of media was added to kill the trypsinization 
process, and cells were pipetted into 15 mL conical tubes (Falcon), using p1000 filter tips 
(FisherBrand). Cells were centrifuged at 1500 RPM for 1.5 minutes in an Eppendorf 
Centrifuge (5702). Upon retrieval cells were resuspended by pipetting 15 times using 1 
mL of media, and subsequently seeded at desired density and/or cell number. 
 Cell types used in this study include the mammary breast cancer cell lines MCF7, 
MCF10As, MDA-MB-231 (Mayo Lab), MDA-MB-231 Metastatic (Guise Lab,) BT474, 
SKBR3s, and the human embryonic kidney cell line, HEK293Ts. All cell lines were 
obtained from ATCC unless otherwise noted. MCF7s, MDA-MB-231, MDA-MB-231 
Metastatic, SKBR3s, and HEK293Ts were cultured in complete media which consists of 
Dulbecco’s Modified Eagles Serum (DMEM)/High Glucose (ThermoFisher) 
supplemented with 10% Fetal Bovine Serum (FBS) (Atlanta Biologics) and 1% 
penicillin-streptomycin solution (Hyoclone). BT474s were cultured in RPMI-1640 
(ThermoFisher) supplemented with 10% FBS (Atlanta Biologics).  
 Cell treatments consist of basal, serum starved (SS), or serum add back (4) 
conditions, unless otherwise noted. Under basal conditions, cells were seeded into 
complete media containing 10% FBS. Under serum starved conditions, cells were seeded 
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into complete media, and after 24 hours the media was replaced with media lacking 10% 
FBS. Serum add back consisted of replacing the serum starved after 24 hours with 
complete media containing 10% FBS for indicated time points. 
 
2.2. Stable Cell Line Generation Using Lentivirus 
Second generation lenti viral constructs were used to transduce cell lines with 
either MISSION® pLKO.1 shRNA, from Sigma Aldrich, or with a mammalian lent viral 
expression plasmid, to create a stable cell population with either a silenced or 
overexpression gene of interest. Four million HEK293Ts were plated into a 10 cm dish 
and grown overnight (Day 1). The following day lenti viral packaging vectors were 
transfected along with either the pLKO.1 shRNA or mammalian lent viral expression 
plasmid (Day 2). For the transfection, 6 ug of pCMV-VSVG, 5 ug of psRSV-REV, 10 ug 
of pMDLg-pRRE, and 20 ug of indicated plasmid were vortexed at medium speed in 1 
mL of serum free media while adding 25 uL of PEI (2mg/mL), dropwise. The mixture 
was allowed to sit for 5 minutes in the biosafety hood. The transfection master mix was 
then added drop wise to an 80% confluent 10 cm plate of HEK293Ts prepared the night 
before. The following morning, the transfection media was removed and replaced with 
complete medium (Day 3). Twenty-four hours later, the viral containing medium was 
collected into a 15 mL Falcon Tube (Day 4). If desired, another round of medium was 
added to the 10 cm plate and collected on Day 5. After collection of the virus, the 
supernatant was passed through a .45 uM filter to remove any debris. Hexadimethrine 
Bromide, also known as Polybrene (5mg/mL), was then added, 1:500, and allowed to mix 
with the viral supernatant for 10 minutes. Virus can be stored at 4oC for up to two weeks. 
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 Target cell lines, those being infected, can be plated out on Day 2 or at anytime up 
to two weeks after collection of the virus. The target cell lines in this study, MCF7 and 
MDA-MB-231 were seeded at 2 million and 4 million cells, respectively in a 10 cm2 
dish. Twenty-four hours after seeding cells were incubated with 6 mLs of viral 
supernatant that was diluted 1:2 unless otherwise indicated. After 4-6 hour incubation, 
medium was changed to complete media. Target cells were given 48 hours to incorporate 
the lenti transduced DNA and then split for an assay. 
 
2.3. Method of Transient Transfection 
 Forward and reverse transient transfection methods were performed depending on 
cell type. Forward transfections were done in HEK293Ts. HEK293Ts cells were seeded 
so that the following day they would be 70-80% confluent. 1 ug of cDNA was transfected 
per 100,000 cells seeded. The cDNA was added to serum free medium in glass disposable 
culture tubes (FisherBrand), the total volume of which did not exceed 5% of the total 
volume of complete medium on the cells. Polyethylenimine (PEI) (2mg/mL) was then 
added at a ratio of 1uL of 2mg/mL PEI/1ug cDNA drop wise to the transfection mixture, 
and allowed to sit for 5 minutes. The final mixture with the transfection reagents was then 
added drop wise to the plates of cells. 
 For a reverse transfection cells were counted and seeded. The same procedure for 
creating the transfection mixture, as highlighted above, was undertaken. The transfection 
mixture was then added drop wise prior to the cells adhering to the plate. 
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2.4. Plasmids, Antibodies, and Lysis Buffers 
Expression Plasmids: cDNA expression plasmids used to screen YAP1-TEAD 
dependent transcription activity are located in Appendix A. Lenti viral packaging 
(psRSV-Rev, pMDLg-RRE, and pCMV-VSVG) and shRNA scramble control (1864) 
vectors were acquired from Addgene. 5XGal4-luc, Gal4-TEAD4, (gifts from L. Quilliam). 3x-
Flag Gα13WT, 3x-Flag Gα13WT R232E, 3x-Flag Gα13QL, and 3x-Flag Gα12WT were cloned by 
B.Heller (originals were obtained from Philip Wedegaertner and Tohru Kazasa).  
Primary Antibodies used for immunoblots: M2 (Sigma, F3165) 1:10000, 9E10 
(in house) 1:1000, p115 (in house (65)) 1:1000, ARHGEF11 (Santa Cruz, sc-67023) 
1:1000, ARHGEF12 (Santa Cruz,sc-25638) 1:1000, pERK (Santa Cruz, sc-7382) 1:1000, 
pERK ( Cell Signaling, 9106S) 1:1000, ERK (Cell Signaling, 9102S) 1:1000, GAPDH 
(Millipore, MAB374) 1:10000,  pYAP1 (Cell Signaling, #4911) 1:1000, YAP1 
(Abnova, H00010413-M01) 1:1000, AIP4 1:1000, cMYC (Cell Signaling, D84C12) 
1:1000, U1 snRNP70 (Santa Cruz, sc-9571).  
Secondary antibodies for immunoblotting were all used at a dilution of 
1:20,000 and applied in the absence of light at room temperature for 30 minutes. These 
antibodies include goat anti-Mouse IRDye 800CW (LI-COR), goat anti-Rabbit IRDye 
680CW (LI-COR), and donkey anti-goat DyLight 800 (Pierce). 
Primary antibodies used for immunofluorescent fixed cell imaging: p115 (in 
house) 1:1000, ARHGEF11 (Bethyl, A301-952A) 1:250, ARHGEF12 (Bethyl, A301-
959A) 1:250, M2 (Sigma, F3165) 1:10000, YAP1 (Abnova, H00010413-M01). 
Secondary antibodies for immunofluorescent fixed cell imaging: Secondary’s 
were all diluted to 1:500 and applied for 30 minutes in the absence of light. Goat-anti 
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Rabbit IgG CFL 488 (Santa Cruz, sc-362262), Goat-anti Mouse IgG Alex Fluor 488 
(Invitrogen A11001), Goat-anti Rabbit IgG-CFL 594 (Santa Cruz, sc-362282), Goat-anti 
Mouse-IgG CFL 594 (Santa Cruz, sc362277). 
RIPA Lysis buffer: (in water: 150 mM NaCl, .1% SDS, 50 mM of pH 8.0m Tris, 
2mM EDTA, 1% TritonX-100). PLC Lysis Buffer: (in water: 50 mM pH 7.5 HEPES, 
150 mM NaCl, 10% Glycerol, 1% TritonX-100, 1.5 mM MgCl2, 1 mM EGTA). Passive 
Lysis Buffer (Promega): Proprietary. Nuclear Fractionation Buffer A: (in water: 10 
mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, and .05% IGEPAL). 
 
2.5. Method of Immunoblot and Western Analysis 
 Protein Extraction and Quantitation from 2D: After treatment, cells were 
removed from the incubator and placed immediately on ice. Serum was then aspirated, 
and cells were washed once with cold PBS, which was subsequently removed. RIPA 
Lysis Buffer supplemented with protease cocktail inhibitor, was then added. An 
appropriate volume, taking into account cell density and plate size was added. 100% 
confluent 6 cm and 10 cm plates were lysed in 200 uL and 1 mL of RIPA, respectively. 
50% confluent 6 cm and 10 cm plates were lysed in 100 uL and 500 uL of RIPA Lysis, 
respectively. Using a scraper, cells were removed from the plate and placed into a 1.7 mL 
microcentrifuge tube and placed on ice for 10 minutes. Lysates were then clarified by 
being spun down in an Eppendorf Centrifuge (5417R) at 14,000 RPM for 10 minutes at 
4oC. A Bicinchoninic acid (BCA) assay was used to determine the protein concentration 
of cell lysates. Lysates were normalized to contain the same protein concentration, with a 
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total of 30-40 ug of protein per 20 uL. Normalized protein samples were then boiled in 1x 
SDS sample buffer.   
 Protein Extraction and Quantitation from 3D: Protein was extracted from 
Matrigel® through a combined method of chemical and physical means. Cells in 
Matrigel® were removed from the incubator and placed on ice. Cells were washed 1x 
with ice cold PBS, careful not to perturb the Matrigel®. 150 uL of RIPA lysis9 buffer, 
supplemented with appropriate protease inhibitors was then added to the dish. The 
Matrigel® was scraped off using a cell scraper and placed into a 1.7 mL microcentrifuge 
tube. Using a p200, the Matrigel® was vigorously broken up into a homogenous solution, 
and snap frozen on dry ice for 10 minutes. Lysates were then hand-thawed, and subjected 
to p200 pipetting. Lysates were clarified through a 4oC spin for 10 minutes at a speed of 
14,000 RPM in an Eppendorf Centrifuge (5417R). The clarified supernatant was then 
boiled in 1x SDS sample buffer for 5-10 minutes at 100oC. It is important to note that a 
BCA assay cannot be run on these samples as the Matrigel® will interfere with the assay. 
The standard practice for normalizing protein concentration for these samples is to run a 
GAPDH blot and perform a densimetric analysis using ImageJ to adjust the ratio of 
sample loading for future blots. 
 Resolution and Transfer: Resolution of proteins was achieved via sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 6-12% polyacrylamide 
gels were made depending on the size of protein being resolved. For proteins in the range 
of 30-115 kD an 8% polyacrylamide gel was prepared. For proteins that exceeded 115 kD 
in size, a 6% polyacrylamide gel was prepared, and for anything smaller that 30 kD a 
12% gel was created. Polyacrylamide gels were placed at 4oC overnight. 20 uL of each 
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sample was loaded into the appropriate percentage 15 well polyacrylamide gel. Protein 
was then resolved in running buffer for 1 hour and 30 minutes at 120 volts using a 
BioRad Powerpack. Proteins were then transferred to Protran BA85 nitrocellulose 
membranes via a Genie-Blotter. Conditions under which different percentage 
polyacrylamide gels were transferred were as follows: 6% gels were transferred at 24 
volts for 2 hours with 10% methanol added to the transfer buffer; 8% gels were 
transferred at 12 volts for 1 hour and 30 minutes with 20% methanol added to the transfer 
buffer; 12% gels were transferred at 12 volts for 45 minutes in buffer that had no SDS 
and supplemented with 20% methanol. Upon completion of the transfer, nitrocellulose 
membranes were placed on an orbital shaker and blocked in 5% (w/v) low-fat milk 
dissolved in TBS for 20 minutes at room temperature. Membranes were washed 3X in 
TBS that contained .1% (v/v) Tween20. Membranes were transferred to a hybridization 
bag and encased with 6-7 mL of primary antibody diluted in TBS/T. Hybridization bags 
were placed on a nutator at 4oC for a minimum of 1 hour for most primary antibody 
incubations, unless primary antibodies against ARHGEF1/11/2 or YAP1 were used and 
those incubations were done overnight. Membranes were then removed from the 
hybridization bags and washed 3x in TBS/T. Incubation with the appropriate secondary 
antibody was done in the dark at room temperature for 30 minutes. Membranes were then 
washed 3x in TBS/T and imaged using Li-COR® Odyssey scanner. 
 
2.6. Method of Nuclear Fractionation 
 4 million MCF7s were seeded into 10 cm plates and allowed to reach 90% 
confluence. Upon treatment cells were removed from the incubator and placed on ice. 
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Cells were then washed 2x in ice cold PBS. 1 mL of Nuclear Fractionation Buffer A, 
supplemented with appropriate protease inhibitors, was added to the cells and using a cell 
scraper they were gently removed from the plate and pipetted into a 1.7 mL 
microcentrifuge tube. Lysates were set on ice for 10 minutes and then spun down at 3000 
RPM for 10 minutes in 4oC Eppendorf centrifuge (5417R). 100 uL of the supernatant was 
then removed and labeled as the “Cytosolic Fraction.” The rest of the supernatant was 
discarded. The pellet, milky in color, was washed in 1 mL of Nuclear Fractionation 
Buffer A by GENTLY pipetting up and down 3 times causing slight dissociation of the 
pellet. The lysate was then spun down at 3000 RPM for 1 minute, and this process of 
washing the nuclear pellet was repeated two more times. After the final wash the 
supernatant is discarded and the pellet is vigorously resuspended in 100 uL of RIPA 
supplemented with protease inhibitors. The lysate is then incubated on ice for 10 minutes 
followed by a spin at 14,000 RPM in an Eppendorf centrifuge (5417R) at 4oC. The 
supernatant is removed and labeled as the “Nuclear Fraction.” Protein concentrations 
were then determined by BCA assay. Normalized samples were boiled in 1x SDS sample 
buffer at 100oC and resolved as described in section 2.5. 
 
2.7. BCA Assay for Protein Concentration 
 Pierce® BCA Protein Assay Kit was purchased and used as directed by 
manufacturer. 2 uL of clarified protein lysate from one sample was added per well of a 96 
well plate. A mastermix of Pierce® BCA Protein Assay Reagent A and Pierce® BCA 
Protein Assay Reagent B was created by adding Reagent B to Reagent A at 1:50 dilution. 
198 uL of the mastermix was added to each well containing clarified protein lysate and 
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the plate was sealed, and allowed to incubate in 37oC water bath for 15 minutes. Upon 
retrieval, the bottom of the plate was dried and placed into a 96 well SpectraMax 250 
(Molecular Devices) plate reader. The plate was read under the BCA assay program. A 
standard curve was created using 2, 4, 8, 12, 16, and 32 uL of 1ug/uL BSA. 
 
2.8. Short Hairpin RNA Information 
 Stable cell lines for silenced gene expression were made using a combination of 
the Sigma Mission® shRNA pLKO.1-puro vectors with lenti viral packaging vectors as 
described in section 2.2. After infection, cells were given 2 Days to produce optimal gene 
knockdown and were split into assays. Mission shRNAs used in this study include: 
shARHGEF1 (TRCN0000033566), shARHGEF1 (TRCN0000033568), shARHGEF11 
(TRCN0000047465), shARHGEF12 (TRCN0000298941), shARHGEF12 
(TRCN0000298942), shYAP1 (TRCN0000107267) and for a control a pLKO.1 
shScramble purchased from Addgene (1864) 
 
2.9. RNA Extraction, cDNA Synthesis, and Quantitative Real Time PCR 
RNA Extraction from 2D:Treated cells were removed from the incubator and 
placed at room temperature. The media was aspirated and 500 uL of TRIZOL® was 
added per 6 cm plate. Using a cell scraper, cells were collected and pipetted into a 1.7 mL 
microcentrifuge tube. Samples sat at room temperature for 10 minutes, and then 100 uL 
of Chloroform was added. Samples were vortexed until the solution was homogenous and 
allowed to sit again at room temperature for 10 minutes. Samples were then spun down in 
an Eppendorf centrifuge (5417R) for 10 minutes at 14,000 RPM and 4oC.  
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 200 uL of the aqueous layer was then removed and added to 150 uL of 
isopropanol to precipitate the RNA. Samples were incubated at room temperature for 10 
minutes and then spun down at 4 oC at 14,000 RPM  for 10 minutes. The RNA pellet was 
washed in 75% ice-cold ethanol, to remove excess salt, and spun down at 9,500 RPM for 
5 minutes. This step was then repeated. After the second wash the majority of ethanol 
was aspirated and the remainder was removed using a p200. The RNA was allowed to air 
dry for 5 minutes and then dissolved in 20 uL of ddH2O. 
RNA Extraction from 3D: Treated cells were removed from the incubator and 
placed at room temperature. The media was aspirated and 1mL of TRIZOL® was added 
per 3.5 cm plate. Using a cell scraper, only the Matrigel® was removed, leaving a ring of 
2D cells left on the plate. The Matrigel®/Trizol mixture was added to a 1.7 mL 
microcentrifuge tube and incubated at room temperature for 10 minutes. Two hundred 
microliters of Chloroform was then added. Samples were vortexed until the solution was 
homogenous and allowed to sit again at room temperature for 10 minutes. Samples were 
then spun down in an Eppendorf centrifuge (5417R) for 10 minutes at 14,000 RPM and 
4oC.  
600 uL of the aqueous layer was then removed and added to 450 uL of 
isopropanol to precipitate the RNA. The mixture was incubated at room temperature for 
10 minutes. Samples were then spun down at 14,000 RPM at 4oC for 10 minutes. The 
RNA pellet was washed in 75% ice-cold ethanol, to remove excess salt, and spun down at 
9,500 RPM for 5 minutes, and repeated. After the second wash the ethanol was aspirated 
and a p200 was used to remove the remaining ethanol. The RNA was allowed to air dry 
for 5 minutes and dissolved in 20 uL of ddH2O. 
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Generation of complimentary DNA (cDNA): 8 uL of RNA (~8ug) from the 
above extractions was added to 2 uL of 50 uM Oligo dT (164) and 4 uL of 10 uM dNTPs 
(Bio Basic Canada). 16 uL of ddH2O was added for a final volume of 24 uL, and the 
mixture was incubated at 65oC for 5 minutes. Tubes were removed from heat source and 
10 uL of ddH2O, 4 uL of 10x Reverse Transcriptase (RT) buffer MulVI (New England 
BioLabs), and 2 uL of in-house reverse transcriptase was added to each tube.. The 
samples were then incubated at 50oC for 45 minutes and immediately spun in 4oC at 
9,500 RPM for 10 minutes. cDNA concentration was determined using a ND-1000 
Spectrophotometer (Nanodrop).  
Quantitative Real Time PCR (qRTPCR): The cDNA made in the above section 
was diluted to 400 ng/uL in ddH2O and qRTPCR was run per manufacturers instructions 
on an Eppendorf Realplex2 epGradient Mastercycler. Each reaction consisted of 5 uL of 
diluted cDNA , 3 uL of ddH2O, 1 uL of the appropriate Sense and Antisense primers, and 
10 uL of 2x SensiMix SYBR No-ROX Mastermix (BioLine) for a total volume of 20 uL. 
Samples were loaded into MicroAmp® Fast Optical 96-Well Reaction Plates (Applied 
Biosystems). PCR was performed following a 2-step cycling method: 1 Cycle at 95oC for 
2 minutes followed by 40 cycles of 95oC for 5 seconds and 60oC for 30 seconds. 
Deltadelta CT (ΔΔCT) values were calculated for each sample, using GAPDH as the 
normalizing control. Comparison of the variable ΔΔCT to control ΔΔCT was then 
performed to determine the relative change in mRNA expression. Sequence sets for the 
primers of specific mRNA targets are found in Appendix B. 
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2.10. Three-Dimensional Growth Assay Procedure 
 Matrigel® was purchased from Corning. At -20oC Matrigel® is frozen, at 0oC the 
material becomes a liquid, and at 37oC it polymerizes to form a laminin enriched 
extracellular matrix. Frozen Matrigel® was placed on ice for 4 hours prior to use to allow 
the material to liquefy. Once in liquid state, 150 uL of Matrigel® was spread out into a 
35 mm2 tissue culture dish, not allowing it to touch the edges of the dish. The dishes were 
then covered and placed into the 37oC tissue culture incubator for at least 15 minutes to 
induce polymerization. During the polymerization phase MCF7s and MDA-MB-231 
breast cancer cells were trypsinized and counted. 300,000K cells were then resuspended 
in 2 mLs of media. Upon polymerization cells were evenly seeded onto the Martrigel®, 
this is considered Day 0. Four images were captured of each condition using a Nikon 
SMZ1500 stereomicroscope at 10x magnification starting on Day 1 and ending on either 
Day 4 or Day 5. Colony size was determined by assessing the cross-sectional area using 
the Adobe Photoshop® Quick Selection tool. Relative colony growth was determined by 
comparing colony size of Day 1 to Day 4 or Day 5. 
 
2.11. Cell Accumulation Assay 
 On Day 0, 100,000 control and variable cells, were seeded in triplicate in 12 well 
dishes. The following day, Day 1, 3 samples of control and each variable condition were 
trypsinized and counted using a hemocytometer to determine cell counts. The same 
procedure was repeated for Days 2-4. Growth rates for both the control and variable 
conditions were then determined as a percent growth normalized to Day 1. 
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2.12. Cell Proliferation Assay (MTT Assay) 
Cells were seeded into 96 well plates at two different densities and allowed to 
grow for 3 days. MCF7s and MDA-MB-231 were seeded at 10,000 and 20,000 per well 
in 100 uL. On Day 3, 15 uL of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide), dissolved in water, at a stock concentration of 5 mg/mL, 
was added to each well for 4 hours. Cells were permeabilized and the converted formazan 
was solubilized by 100 uL of MTT Solvent Buffer (4 mM HCl, .1% Nondet P-40, in 
isopropanol) for 1 hour. The 96 well plate was then read by a SpectraMax 250 (Molecular 
Devices) plate reader, at a wavelength of 570 nm. Absorbance was then normalized to 
control. 
 
2.13. Scratch Wound Assay 
 On Day 0, 1 million cells were seeded into a 35 mm2 plate (100% confluence). 
The following day, Day 1 a scratch was introduced using a p200 filter tip from one edge 
of the plate to the other (Time 0). Images were obtained at Time 0, 12, and 24 hours 
using Brightfield Microscopy, as described in section 2.20. Percent wound closure was 
calculated using the Adobe Photoshop® Quick Selection Tool, calculating the area from 
one edge of the wound to the other. Each hour time point was normalized to Time 0.` 
 
2.14. TEAD Reporter Assay 
 Set up & lysate collection: 400,000 BT474 cells were seeded into 12 well plates 
and cultured for 18 hours before being transfected with 0.04 µg TK_Renilla (V3605), 
0.05 µg TEAD4_ GAL (Addgene 24640), 0.4 µg GAL-Luciferase Reporter (V3105), 
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0.23 µg 3xFLAG YAP1, and 1 µg of the indicated plasmid. 18 hours post transfection 
cells were washed in PBS three times and then 250 uL of Passive Lysis Buffer (Promega) 
was added. Plates were placed on an orbital shaker for 15 minutes to dislodge adherent 
cells. Lysates were then collected and cooled on ice for 10 minutes. Lysates were 
clarified through a 4oC spin for 10 minutes at a speed of 14,000 RPM in an Eppendorf 
centrifuge (5417R). 50 uL was aliquoted into 1.7 mL microcentrifuge tubes. 
 Dual Luciferase Assay: The Dual-Luciferase Assay System (Promega) was used 
in tandem with a 20/20n Luminometer (Turner Biosystems) to detect luminescence. For 
each reaction 50 uL of LAR II was added and luciferase was measured. 50 uL of Stop & 
Glo substrate was then added and subsequent luciferase measurement was taken. The 
ratio of LAR II/Stop & Glo luciferase units was then calculated. All data was derived 
from at least three separate experiments that were performed in three biological 
replicates. Error bars represent standard deviation of mean. 
 
2.15. CTGF Reporter Construct Cloning 
 Original CTGF 4.5 kb and 1st SRF mutant luciferase coupled promoter as 
described in (165) were obtained from Dr. Margarete Goppelt-Struebe. These promoters 
were inserted into the MCS of pGL3-basic vector using a 5’ KpnI and 3’ XhoI restriction 
enzyme sites. Within the CTGF promoter there are two MluI restriction enzyme sites, one 
that lies ~600 bp 3’ to the 5’ KPNI and one that lies ~4000 kbp from the 5’ KpnI 
restriction enzyme site. Using PCR based cloning we designed primers to ablate the 5’ 
MluI site and reintroduce a 5’ KpnI site to be used for insertion into the MCS. The CTGF 
reporter made from this strategy is considered the long form encompassing ~3.7 kbp. 
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From this construct the short ~700 bp CTGF promoter was made through restriction 
digest with MluI and XhoI, which was then ligated into an empty MCS of a basic-pGL3 
vector. Site directed mutagenesis of SRF binding sites (2-3) (TATàCCC) (165) and 
TEAD binding sites (1-2) (AATàGCG)(134) were conducted by the Stratagene method 
using the primers listed in Supplemental Table 2. A gBlock was synthesized by IDT that 
contained the desired mutations for TEAD5-7 binding sites. This gBlock was inserted 
into the short and long promoter using a 5’MluI (the reason for ablating the original MluI 
site in the long promoter) and a 3’ SacII restriction enzyme sites, following IDT protocol 
(Figure 2-1). All clones were sequences verified using GeneScript DNA Sequencing. 
Primer List in Appendix B. 
2.16. CTGF Reporter Assay 
 HEK293Ts were plated at 200K per well of a 12 well plate. 24 hours later cells 
were transfected with 0.5 ug of indicated CTGF promoter luciferase construct and 0.5 ug 
of control TK_Renilla construct. The same procedure for “Dual Luciferase Assay” in 
section 2.14 was followed to collect luciferase data. 
 
2.17. Reverse Phase Protein Array 
 MCF7s were transduced with either a shScramble or shARHGEF1 and serum 
starved for 24 hours. Following a 30 minute treatment with complete media cells, were 
lysed in RIPA lysis buffer. Protein concentration was measured by BCA assay, and 
lysates were adjusted to contain a final concentration of 1.0 ug/uL, in 1x SDS. 50 uL of 
lysate were transferred to a new 1.7 mL microcentrifuge, and 2 uL of β-mercaptoethanol 
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was added. Lysates were frozen and shipped to the Functional Proteomics RPPA Core 
Facility at MD Anderson Center. Complete results are in Appendix C. 
 
2.18. Propidium Iodide Flow Cytometry 
MCF7 cells were trypsinized and spun down at 1500 RPM for 1.5 minutes in an 
Eppendorf 5702 tabletop centrifuge. Cells were then washed in PBS and spun down for a 
second time. PBS was removed and cells were resuspended using a p1000 in 100 uL of 
PBS. 1 mL of 70% freshly prepared ice cold Ethanol was added drop-wise while 
vortexing at medium speed (4-5) to prevent cell aggregation. After drop-wise addition of 
1 mL 70% ethanol, another 1 mL of ice cold ethanol was added and cells were placed on 
the nutator at 4oC for overnight incubation. After fixation was complete the following 
morning cells were removed from 4oC and stored at -20oC until analysis. On the day of 
analysis cell were washed in PBS, spun down, and incubated in 500uL FxCycle PI/RNase 
Staining Solution (Life Technologies) for 30 minutes in the dark. PI fluorescence was 
then measured with a 590/40-emission filter (BL2) on an Attune Acoustic Focusing Flow 
Cytometer (Life Technologies). Live cells were gated based on forward (FSC) and side 
(SSC) scattering light area. 100,000 live events were captured and characterized for each 
sample. Appropriate cell populations were calculated using Attune Cytometric software 
and presented as a percentage of total live cells.  
 
2.19. Cell Fixation for Immunofluorescence 
 MCF7 cells were plated onto glass coverslips in a 12 well dish. Following 
indicated perturbations, cells were washed in PBS and fixed with 4% Paraformaldehyde 
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for 5 minutes at 4oC. Cells were then washed again with PBS and blocking buffer was 
added for at least an hour and up to 24 hours. Primary antibodies were incubated at 
indicated concentrations in section 2.4 for 1 hour, followed with a PBS wash. Secondary 
antibodies were applied at 1:500 for 30 minutes. Cells were then washed in blocking 
buffer 3 times and if phalloidin was used to stain for F-actin it was applied for 20 minutes 
after being diluted 1:4000 in blocking buffer. Cells were again washed in blocking buffer 
and then nuclei were stained with Hoechst (1:3000) for 7 minutes. Coverslips were then 
dipped into ddH2O and mounted onto slides using 10 uL of ProLong® Gold antifade 
reagent (Life Technologies), and allowed to dry overnight. 
 
2.20. Immunofluorescence, Brightfield and Stereomicroscopy 
 Immunofluorescence: Epifluorescent confocal images of fixed cells, as 
described in section 2.19, were acquired using structured light via an Apotome on a Zeiss 
Axio ObserverZ1. Staining dilutions of antibodies used and duration of incubation are 
specified in sections 2.4 and 2.19, respectively. Quantification of pixel intensity and co-
localization was calculated using Zeiss Zen software. Images were processed with Adobe 
Photoshop®. 
 Brightfield: Brightfield images were obtained using the Zeiss Axio ObserverZ1 
under the Dapi filter at 450 nm. The transmitted light was elevated to the level that 
saturated the fluorescent signal. Images were then taken under a phase contrast (ph) 1 or 
2 setting. Phase two was used to limit the “Halo” effect seen in ph 1 images. Images were 
processed with Adobe Photoshop®. 
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 Stereomicroscopy: Images were taken at a 10x magnification with a Nikon 
SMZ1500 stereomicroscope. Images were processed with Adobe Photoshop®. 
2.21. Illumina HiSeq 
 Total transcriptional analysis was performed using a Illumina HiSeq sequencing 
platform. MCF7 cells were infected with either shScramble or shArhGEF1 using lenti 
viral transduction to create stable cell lines. Each condition was expanded to an N=4. 1 
Day post seeding, cells total RNA was collected using RNeasy Kit from Qiagen. Total 
RNA was frozen at -70oC and then shipped to IU Bloomington for sequencing. 
 
2.22. Statistical Analysis 
Relative levels of mRNA, cell proliferation, cell-accumulation, cell viability, total 
cross-sectional area/acini are presented as the means standard deviation. P-values were 
calculated by an unpaired two-tailed t-test. 
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Figure 2-1: CTGF Promoter Luciferase Reporter Constructs Cloned. 
A. Schematic of all long form CTGF promoters cloned. B. Schematic of all short form CTGF 
promoters cloned. Red indicates mutated SRF or TEAD response element as described in 
materials and methods. TEAD responsive sites 3 and 4 are located at the dashed lines and were 
not mutated in any of the reporters above. 
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CHAPTER 3. THE RGS-RHOGEFS COORDINATE SERUM INITIATED 
SIGNALING ONTO THE REGULATION OF RHOA DEPENDENT YAP1 
ACTIVITY 
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3.1 INTRODUCTION 
 Both the state of cellular adhesion (120) and the activity of multiple ligand 
receptor systems (122, 166-168) feed onto the HIPPO signaling pathway to control 
transcriptional programs that drive cell growth and survival. The core HIPPO pathway 
consists of MST1/2 kinase, which phosphorylates and thereby activates LATS1/2 kinase 
(120, 156). LATS1/2 mainly functions to phosphorylate the transcriptional co-activators 
YAP1 and TAZ (120, 156) as well as the family of Amot adaptor proteins (125). These 
phosphorylation events result in the inhibition of YAP1 transcriptional activity by 
sequestrating it in the cytosol (169) or promoting its degradation. Nuclear YAP1 binds 
and co-activates multiple transcription factors, most notably TEAD1-4 (134), that control 
the expression of extracellular matrix-associated growth factors such as CTGF and 
Cyr61. These factors in turn are essential for wound healing and organ growth (120, 169), 
while their deregulation promotes many diseases including various cancers. The 
activation of HIPPO signaling by the formation of intercellular contacts is a cornerstone 
in limiting these processes in normal tissues. Conversely, connections to the extracellular 
matrix that produce mechanical loading and consequently increased formation of actin 
stress fibers are necessary for YAP1 to enter the nucleus (170). 
 Growth factors have been found to alter the activity of the HIPPO kinases, the 
stability of YAP1, and/or modulate the proclivity of YAP1 to enter the nucleus and be 
active. For example, activation of the PI3-Kinase pathway via EGFR, inhibits the HIPPO 
pathway in an AKT independent manner resulting in the activation of YAP1 
transcriptional activity (123). Conversely, LIFR activates HIPPO signaling to prevent 
YAP1 dependent migration and invasion of breast cancer cells (168). Signaling by 
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GPCRs that couple to Gα12/13, Gα11, Gαi, GαO and Gαq also have important roles in 
activating YAP1 (171). This is particularly evident for serum lipid mitogens including 
lysophasphatidic acid (LPA) and spingosine-1 phosphate (S1P), which agonize Gα12/13 
(122, 166). While these discoveries highlight the importance of soluble factors in 
controlling YAP1, the signaling that mediates their effects are still not fully understood. 
 While growth factors impact HIPPO signaling in many ways, in all cases, actin 
filament formation is essential for the nuclear translocation of YAP1 (142). The Rho 
family of GTPases, RhoA, Rac1 and Cdc42 have fundamental roles in cytoskeletal 
dynamics and cell growth mainly as reusable switches. Rho GTPases are active when 
bound to GTP and carry out little or no signaling when bound to GDP. Guanine 
Exchange Factors (GEFs) stimulate nucleotide release to enable binding to the more 
prevalent GTP. Conversely, when GTPases bind GTPase Activating Proteins (GAPs) 
their intrinsic GTPase activity enhances the hydrolysis of GTP to GDP (172, 173). Both 
RhoA (142) and Cdc42 (174), through their control of actin dynamics play key roles in 
regulating HIPPO signaling. To understand how growth factors control different 
subpopulations of Rho GTPases that are committed to regulating HIPPO signaling, it is 
important to understand the temporal and localized activation of the GEFs and GAPs 
within the cell. Because only a handful of Rho family GEFs and GAPs are implicated in 
regulating YAP1 localization or activity (126, 163, 175), this study investigated the 
relative effects of expression of 67 Rho family GEFs and GAPs (representing every 
major subclass of these proteins) on YAP1 dependent transcription. This and subsequent 
characterization revealed that the RGS-RhoGEFs, ARHGEF1, ARHGEF11, and 
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ARHGEF12 robustly modulate YAP1 dependent transcription via the Gα12/13 signaling 
axis. 
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3.2 RESULTS 
3.2.1 Defining the Elements of CTGF Promoter that are Required for Serum Induced 
Transcription 
YAP1 through its co-activation of TEAD family transcription factors is a 
fundamental determinant of organ size control and oncogenesis (133, 134). Connective 
tissue growth factor is a key target of TEAD transcription and its levels often correspond 
closely to TEAD activity (134). Consequently, measurements of the relative levels of 
CTGF transcript have become the most common way to infer YAP1/TEAD activity. 
However, RhoA induced formation of actin fibers can also drive the transcription of 
CTGF via the depletion of monomeric globular actin, which frees MRTF to translocate 
into the nucleus and dimerize with SRF (Figure 3-1A) (82, 83). This, in certain contexts, 
is also necessary and sufficient for CTGF expression (165). However, to our knowledge, 
the relative requirement for SRF versus TEAD in the direct transcriptional activation of 
CTGF by RhoA/Actin has not been defined (Figure 3-1B).  
The role of TEAD and SRF response elements in RhoA induced activation of 
both a long (~3.9 kb) (Figure 3-1C) and a short (700 bp) (Figure 3-1C) version of the 
CTGF promoter. The long CTGF promoter encodes three predicted SRF and seven 
TEAD binding elements (Figure 3-1C). The SRF site most distal to the transcription start 
site (TSS) was found to be necessary for this promoter to be activated by actin 
polymerization (165). Whereas, the short version of the CTGF promoter which contains 1 
SRF and 3 TEAD response elements requires the TEAD elements to be activated by 
YAP1 or TEAD (Figure 3-1D) (134).  Expression of the constitutively active RhoA 
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(Q63L) mutant stimulated the transcription of the reporter plasmids with the long CTGF 
promoter (long wild-type) or a variant in which all 3 SRF elements had been ablated 
(long 3X-SRF) by 2-fold. However, a reporter with a mutated long promoter that lacked 5 
of the TEAD binding sites (long 5X-TEAD) was refractory to activation by RhoA 
(Q63L) expression (Figure 3-1E). Similarly, the expression of RhoA (Q63L) activated 
transcription of the reporter plasmids with the short wild-type CTGF promoter (short 
wild-type) or short CTGF promoter with a mutant SRF element (short 1X-SRF), but not 
the reporter with mutations in all three TEAD binding elements (short 3X TEAD) (Figure 
3-1F). Consistently, treatment of cells with the drug verteporfin, which competitively 
blocks the interaction of YAP1 with TEAD (176), abolished the induction of CTGF 
transcript by serum treatment (Figure 3-1G). These results strongly point to the 
importance of TEAD but not SRF response elements in mediating the activation of 
transcription of CTGF by RhoA induced actin fiber formation. 
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Figure 3-1: Delineating the Requirements of TEAD vs. SRF in RhoA-Dependent CTGF 
Transcription.  
A. A model for the role of RhoA induced stress fiber formation that is coupled to the activation of 
MRTF and YAP1. B. Depiction of the ~4kb CTGF promoter with the SRF and TEAD binding 
elements. C. Schematic of the long forms of the CTGF wild-type long, 3x-SRF long, and 5x-
TEAD long promoters. (Red indicates mutated response element) D. Schematic of the short forms 
of the CTGF wildtype short, 1x-SRF short, and 3x-TEAD short promoters (Red indicates mutated 
response element). E. Graph of the fold-activation of transcriptional reporters with the indicated 
variants of the 4 kb promoter of CTGF in MCF7 cells expressing CA-RhoA (Q63L) versus a 
control plasmid. All raw luciferase values were initially normalized to activity of TK-Renilla. 
SRF (3x) indicates 3 SRF response elements mutated, while TEAD (5X) indicates 5 TEAD 
response elements are mutated F. Graph of the fold-activation of transcriptional reporters with the 
indicated variants of the 700 bp promoter of CTGF in MCF7 cells expressing CA-RhoA (Q63L) 
versus a control plasmid. All raw luciferase values were initially normalized to activity of TK-
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Renilla. SRF (3x) indicates 3 SRF response elements mutated, while TEAD (3X) indicates 3 
TEAD response elements are mutated G. CT value of CTGF mRNA transcript was measured by 
qRT-PCR of MCF7 treated with 1uM of Verteporfin following 24 hours serum starvation and 30 
minute treatment of 10% serum. Relative level of CTGF mRNA fold change (ΔΔCT) was then 
calculated for each sample compared to control expressing MCF7 cells.  
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3.2.2 Calibration of YAP1-Dependent TEAD Luciferase Assay 
 To identify which GEFs and GAPs regulate YAP1-dependent transcription the 
TEAD4-β-galactosidase coupled luciferase system was enlisted to identify the dynamic 
range of YAP1 activity in relevant models. Initial optimization studies of this assay, 
scanned a panel of breast cancer cell lines to determine their transfection efficiency, 
practicality in cell lysing, and whether TEAD dependent transcription required YAP1 
activity. Among a panel of breast cancer cell lines, BT474 and MCF10A cells showed a 
2-fold and 5-fold increase, respectively, in TEAD4 activity after transfection with wild 
type YAP1 for 24 hours (Figure 3-2A). The remaining breast cancer cell lines showed 
little to no response. BT474 were further chosen as the model system, due in part for their 
practicality in being lysed in Passive Lysis Buffer that was supplied by Promega Dual 
Luciferase Reporter kit, as MCF10A were refractory to this procedure. Identifying the 
dynamic range of maximal YAP1-dependent TEAD transcription was then further 
characterized over numerous time points in BT474s. Wild type 3x-Flag tagged YAP1 
WT and 3x-Flag tagged YAP1 S127A, which cannot be regulated by LATS1/2 dependent 
phosphorylation were transiently transfected along with the TEAD4-β-galactosidase and 
Gal4-Reporter constructs into BT474 cells. Subsequently, lysates were collected at 
indicated time points. The maximal difference in TEAD transcriptional activity between 
YAP1 WT and YAP1 S127A, was observed between 15 and 20 hours (Figure 3-2B). To 
ensure maximal dependence on YAP1, assays were conducted on lysates that were 
collected following 18 hours of transfection. To ensure the effects of 3x-Flag tagged 
YAP1 WT were linearly dependent on the amount of DNA transfected, , increasing 
amount of 3x-Flag tagged YAP1 WT were transfected and lysates were collected at 18 
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hours. This produced a linear dose response with an R2 value of .97 (Figure 3-2C). To 
validate that the YAP1-dependent activation of TEAD4-β-galactosidase were dependent 
on RhoA and not Rac1 or Cdc42, constitutive active mutants of all three GTPase were 
transfected separately into BT474 cells with the reporter constructs. This revealed that 
only RhoA significantly increased in TEAD4 transcription (Figure 3-2D). This tightly 
calibrated reporter system was then used to screen 67 GEFs and GAPs for their ability to 
regulated YAP1-dependent transcription. 
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Figure 3-2: Calibration of YAP1-Dependent TEAD4x-Gal Luciferase Activity.  
A. A graph of the fold change activation of TEAD4-Gal coupled 5xGal4-luciferase reporter to 
TK_Renilla reporter, after 18 hour transient overexpression of YAP1 in various breast cancer cell 
lines at high (400,000 cells) and low density (200,000 cells). B. A graph of the fold change 
activation of TEAD-Gal coupled 5xGal4-luciferase to TK_Renilla reporter, after transient 
overexpression of wild-type flag-tagged YAP1, flag-tagged mutant YAP1 (S127A), or control at 
indicated time points post transfection in BT474. C. A graph comparing dose dependent transient 
expression of flag-tagged YAP1 on the activation of TEAD-Gal coupled 5xGal4-luciferase 
normalized by TK_Renilla reporter in BT474s (Upper panel). Expression of flag-tagged proteins 
was detected by immunoblot with the M2 antibody (Bottom Panel). D. A graph measuring the 
activation of TEAD-Gal coupled 5xGal4-luciferase reporter normalized to TK_Renilla reporter 
for transient overexpression of RhoA (Q63L), Rac1 (Q61L), and Cdc42 (Q63L) in BT474. 
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3.2.3 Identification of Rho GEFs & GAPs that Regulate YAP1-Dependent Transcription 
 The effects of heterologous expression of 67 Rho GEFs and GAPs described in 
(177) on the activity of a TEAD4-β-galactosidase coupled luciferase reporter was 
determined. All 67 RhoGEFs and RhoGAPs were ordered based on their impact on the 
activity of the TEAD reporter (average of at least 3 separate experiments of 3 biological 
replicates each) (Figure 3-3A). This revealed that proteins with a DH domain with 
RhoGEF activity were 3 times more likely to activate the TEAD reporter versus proteins 
with a RhoGAP domain. Further, only proteins with a RhoGEF domain stimulated TEAD 
reporter activity over 2-fold (Figure 3-3B). Of these, ArhGEFs1/11/12 (74, 178-180), 
Plekhg6 (158), and Ect2 (181) are reported to stimulate the exchange of nucleotide for 
RhoA. Only, Vav1 (182) and Prex1 (183) are selective for Rac1. ArhGEF2 exhibits 
specificity towards RhoA and Rac1 (184). While Intersectin1 was the only GEF that is 
specific for Cdc42 (185) ( Figure 3-3B). Taken together, RhoGEFs with activity against 
RhoA were the most prevalent and efficacious activators of the TEAD reporter. 
 Conversely, inhibitors of the TEAD reporter, while more likely to encode a 
RhoGAP domain, also comprised many proteins with RhoGEF domains. Of the 13 
proteins that inhibited TEAD activity more than 2-fold (top inhibitors), seven encode a 
GAP domain (STARD8, STARD13, ArhGAP26, ArhGAP8, ArhGAP1, HMHA1 and 
SYDE1), 5 a DH domain (ArhGEF39, ArhGEF16, ArhGEF7, ArhGEF9, ArhGEF25) and 
DOCK6 encodes a DOCK homology region 2 domain. STARD8 and STARD13, which 
are members of the Deleted in Liver Cancer family (DLC), were further validated as 
inhibitors by showing that their transient expression significantly reduced the levels of 
endogenous CTGF transcript (Figure 3-3C). While SYD1, HMA1 and ArhGEF39 have 
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no reported GTPase selectivity; the remaining top inhibitors are all known to act on 
Cdc42 (Figure 3-3B). This is consistent with previous reports that Cdc42 is a significant 
player in HIPPO signaling (174). Interestingly, all of the RhoGAPs identified as top 
inhibitors have been reported to accelerate the GTPase activity of RhoA (162, 186). 
However, amongst the GEFs, that inhibited the TEAD reporter, only ArhGEF25 is 
reported to have exchange activity towards RhoA. Dock6, ArhGEF25, and ArhGEF7 
have GEF activity for Rac1 (Figure 3-3B). Overall, the five top inhibitors with a RhoGEF 
domain have exchange activity for Cdc42 (Figure 3-3B). Four of these also act on Rac1 
and in a single case also on RhoA. Whereas, RhoGAPs with strong inhibitory activity all 
act on RhoA as well as on Cdc42.  
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Figure 3-3: Identification of GEFs and GAPs that Activate or Inhibit YAP1-Dependent 
TEAD Transcription.  
A. A graph measuring the fold activation of a TEAD-Gal coupled 5xGal4-luciferase reporter 
normalized to TK_Renilla in response to the transient overexpression of indicated flag-tagged 
GEF or GAP along with 0.23 µg of flag-tagged YAP1 in BT474 cells. All samples were 
normalized to blank control. B. A heat map showing the relative luciferase activity expressed in a 
YAP1 dependent manner from a TEAD-Gal coupled 5xGal4-luciferase reporter in BT474 cells 
grown under basal conditions (10% FBS), expressing the indicated RhoGEF or RhoGAP versus 
BT474 cell with a control plasmid. In B, every condition represents > 9 biologic replicates. Error 
bars represent Standard Deviation of Mean. P-values * < 0.05; ** < 0.01; *** < 0.001. C. CT 
value of CTGF mRNA transcript was measured by qRT-PCR in MCF7 cells transiently 
overexpressing of flag-tagged SD13 or SD8 compared to empty vector control following a 24-
hour serum starvation and 10% serum treatment for 30 minutes (Upper Panel). Expression of 
flag-tagged proteins was detected by immunoblot with the M2 antibody (Bottom Panel). 
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3.2.4 RGS-RhoGEFs Mediate Signaling from Gα12/13 onto Induction of CTGF by RhoA 
Given the importance of the RGS-RhoGEFs in signaling from lipid mitogens onto 
the activation of RhoA, further investigations focused on their role in transmitting serum 
cues onto the regulation of YAP1/TEAD to control CTGF expression. All three RGS-
RhoGEFs activate RhoA (74, 178-180) through a Dbl homology (DH) domain and 
encode an N-terminal RGS domain that exhibits GAP activity towards Gα12 and/or Gα13 
(68, 187). Factors in serum including lipids such as LPA and thrombin proteases agonize 
G-protein coupled Receptors (GPCR) that recruit and activate the heterotrimeric G-
proteins Gα12 and Gα13 (77, 188). The RGS-RhoGEFs consequently are recruited by the 
activated G-protein at the membrane mainly through interactions with their RGS domain 
(65). This enables a secondary low affinity interaction between Gα13 and the DH domain 
that enhances exchange activity (189, 190) (Figure 3-4A). Induction of CTGF transcript 
levels by serum after 1 hour was significantly lower in MCF7 cells transiently expressing 
the RGS domain of ArhGEF1, which selectively inhibits Gα12 and Gα13 (187), versus 
cells expressing a control plasmid (Figure 3-4B). This is consistent with previous work 
showing that serum strongly requires Gα12 and/or Gα13 to activate YAP1/TEAD (171). 
The significantly reduced levels of CTGF transcript in MC7 cells expressing the Gα13 
(R232E) mutant, which binds to the RGS-RhoGEFs but cannot stimulate their exchange 
activity (67), versus wild-type Gα13 denotes that the RGS-RhoGEFs are required for 
serum induced activation of YAP1/TEAD (Figure 3-4C). The modest induction of CTGF 
by the Gα13 (R232E) mutant may result from Gα13 (R232E) affecting the RGS-RhoGEFs 
independently of direct stimulation of exchange activity, e.g. recruitment to the 
membrane (191). Together, the activation of RhoA by Gα12 and Gα13 through the RGS-
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RhoGEFs is found to constitute a primary pathway for the activation of YAP1 dependent 
transcription of CTGF by serum. 
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Figure 3-4: Gα13 Signaling through the RGS-RhoGEFs Induces CTGF Transcript Levels.  
A. Model for the activation of Gα12/13 heterotrimeric g-proteins and their consequent bi-
directional signaling with ArhGEF1, 11, 12. B. CT value of CTGF mRNA transcript was 
measured by qRT-PCR in MCF7 cells transiently expressing either the RGS domain of ArhGEF1 
or a control plasmid. MCF7 cells were also incubated without serum for 24-hours and then with 
10% FBS (Serum Add Back; S.A.B.) for the indicated times. Relative level of CTGF mRNA fold 
change (ΔΔCT) was then calculated for each sample compared to control expressing MCF7 cells 
at time 0’. Biological replicates side by side. C. CT value of CTGF mRNA transcript was 
measured by qRT-PCR in MCF7 cells transduced by lentivirus for the expression of Flag-tagged 
Gα13 wild-type or the Flag-tagged Gα13 (R232E) mutant, which cannot stimulate exchange 
activity of bound RGS-RhoGEF (Top Graph) Relative level of CTGF mRNA fold change 
(ΔΔCT) was then calculated for each sample compared to control expressing MCF7 cells. 
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Expression of flag-tagged proteins was detected by immunoblot with the M2 antibody (Bottom 
Panel).  
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3.2.5 ArhGEF11 and ArhGEF12 Transmit Gα12/13 Signaling onto the Activation of 
YAP1/TEAD 
While heterologous expression of all of the RGS-RhoGEFs resulted in the YAP1 
dependent activation of the TEAD reporter, the physiologic circumstances for these 
activities are unclear. The lack of induction of the levels of CTGF transcript in cells 
expressing either ArhGEF11 or ArhGEF12 in combination with the exoenzyme C3 
transferase exotoxin (a selective inhibitor of RhoA) confirms that they require RhoA 
activity to activate YAP1 (Figure 3-5A). A more dominant role of ArhGEF12 in this 
pathway, in MCF7 cells, is supported by the ~ 80 % decrease in the levels of CTGF 
transcript following serum treatment of ArhGEF12 silenced cells versus a 50 % decrease 
in cells silenced for ArhGEF11 (Figure 3-5B). While LPA is the most studied agonists 
for GPCRs that couple to Gα12/13, several other factors including Sphingosine-1-
phosphate, thrombin proteases, and calcium activate these GTPases (188, 192). Along 
these lines, the induction of CTGF transcript levels in cells treated with LPA or with a 
peptide agonists for the Protease Activated Receptor (PAR) 2 but not a peptide agonist 
for PAR1 were significantly less in cells silenced for ArhGEF12 expression versus 
control cells (Figure 3-5D). Similarly, induction of CTGF transcript levels upon 
expression of Gα12 (Figure 3-5E) or Gα13 (Figure 3-5F) was diminished by over 80 % if 
the cells were also silenced for ArhGEF12. Whereas, cells silenced for ArhGEF11 
reduced CTGF transcription by 50% after LPA treatment, versus control cells, but 
retained similar levels of CTGF transcription after treatment with the peptide agonists for 
the PAR1 or PAR2 receptors (Figure 3-5G). Upon stable expression of Gα12 (Figure 3-
5H) or Gα13 (Figure 3-5I), knockdown of ArhGEF11, like ArhGEF12, showed an ~80% 
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reduction in CTGF transcript levels. ArhGEF12 therefore appears to mediate the majority 
of signaling onto YAP1 activation that is initiated by the LPA and PAR receptors versus 
ArhGEFF11. Consistent with these data, cells silenced for ArhGEF12 (Figure 3-5K) 
expression showed profoundly greater losses of actin fibers and a rounded morphology 
versus cells silenced for ArhGEF11 (Figure 3-5L). 
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Figure 3-5: ARHGEF11 and ARHGEF12 are Essential for the Induction of CTGF by Gα12 
and Gα13 Dependent Signaling.  
A. CT value of CTGF mRNA transcript was measured by qRT-PCR in MCF7 cells that 
transiently expressed Flag-Tagged tagged ArhGEF11 or Flag-tagged ArhGEF12 in combination 
with transient expression of C3 exotoxin plasmid or a control (Top Graph). Relative level of 
CTGF mRNA fold change (ΔΔCT) was then calculated for each sample compared to control 
expressing MCF7 cells. Immunoblot with antibodies against Flag-tag (M2) or GAPDH (bottom 
panels) B. CT value of CTGF mRNA transcript was measured by qRT-PCR in MCF7 cells stably 
silenced through lenti viral transduction of shScramble, shArhGEF11 or shArhGEF12 and subject 
to 24 hour serum starvation followed with a 30 minute treatment of 10% FBS (S.A.B.) (Top 
Graph). Relative level of CTGF mRNA fold change (ΔΔCT) was then calculated for each sample 
compared to control expressing serum starved MCF7 cells. The relative levels of YAP1, 
ArhGEF11 (ARG11), ArhGEF12 (ARG12) and GAPDH were detected by immunoblot (Bottom 
Panels) C. Immunoblot of endogenous protein expression in MCF7 cells knocked down for 
ArhGEF1, ArhGEF11, and ArhGEF12 using lenti viral delivered shRNA. D. CT value of CTGF 
mRNA transcript was measured by qRT-PCR in MCF7 cells stably silenced through lenti viral 
transduction of shRNA for ArhGEF12 (shAG12) or with control shRNA and serum starved for 
24 hours before incubation with agonists of the LPA (1uM), PAR1 (TFLLR-NH2: 10 uM) or 
PAR2 receptors (2-furoyl-LIGRLO-NH2 5 uM). Relative level of CTGF mRNA fold change 
(ΔΔCT) was then calculated for each sample compared to serum starved MCF7 cells not 
stimulated by agonist. (3 Biological Replicates) E. CT value of CTGF mRNA transcript was 
measured by qRT-PCR in MCF7 upon lenti viral transduced stable expression of Flag-tagged 
Gα12 versus Flag control, between cells stable silenced for ArhGEF12 (shARG12) or a control 
shRNA using lentiviral transduction. Relative level of CTGF mRNA fold change (ΔΔCT) was 
then calculated for each sample compared to serum starved MCF7 cells not stimulated by agonist. 
(3 Biological Replicates) F. CT value of CTGF mRNA transcript was measured by qRT-PCR in 
MCF7 upon lentiviral transduced stable expression of Flag-tagged Gα13 versus Flag control, 
between cells stable silenced for ArhGEF12 (shARG12) or a control shRNA using lentiviral 
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transduction. Relative level of CTGF mRNA fold change (ΔΔCT) was then calculated for each 
sample compared to serum starved MCF7 cells not stimulated by agonist. (2 Biological 
Replicates G. CT value of CTGF mRNA transcript was measured by qRT-PCR in MCF7 cells 
silenced for ArhGEF11 (shAG11) or control shRNA, using lentiviral transduction, and serum 
starved for 24 hours before incubation with agonists of the LPA (1uM), PAR1 (TFLLR-NH2: 10 
uM) or PAR2 receptors (2-furoyl-LIGRLO-NH2 5 uM). (3 Biological Replicates) H. CT value of 
CTGF mRNA transcript was measured by qRT-PCR in MCF7 cells following stable by lentiviral 
transduction expression of Flag-tagged Gα12 (versus expression of Flag control between cells 
infected with sahAG11 or control shRNA. (3 Biological Replicates). I. CT value of CTGF 
mRNA transcript was measured by qRT-PCR in MCF7 cells following stable by lentiviral 
transduction expression of flag-tagged Gα13 (Right Panel) versus expression of flag control 
between cells infected with sahAG11 or control shRNA. (3 Biological Replicates). J. 
Immunoblot of endogenous expression of RGS-RhoGEFs and Flag-tagged Gα13 (M2 antibody) in 
MCF7 cells stably expression Gα13, Gα13 QL, or control cells in combination with stably silenced 
RGS-RhoGEF. K. Brightfield imaging of MCF7 cells stably silenced for ArhGEF12 (Top Panel) 
through lentiviral delivery of shRNA. Stably silenced cells MCF7 were serum starved and treated 
with 10% serum for 30 minutes then fixed and immunostained for ArhGEF12 and YAP1 merged 
with nuclei stained with Hoechst dye (Bottom Panel). L. Brightfield imaging of MCF7 cells 
stably silenced for ArhGEF11 (Top Panel) through lentiviral mediated delivery of shRNA. Stably 
silenced MCF7 cells were serum starved and treated with 10% serum for 30 minutes then fixed 
and immunostained for ArhGEF11 and YAP1 then merged with nuclei stained with Hoechst dye 
(Bottom Panel). 
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3.2.6 ArhGEF1 Dampens Gα12/13 Signaling Initiated by Mitogens in Serum 
The role of ArhGEF1 in transducing the effects of serum onto YAP1/TEAD 
activation was compared to those of ArhGEF11 and ArhGEF12. Surprisingly, MCF7 
cells stably silenced for the expression of ArhGEF1 had elevated levels of CTGF at 2, 4 
and 5 hours in comparison to control cells following the add back of serum (Figure 3-
6A). This effect likely requires RhoA activation as the expression of ArhGEF1 with C3-
toxin had similar levels of CTGF as control cells (Figure 3-6B). Given the disparity of 
these two results and with the original observation that ArhGEF1 overexpression 
enhances TEAD4 transcriptional activity, the impact of ArhGEF1 expression on the 
induction of CTGF transcript levels by serum was determined. Similar to the candidate 
expression screen, MCF7 cells stably expressing ArhGEF1 grown in the absence of 
serum for 24-hours produced a 2-fold induction of CTGF transcript versus control MCF7 
cells (Figure 3-6C). Conversely, significantly lower levels of CTGF transcript was 
observed in cells following a 30 minute exposure to media with 10 % serum versus 
control (Figure 3-6C). The effects of ArhGEF1 loss on CTGF transcript levels were also 
highly impacted by cell density. ArhGEF1 silenced MCF7 cells grown at low density or 
at very high density exhibited similar or only modestly higher levels of CTGF transcript 
versus control MCF7 cells grown to a corresponding density after serum treatment 
(Figure 3-6D). These data highlight the ability of ArhGEF1 to  limit serum induction of 
CTGF transcription in a manner that is highly sensitive to RhoA activity and cell density.  
Given our findings that TEAD elements are primarily mediating the activation of 
the CTGF promoter by RhoA, the role of YAP1 in mediating the affects of ArhGEF1 
onto the induction of CTGF was investigated. Consistent with YAP1 activation, 
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immunoblot analysis revealed that the ratio of S-127 phosphorylated YAP1 over total 
YAP1 decreased in lysates from ArhGEF1 silenced MCF7 cells following a serum 
starvation serum, add back treatment versus MCF7 cells infected with a control shRNA 
(Figure 3-6E). This was further confirmed by the enhanced distribution of YAP1 in the 
nucleus of cells (grown to intermediate density) with the highest degree of ArhGEF1 
silencing (Figure 3-6F), compared to its exclusion in control MCF7 cells. This effect was 
not evident in cells at low density where YAP1 almost exclusively localized in the 
nucleus (Figure 3-6G), nor in cells grown at high density where YAP1 was 
overwhelmingly localized in the cytosol (Figure 3-6H). A requirement for YAP1 
activation for enhanced induction of CTGF transcript by serum in MCF7 cells silenced 
for ArhGEF1, is strongly indicated by loss of this effect in cells simultaneously silenced 
for YAP1 by as little as 50 % (Figure 3-6I). Overall, these results demonstrate that 
ArhGEF1 limits the effects of serum signaling onto CTGF transcription by preventing 
YAP1 activation in cells that are in the processes of forming intercellular contacts 
(intermediate density).  
The knockdown of ArhGEF1 enhances serum induced YAP1 dependent CTGF 
transcription; the role of how actin dynamics regulate this process was further 
investigated. By increasing the multiplicity of infection of MCF7 cells with lenti virus 
containing shRNA against ArhGEF1, moderate (50-60 %), high (80-90 %) and complete 
(undetectable) loss of protein expression of ArhGEF1 was achieved, as measured by 
western blot. While cells with high and complete levels of ArhGEF1 silencing showed 
similar levels of induction of CTGF following treatment with serum, complete silencing 
resulted in significantly higher levels of CTGF transcript (albeit much lower than in cells 
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after serum-add back) under serum starved conditions versus cells with even 90 % loss of 
ArhGEF1 expression (Figure 3-7A). Cells with complete silencing also showed an 
extreme flattened morphology (Figure 3-7B) and a drastic increase in filamentous actin 
(Figure 3-7C) versus cells with high or moderate levels of ArhGEF1 silencing. Because a 
certain level of filamentous actin is required for YAP1 to enter the nucleus (142, 170), a 
partial loss of ArhGEF1 is proposed to increase the formation of f-actin and thereby 
sensitize cells to the activation of YAP1 by serum. Interestingly an almost  complete loss 
ArhGEF1 results in a dramatic shift in morphology resulting in YAP1 activation in cells 
grown in the absence of serum for 24-hours. These data indicate that only modest levels 
of ArhGEF1 are needed to maintain control of YAP1 nuclear translocation. 
 The dominant role of ArhGEF1 in blocking serum signaling onto YAP1 
activation may be explained by its RGS domain accelerating the GTPase activity of Gα12 
and/or Gα13 (187, 189). However, it is not clear whether ArhGEF1 in cells functions 
selectively in response to different receptors that couple to Gα12/13. It is also not clear 
whether ArhGEF1 functions similarly towards Gα12 and Gα13 in cells. Consistent with 
results from serum, the induction of CTGF transcript in MCF7 cells stably silenced for 
ArhGEF1 was significantly greater after treatment with LPA or a peptide that specifically 
activates PAR2 versus cells that express normal levels of ArhGEF1. However, loss of 
ArhGEF1 expression had no impact on the induction of CTGF by a peptide that only 
activates PAR1 (Figure 3-8A). Further, cells silenced for ArhGEF1 exhibited an over 5-
fold increase in the levels of CTGF transcript following transient expression of Gα13 but 
reduced CTGF induction in cells expressing Gα12 when compared to non-silenced cells 
expressing these respective GTPases. Similarly, ArhGEF1 silencing suppressed the 
 80 
induction of CTGF by the expression of the GTPase deficient Gα13 mutant Gα13 (QL) 
(Figure 3-8B). ArhGEF1 in cells therefore appears to mainly function as a GAP against 
Gα13 but not Gα12 following receptor activation. Further, if ArhGEF1 cannot act as a 
GAP, it then appears to be stimulated by Gα12/13 to transmit signaling that activates YAP1 
dependent transcription of CTGF, as evident when silenced in a Gα13QL stable 
overexpression background. 
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Figure 3-6: Loss of ARHGEF1 Expression Activates YAP1 in Cells After Prolonged Serum 
Treatment.  
A. CT value of CTGF mRNA transcript was measured by qRT-PCR in MCF7 cells stably 
silenced for ArhGEF1 (shAG1) or treated with shRNA control following serum starvation and 
then add back of media with 10 % FBS (S.A.B.) for the indicated times. Relative level of CTGF 
mRNA fold change (ΔΔCT) was then calculated for each sample compared to control expressing, 
serum starved MCF7 cells (Top Graph)(Replicates in Fig. S4A, B). Levels of ArhGEF1 and 
GAPDH were measured by immunoblot (Bottom Panel) B. CT value of CTGF mRNA transcript 
was measured by qRT-PCR in MCF7 cells expressing transient overexpression of Flag-tagged 
ArhGEF1 in MCF7 compared to control in combination with RhoA specific inhibitor C3 (Top 
Panel). Immunoblot of overexpressed Flag-tagged ArhGEF1 by M2 antibody. C. CT value of 
CTGF mRNA transcript was measured by qRT-PCR in MCF7 cells expressing myc-control or 
myc-ArhGEF1 after 24 hours serum starvation followed by treatment for 30 minutes with media 
alone or media with 10 % FBS (S.A.B.). Relative level of CTGF mRNA fold change (ΔΔCT) was 
then calculated for each sample compared to control serum-starved MCF7 cells. Furthermore, 
myc-ArhGEF1 that was subject to 10% FBS (S.A.B.), ΔΔCT, was normalized to control MCF7 
cells subject to 10% FBS (S.A.B) ΔΔCT. D. Relative levels of CTGF transcript (measured by 
qRTPCR) in sparse cells stably silenced for ArhGEF1 (ARG1) or treated with shRNA control 
following serum starvation and then add back of media with 10 % FBS for 30 minutes. E. 
Relative levels of CTGF transcript (measured by qRTPCR) in confluent cells stably silenced for 
ArhGEF1 (ARG1) or treated with shRNA control following serum starvation and then add back 
of media with 10 % FBS for 30 minutes. F Levels of ArhGEF1, phospho-YAP1, total YAP1 and 
GAPDH were measured by immunoblot from lysates prepared from MCF7 silenced for ArhGEF1 
following a 24-hour serum starvation and subsequent treatment for 30 min with media or media 
with 10% FBS (S.A.B.). G. MCF7 cells infected with shAG1 were serum starved and then fixed 
and immunostained for ArhGEF1 (Top Panel) and YAP1 (Middle Panel) merge with nuclei 
stained with Hoechst dye (Bottom Panel). H. MCF7 genetically silenced for ArhGEF1 through 
lentiviral delivered shRNA were plated at low density and were serum starved (Top panel) or 
serum starved and treated with 10% FBS for 30 minutes (Bottom Panel) then fixed and 
immunostained for ArhGEF1, YAP1, and Hoechst dye. I. MCF7 genetically silenced for 
ArhGEF1 through lentiviral delivered shRNA were plated at high density and were serum starved 
(Top panel) or serum starved and treated with 10% FBS for 30 minutes (Bottom Panel) then fixed 
and immunostained for ArhGEF1, YAP1, and Hoechst dye. J. CT value of CTGF mRNA 
transcript was measured by qRT-PCR in MCF7 cells stably silenced for ArhGEF1 or YAP1 alone 
or in combination that were then serum starved before being treated with media alone or media 
containing 10 % FBS (S.A.B.). Relative level of CTGF mRNA fold change (ΔΔCT) was then 
calculated for each sample compared to control serum-starved MCF7 cells. (Top Panel). The 
levels of ArhGEF1 (AG1), YAP1 and GAPDH were measured by immunoblot (Bottom Panels). 
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Figure 3-7: Complete Loss of ArhGEF1 Expression Induces YAP1 Activation in Serum 
Starved Cells that also Exhibit a Dramatic Increase in F-Actin Fibers and Cell Flattening.  
A. CT value of CTGF mRNA transcript was measured by qRT-PCR in MCF7  cells with 
complete, high and moderate stable silencing of ArhGEF1 (AG1) MCF7 cells that were starved 
of serum before being treated for 30 min with media alone or media with 10% FBS (S.A.B.). 
Relative level of CTGF mRNA fold change (ΔΔCT) was then calculated for each sample 
compared to control expressing, serum starved MCF7 cells (Top Graph). ArhGEF1 (AG1) and 
GAPDH levels were measured by immunoblot (Bottom Panel). B. Brightfield images of cells 
from (A). C. Cells with differential stable silencing of AG1 after serum starvation and treatment 
with media alone or media with 10 % FBS (S.A.B.) were fixed and immunostained for ArhGEF1 
(Left Panel) and phalloidin to visualize Actin (Middle Panel) and merged image with Nuclei 
stained with Hoechst (Right Panel).  
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Figure 3-8: ArhGEF1 Selectively Inhibits Signaling from Gα13 and Transmits Signaling 
from Gα12.  
A. CT value of CTGF mRNA transcript was measured by qRT-PCR in MCF7 cells stably 
silenced for ArhGEF1 or control that were serum starved before a 30 minute treatment with 
vehicle or agonists against the LPA (1uM), PAR1 (TFLLR-NH2: 10 uM) or PAR2 receptors (2-
furoyl-LIGRLO-NH2 5 uM). Relative level of CTGF mRNA fold change (ΔΔCT) was then 
calculated for each sample compared to control expressing, serum starved MCF7 cells. (3 
Biological Replicates) B. CT value of CTGF mRNA transcript was measured by qRT-PCR in 
MCF7 cells stably expressing Flag-tagged Gα12, Flag-tagged wild-type Gα13 or a Flag-tagged 
mutant Gα13 (QL) in combination with shRNA against ArhGEF1 or shScramble. Relative level of 
CTGF mRNA fold change (ΔΔCT) was then calculated for each sample compared to control 
expressing, serum starved MCF7 cells. Fold increase was further calculated by subtracting the 
ΔΔCT of the shScramble expressing vector blank control from those samples expressing the Gα 
subunit.  
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3.2.7 Model of RGS-RhoGEFs Regulation of YAP1 
The requirements for ArhGEF11 and ArhGEF12 for the induction of CTGF by 
serum in a background of low ArhGEF1 activity were determined. The enhanced 
induction of CTGF following serum addition in MCF7 cells stably knocked down for 
ArhGEF1 expression was not evident if these cells were also silenced for expression of 
either ArhGEG11 or ArhGEF12 (Figure 3-9A). This further confirms that ArhGEF11 and 
ArhGEF12 both transmit signaling from Gα13. It also indicates an essential non-
redundant role for each exchange factor in serum induced Gα12/13 to RhoA signaling. 
Overall, a model is proposed whereby cells under low pro-proliferation stimulation 
maximize Gα13 signaling by promoting ArhGEF1 to have low GAP activity and to 
primarily function along with ArhGEF11 and ArhGEF12 to transmit signaling onto 
RhoA. This also seems to be the case during an Early Serum Response. However, in cells 
experiencing prolonged exposure to serum, the GAP activity of ArhGEF1 for Gα13 
becomes dominant and this is essential for limiting the ability of serum to further 
stimulate RhoA and in turn YAP1 dependent transcription (Figure 3-9B).  
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Figure 3-9: Requirements for ArhGEF11 and ArhGEF12 for the Induction of CTGF by 
Serum in Cells with Reduced ArhGEF1.  
A. CT value of CTGF mRNA transcript was measured by qRT-PCR in MCF7 cells stably 
silenced for ArhGEF11 or ArhGEF12 alone or in combination with silencing of ArhGEF1 and 
were serum starved and then treated for 30 min with media or media containing 10 % FBS 
(S.A.B.). Relative level of CTGF mRNA fold change (ΔΔCT) was then calculated for each 
sample compared to control expressing, serum starved MCF7 cells (Top Graph).  The levels of 
total YAP, GAPDH, ArhGEF1 (AG1), ArhGEF11 (AG11) and ArhGEF12 (AG12) were 
measured by immunoblot (Bottom panels) B. A model for the roles of ArhGEFs1/11/12 in the 
Early versus Late Serum Response onto the regulation of RhoA/Actin and YAP1/TEAD/CTGF. 
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3.3 DISCUSSION 
3.3.1 Contributions of GEFs and GAPs to the Regulation YAP1  
Defining how a sub-fraction of RhoGEFs and RhoGAPs regulate TEAD mediated 
transcription adds insight to their previously described functions. For instance, ArhGEF7 
(aka β-PIX), has been shown to couple LATS1/2 to the phosphorylation of YAP1 and 
TAZ, to promote their exclusion from the nucleus through a mechanisms that is 
independent of its GEF domain (163). The ability of β-PIX to inhibit YAP1/TEAD 
dependent transcription upon its overexpression, functionally validated its role in 
mediating LATS1/2 dependent exclusion of YAP1 from the nucleus (163). Whereas, 
ArhGEF5 stimulation of YAP1/TEAD activity may explain its known functions in 
enhancing the proliferation and the malignant properties of breast (193) and lung (194) 
cancer cells. Interestingly, two of the best YAP1/TEAD activators, Ect2 (181) and 
PLEKHG6 (158) have key roles in cytokinesis, a process that is mediated by YAP1, 
independent of its transcriptional functionality (195). This would suggest that RhoA 
activation during cytokinesis also contributes to YAP1/TEAD dependent transcription. 
Alternatively, ArhGAP18 promotes actinomyosin-mediated tissue tension, as an effector 
of YAP1 (175), which is congruent with its inhibition of TEAD shown here and the well-
established role of tension in activating YAP1. Along these lines of cytoskeleton 
regulation of YAP1, the cell rounding induced by STARD13 and DLC1 (175) is 
consistent with their ability to reduce both YAP1-dependent TEAD transcription and 
serum induced CTGF transcription. Conversely, GEFH1/ArhGEF2 is reported to inhibit 
YAP1 activity through activation of RhoB (196), whereas it strongly activated TEAD 
dependent transcription. This may be due to differences among the cellular backgrounds 
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or it may suggest, like ArhGEF1, ArhGEF2 can exhibit context dependent effects on 
YAP1. 
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3.3.2 RGS-RhoGEFs are Integral to Modulating the Signaling Flux of the Serum 
Response Network  
The RGS-RhoGEFs are integral to mediating the serum response network, 
through the regulation of Gα12/13 activation of RhoA induced stress fiber formation. The 
induction of stress fibers by RhoA in response to the activation of the serum response 
network, has been classically defined to promote the transcription of “immediate early” 
genes, such as Cyclin D1 and cFOS, inducing cell growth. However the relative 
physiological requirement of the RGS-RhoGEFs in this process have largely not been 
defined. Each member of the RGS-RhoGEFs has both a structural GAP domain and GEF 
domain for Gα12/13 and RhoA, respectively. However, in vitro data would suggest that 
ArhGEF1 has the only functional GAP domain of the family, increasing the GTPase 
activity of Gα12/13 when bound, whereas ArhGEF11 and ArhGEF12 cannot (99). 
Identified here using CTGF transcription as a primary readout, the RGS-RhoGEFs 
integrate external to internal signaling to regulate the serum response pathway. 
ArhGEF12, and to a lesser extent ArhGEF11, function to solely transmit signaling onto 
RhoA. Conversely, ArhGEF1 is a bi-directional switch, capable of mediating flux 
through the pathway. For example, ArhGEF1 transmits signaling from Gα12/13 to GEF 
RhoA. However, in environments where growth is unwarranted, as in excessive 
signaling, ArhGEF1 function switches to GAP Gα13 turning “off” the cascade. How these 
environments switch ArhGEF1 function is unknown, however recent studies highlight it 
is regulated by post-translational modifications. One study reveals that serine-330 is 
phosphorylated by an unknown kinase and that phosphorylation event increases its GEF 
activity (197). Further analysis of the ArhGEF1 amino acid sequence reveals consensus 
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LATS1/2 phosphorylation sites that fall within its DH/PH domain. These sites offer a 
potential regulatory mechanism in the times of high LATS1/2 activity that may inactivate 
its GEF function and prevent subsequent RhoA activity. The requirement of the RGS-
RhoGEFs in regulating the serum response network highlights the importance of GEFs 
and GAPs in mediating GTPase activity and the role they play in maintaining cellular 
homeostasis. 
Recently the activation of the serum response network was shown to induce 
YAP1 nuclear translocation, however the mechanism by which the RGS-RhoGEFs 
contribute to YAP1 activity is unclear. ArhGEF11 and ArhGEF12 seem to have non-
redundant roles in regulating YAP1 activity, as the loss of either one prevents serum 
induced CTGF transcription with ArhGEF12 seemingly more potent. Their non-
redundant roles in contributing to serum induced CTGF transcription may be a result of 
their individual requirements for the regulation of actin dynamics. Knockdown of 
ArhGEF11 shows no distinguishable cellular morphological difference compared to wild-
type cells, whereas the knockdown of ArhGEF12 promotes cellular rounding. This 
rounding phenotype suggests that there is a global loss in RhoA dependent stress fiber 
formation, a required event for YAP1 nuclear translocation. The loss in actin as measured 
by phalloidin staining, may contribute to YAP1 degradation through the release of 
Angiomotin from filamentous actin and enhancing its associate with AIP4. This complex 
is well established to contribute to the ubiquitin mediated degradation of YAP1, and 
offers a potential mechanism to how ArhGEF12 may regulate YAP1 activity (124). Loss 
of ArhGEF1 promotes a sever actin phenotype, which could lead to the sequestration of 
Angiomotin on actin filaments, thereby uncoupling it from AIP4-dependent 
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ubiquitination and degradation of YAP1. This predicted mechanism would explain the 
hyper-induction of CTGF transcription in response to serum in MCF7 cells genetically 
inactivated for ArhGEF1. However, the mechanism by which ArhGEF11 loss contributes 
to YAP1 degradation is still up for speculation. These data suggest that Gα13 is the 
primary driver of CTGF transcription in response to serum and the cyclic regulation of 
Gα13 GDP/GTP cycle is important for YAP1 activity.  
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3.3.3 Biological Relevance of Gα13 GDP/GTP Cycle 
Serum signaling contains many growth factors and the ability of a cell to turn 
those growth-activating signals into precise transcriptional outputs is a coordinated 
process that is checked at many regulatory levels. Evidence suggests that prolonged 
signaling is not beneficial for cells. For instance, overexpression of a constitutive active 
RAS in a p53 wild type background creates a situation where excess MAP kinase 
signaling induces cellular senescence (198). Further evidence also suggests that chronic 
mitogenic signaling in the presence of activated RB pathway leads to an increase in 
Reactive Oxygen Species (ROS) and induces cellular senescence, rather than propagating 
growth (199). These “fail-safe” mechanisms are in place to prevent unwarranted cell 
growth and are often circumvented by cancer cells. 
ArhGEF1, as suggested by this data, is a temporal regulator of the serum response 
network by maintaining proper down regulation of Gα13. Until this study, the intracellular 
relevance of the cyclic regulation of Gα13, by ArhGEF1 was not well understood. 
Knockout of Gα13 but not Gα12 is embryonic lethal in mice demonstrating the 
requirement for Gα13 activity for survival and growth (200). Evidence would suggest that 
the cyclic regulation of the GTPases is a “fail-safe” mechanism to prevent excess growth 
signaling from propagating unwanted growth. As shown in this work, the loss of 
ArhGEF1 promotes the dephosphorylation, and nuclear accumulation of YAP1 leading to 
an increase in CTGF transcription in response to serum. Components of serum and an 
increase in actin stress fibers are bona fide regulators of YAP1 transcriptional activity, 
which is presumed to invoke a pro-growth phenotype That explains why elevated YAP1 
activity has been found to drive a variety of cancers. The remaining work in this 
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dissertation looks to address whether or not activated YAP1 signaling induced by the 
chronic activation of Gα13 promotes cellular growth or does the chronic activation engage 
senescence pathways, as described above, to promote  a “fail-safe” mechanism 
preventing unwarranted growth.  
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CHAPTER 4. ARHGEF1 CYCLIC REGULATION OF Gα13 IS ESSENTIAL FOR 
MAINTAINING CELLULAR HOMEOSTASIS 
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4.1 INTRODUCTION 
Cellular proliferation is a tightly coordinated process that is instigated by external 
biochemical and biophysical cues that are transduced onto the induction of transcriptional 
programs that eventually bring about mitosis. A key element in this process is the  
dynamic reorganization of the actin cytoskeleton. Actin dynamics are dictated by the Rho 
family of GTPase that are in turn spatially and temporally regulated by GEFs and GAPs. 
Recently, RhoA dependent actin stress fiber formation was shown to be required for the 
translocation YAP1 into the nucleus (142). This is essential for  YAP1 to bind and co-
activate multiple transcription factors, most notably TEAD1-4 (134); this results in levels 
of   transcription of pro-growth and survival genes that are necessary to effect cellular 
state change. Here, the roles of the RGS-RhoGEFs identified in experiments described in 
Chapter 3 to mediate serum regulation of YAP1 activity in cell growth and survival were 
investigated. 
YAP1/TEAD transcriptional activity is typically associated with pro-growth or 
pro-survival transcriptional programs. Overexpression of YAP1 in most cases leads to 
aberrant cell growth in culture systems and animal models (169, 201, 202). YAP1 
expression is also elevated in a variety of cancers (203). In chapter 3, ArhGEF12 and 
ArhGEF11  were identified to be critical for transmitting Gα12/13 activity onto YAP1 
mediated transcription. ArhGEF1 was also found to be the primary GAP for Gα13 during 
“Late Stage” serum response activity. This activity was further found to be sufficient to 
prevent RhoA and YAP1 activation. However, the impact of this regulation on cell 
growth and survival is not understood. 
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4.2 RESULTS 
4.2.1 RGS-RhoGEFs Affects on MAPK Signaling 
 
Gα12/13 are well-established activators of YAP1-dependent transcription and 
MAPK cascades. Both Gα12 and Gα13 promote the activation of ERK1/2 and JNK1/2 via 
the activation of RAS and RhoA (115, 204-206). However, Gα12 can under some 
circumstances inhibit both ERK1/2 and JNK1/2 activity (116). Consistently, individually, 
the RGS-RhoGEF have been found to promote MAPK signaling (115). However, it is 
unclear how all three RGS-RhoGEFs work coordinately to integrate Gα12/13 signaling 
onto the  regulation of RhoA.   
The dephosphorylation of YAP1 at serine 127 is  a surrogate measure for cells in 
growth inducing environments, e.g. cells that lack contacts with neighboring epithelial 
cells. (Figure 4-1A). As observed in Chapter 3, knockdown of ArhGEF1 in MCF7 cells 
also induces YAP1 dephosphorylation, but the affects on growth are unknown. The 
Serum Response Network is intricately linked to the activation of the MAPK pathway 
and in the regulation of HIPPO signaling.  Understanding the role ArhGEF1 plays in this 
network may therefore provide insight into its ability to coordinately regulate cell growth 
via its control of MAPK and  YAP1 activities. To more globally define the importance of 
ArhGEF1 in cell growth control signaling, the impact of silencing ArhGEF1 on the total 
and phospho-levels of proteins represented in the reverse phase protein analysis (RPPA) 
was determined. For this purpose,   MCF7 cells that were stably silenced for ArhGEF1 
were subjected to serum starvation for 24 hours and treated with 10% FBS for 30 
minutes. Cell lysates were then collected and sent for analysis by the  Reverse Phase 
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Protein Array (RPPA) core at the MD Anderson Cancer Center. RPPA utilizes nearly 350 
different antibodies against different proteins or phospho-proteins to measure differences 
in their  relative levels. Under serum add back conditions, MCF7 cells in which  
ArhGEF1 was silenced showed  statistically significant increase in phosphorylation of 
threonine and tyrosine residues that are surrogate measures for the activation of  MAPK, 
ERK, JNK, and p38 versus control MCF7 cells (Figure 4-1B). Levels of NRAS and 
MEK1 as well as the levels of phosphorylated cRAF (S338) and bRAF (S445), were 
significantly greater in ArhGEF1 silenced MCF7 cells (Figure 4-1B). Independent 
validation showed that serum induced ERK1/2 and JNK1/2 phosphorylation to a greater 
extent in ArhGEF1 silenced MCF7 cells versus cells expressing shScramble. Specifically, 
pERK1/2 levels were 3-fold higher at 120 minutes in ArhGEF1 silenced cells and at 300 
minutes unlike control cells where p-ERK1/2 was not detectable (Figure 4-1C). 
Conversely, MCF7 cells silenced for ArhGEF12 showed a 70% reduction in ERK1/2 
phosphorylation when treated with serum after 30 minutes. However, no discernable 
effects on the levels of phospho-ERK1/2 were seen when ArhGEF11 was knocked down 
(Figure 4-2A & 2B). Similar to results from the RPPA, ArhGEF1 knockdown in MCF7 
cells enhanced JNK1 but not JNK2 phosphorylation at threonine 183 and tyrosine 185 
(Figure 4-1D). The downstream target of JNK, cJUN, also had statistically greater levels 
of phosphorylation at serine 73, validating that JNK1/2 activity was elevated (Figure 4-
1B). Interestingly, the effects of silencing the RGS-RhoGEFs on YAP1-dependent 
activity, were  mirrored by  the effects observed for MAPK signaling. These data 
highlight the importance of the RGS-RhoGEFs in the Serum Response Network for the 
activation of both YAP1 and MAPK cascades. 
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Figure 4-1: ArhGEF1 is Essential for Maintaining Serum Response Activation of CTGF 
and Early Phase MAPK Activity. 
A. CT value of CTGF mRNA transcript was measured by qRT-PCR in MDA-MB-231 cells that 
genetically inactivated for ArhGEF1 expression using shRNA (AG1), and grown in 3D Matrigel 
for 2 days. Cells were then subjected to a 24 hours serum starvation and treated with 10% FBS 
for 30 minutes (Top Panel). Relative level of CTGF mRNA fold change (ΔΔCT) was then 
calculated for each sample compared to MDA-MB-231 transduced with the shRNA control. 
Immunoblot of total protein with either anti-ArhGEF1 (AG1) or anti-GAPDH (Bottom Panel). B. 
Relative changes in protein expression between MCF7 cells genetically silenced for ArhGEF1 by 
lenti viral transduction compared to shRNA control as measured by Reverse Phase Protein Array 
(RPPA). Samples were serum starved for 24 hours and treated for 30 minutes with serum. Colors: 
Black indicates protein was not present in array, Purple indicates no significance between 
shARG1 and control, Red indicates significant decrease (P <. 05) in expression, and Green 
indicates significant increase (P < .05) in expression. C. MCF7 cells were transduced with either 
a lentiviral shRNA directed towards ArhGEF1 or a control. MCF7 cells were serum starved for 
24 hours and 10% FBS was added for the indicated time. The levels of total ArhGEF1 (ARG1), 
pERK, ERK and GAPDH were measured by immunoblot D. MCF7 cells were transduced with 
either a lentiviral shRNA directed towards ArhGEF1 or a control. MCF7 cells were serum starved 
for 24 hours and 10% FBS was added for 30 minutes. The levels of total ArhGEF1 (ARG1), 
pJNK, GAPDH were measured by immunoblot. 
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Figure 4-2: ArhGEF12 is Essential for ERK1/2 Activity.  
A. MCF7 cells were transduced with either a lentiviral shRNA directed towards ArhGEF12 
(shARG12) or a control. MCF7 cells were serum starved for 24 hours and 10% FBS was added 
for the indicated time. The levels of total ArhGEF12 (ARG12), pERK, ERK and GAPDH were 
measured by immunoblot. B. MCF7 cells were transduced with either a lentiviral shRNA directed 
towards ArhGEF11 (shARG11) or a control. MCF7 cells were serum starved for 24 hours and 
10% FBS was added for 30 minutes. The levels of total ArhGEF11 (ARG11), pERK, ERK and 
GAPDH were measured by immunoblot. 
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4.2.2 Cell Growth Requires the RGS-RhoGEFs 
 
Activation of ERK1/2, and YAP1 are strongly associated with committing a cell 
to proliferate (203). This study finds that the RGS-RhoGEFs are critical mediators of 
serum activation of both YAP1 and MAPK. Loss of ArhGEF11 or ArhGEF12 was 
therefore expected to reduce the growth of cells in serum as this retards the activation of 
YAP1 and MAPK by the mitogens in serum.  Conversely, the loss of ArhGEF1 was 
anticipated to enhance cell growth especially under serum limiting conditions as its 
presence inhibited the activation of YAP1 and MAPK signaling by serum. In reality, the 
individual knockdown of each RGS-RhoGEF in MCF7 cells resulted in a similar 
inhibition of cell accumulation by ~40% over the course of 3 Days (Figure 4-3A). 
Similarly, the growth in size of colonies of ArhGEF1 silenced MCF7 and MDA-MB-231 
cells in Matrigel over 5 Days was reduced by 35% and 60%, respectively, versus control 
cells (Figure 4-3B). The growth inhibiting effects of silencing ArhGEF1  was 
corroborated by a significant decrease in the reduction of MTT to formazan, a measure of 
mitochondrial respiration, by both ArhGEF1 silenced MCF7 (-50%) and MDA-MB-231 
(-15%) cells (Figure 4-3C). This measure of cell viability was also significantly reduced 
by 20% in MCF7 cells knocked down for ArhGEF12 after 3 Days of growth (Figure 4-
3E). Overexpression of the constitutively active Gα13QL mutant in MCF7 cells also 
reduced growth in 3D by 60% (Figure 4-3F), with a concurrent reduction of MTT to 
formazan when compared to control of ~20% (Figure 4-3G).  These data demonstrate that 
all three RGS-RhoGEFs are required for the growth of multiple breast cancer cells lines 
in both 2D and 3D environments. The unexpected loss of growth in cells in which 
ArhGEF1 was silenced or  Gα13QL was overexpressed, suggests that both hyper-
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activation and hypo-activation of  Gα13 results in a loss of cell growth. Given the strong 
activation of MAPK and YAP1 signaling upon hyper Gα13 activation, the mechanism that 
leads to a loss of growth was perplexing.  The unraveling of this mechanism was 
consequently a major  focus of the work that is presented in this dissertation. 
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Figure 4-3: RGS-RhoGEFs are Required for Cellular Growth.  
A. MCF7 cells stably silenced for the indicated RGS-RhoGEF through lentiviral transduction of 
the shRNA, were plated at 25,000 cells per 6 well plates and trypsinized on the indicated day and 
counted. Samples were done in biological triplicate and averaged together. B. Stereoimages of 
control MCF7 and MCF7 cells genetically inactivated for ArhGEF1 (shARG1) expression using 
shRNA. Pictures taken on Day 1 and Day 5. Colony area is measured in pixels using Adobe 
Photoshop (Left Panel), +/- the standard error (S.E.). Stereoimages of control MDA-MB-231 and 
MDA-MB-231 cells genetically inactivated for ArhGEF1 (shARG1) expression using shRNA. 
Pictures taken on Day1 and Day 4. Colony area is measured in pixels using Adobe Photoshop 
(Right Panel), +/- the standard error (S.E.). C. MCF7 (Left Panel) or MDA-MB-231 (Right 
Panel) cells stably silenced for ArhGEF1 (shAG1) were allowed to grow for 3 Days in a 96-well 
plate. On Day 3 15 uL of 5mg/mL of MTT was added for 4 hours, followed by the addition of 
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100 uL of MTT solvent for 1 hour. Cells were resuspended and absorbance at 570 nm was 
recorded and normalized to control. D. Using a second shRNA directed towards ArhGEF1, cells 
were allowed to grow for 3 Days in a 96-well plate. 15 uL of MTT solvent was added for 4 hours 
followed with MTT solvent for 1 hour. Cells were resuspended and absorbance at 570 nm was 
recorded and normalized to control. E. MCF7 cells stably silenced for ArhGEF11 (shARG11) or 
ArhGEF12 (shARG12) were allowed to grow for 3 Days in a 96-well plate. On Day 3 15 uL of 
5mg/mL of MTT was added for 4 hours, followed by the addition of 100 uL of MTT solvent for 1 
hour. Cells were resuspended and absorbance at 570 nm was recorded and normalized to control. 
F. Stereoimages of control MCF7 and MCF7 cells expressing stable Gα13 QL. Pictures taken on 
Day1 and Day 4, acini area was calculated using pixels in Adobe Photoshop. G. MCF7 cells 
stably expressing Gα13WT or Gα13QL were allowed to grow for 3 Days in a 96-well plate. On 
Day 3 15 uL of 5mg/mL of MTT was added for 4 hours, followed by the addition of 100 uL of 
MTT solvent for 1 hour. Cells were resuspended and absorbance at 570 nm was recorded (Top 
Panel). Immunoblot of 3xFlag-tagged Gα13WT and Gα13QL using M2 antibody (Bottom Panel). 
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4.2.3 Loss of ArhGEF1 Results in Cell Cycle Arrest and a Reduction in Global 
Translation Elongation 
 The induction of transcription of Cyclin D1 is a major pro-growth event that is 
produced upon the activation of the serum response network by mitogenic lipids., 
Accumulation of Cyclin D1 is necessary to initiate the G1 phase of the cell cycle. Cyclin 
D1 transcription is facilitated by the AP-1 transcription factor complex, which consists of 
cFOS/cJUN or cJUN/cJUN dimers. The effects of silencing the RGS-RhoGEFs on the 
transcription of Cyclin D1 in MCF7 and MDA-MB-231 cells were therefore investigated. 
This revealed that MCF7 cells silenced for ArhGEF1, were desensitized to the induction 
of Cyclin D1 transcription by serum. Specifically, the levels of Cyclin D1 transcript were 
reduced by 90% ,as measured by qRTPCR, in MCF7 cells silenced for ArhGEF1 
following serum add-back versus control cells (Figure 4-4A). While a reduction in basal 
Cyclin D1 levels in MCF7 cells was directly associated with the degree of AhrGEF1 
silencing, even moderate (~50 %) ArhGEF1 silencing blocked the induction of CyclinD1 
transcript levels by serum (Figure 4-1B). Furthermore, MCF7 cells with stable 
overexpression of Gα13QL had 40% less Cyclin D1 transcript levels when compared to 
control MCF7 cells (Figure 4-4C). Thus, ArhGEF1 silencing and heterologous expression 
of Gα13QL reduces cell growth and Cyclin D1 transcription while inducing YAP1 and 
MAPK activity. This strongly suggests that hyper activation of Gα13 induces Cyclin D1 
loss, which likely circumvents the pro-growth effects of both YAP1 and MAPK 
activation.  Because MCF7 cells silenced for ArhGEF1 showed 2-fold higher levels of 
cJUN transcript after serum add-back and  no difference in cFOS transcript versus control 
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cells,  prolonged Gα13 activation likely inhibits Cyclin D1 in a manner that is independent 
of AP1. (Figure 4-4D & 4E). 
Consistent with ArhGEF1 silencing causing a loss of CyclinD1 activity,  RPPA 
analysis of lysates from ArhGEF1 silenced cells showed a broad inhibition of proteins 
that control the cell cycle  versus lysates from control cells. MCF7 cells with ArhGEF1 
knockdown had significantly reduced levels of Cyclin E1, Cyclin Dependent Kinase 1 
(CDK1), proliferating cell nuclear antigen (PCNA), and the Cyclin B1 phosphatase 
Cdc25 (Figure 4-4F). Overall, this is consistent with an inability of these cells to enter S 
phase from G1 as the activation of Cyclin dependent kinase 2 (CDK2) by Cyclin E1 is 
required for this transition (20). Further, the loss of PCNA, which was validated by 
immunoblot (Figure 4-4G), indicates a defect in DNA synthesis due to its essential 
function as a DNA clamp during S-phase (207) The significant reduction in the levels of 
the Cdc25 phosphatase, as measured by RPPA (Figure 4-4F), presumably prevents 
dephosphorylation of its substrate Cyclin B1 at tyrosine residue 15. This is essential for 
Cyclin B1 to complex with CDK1 and thereby promote the transition of the cell into 
G2/M (24). 
As expected, the knockdown of ArhGEF11 or ArhGEF12 in MCF7 cells , results 
in a significant desensitization  of these cells to being induced by serum to express Cyclin 
D1  as measured by qRTPCR (~10 fold decrease in Cyclin D1 transcript levels for both 
compared to control cells) (Figure 4-5A). Furthermore, MCF7 cells silenced for either 
ArhGEF11 or ArhGEF12 have significantly lower levels of PCNA protein (Figure 4-5D). 
The reduced levels of Cyclin D1 transcript and subsequent reduced rates of growth of 
MCF7 cells silenced for ArhGEF11 or ArhGEF12 may be explained by the observation 
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that they have significantly lower levels of  cJUN mRNA versus control cells (Figure 4-
5C).  Further, ArhGEF12 silenced cells have significantly lower levels of cFOS transcript 
(Figure 4-5C). All together, the inhibition of these core regulators of the cell cycle upon 
inactivation of RGS-RhoGEFs that lead to either reduced or hyperactivated Gα13 
signaling  underscore the importance of such signaling for cell growth control. 
Early studies of cell growth identified nutrient availability as a major regulator of 
DNA transcription, mRNA translation and protein maturation (9). Both the initiation and 
elongation stages of protein translation are regulated by the mammalian target of 
rapamyacin (mTOR) pathway; which is itself controlled by the phosphoinositide 3 
Kinase (PI3K) - AKT signaling network. Receptor Tyrosine Kinases (RTK)s are 
agonized by extracellular factors including Insulin Growth Factor (IGF), Epidermal 
Growth Factor (EGF), Platelet Derive Growth Factor (PDGF), etc. Ligand bound  RTKs  
both homodimerize and heterodimerize  with other RTKs to enable auto-phosphorylation 
at residues in the cytoplasmic C-terminal tail. The recruitment of downstream effectors to 
these phosphorylated motifs  such as the catalytic subunit of P13K, p110, stimulates the 
conversion of PIP2 to PIP3 in the plasma membrane. PIP3 activates PDK1 to 
phosphorylate AKT at threonine 308 (208). AKT is further phosphorylated at serine 473 
by mTORC2 (209). Phosphorylated AKT then inhibits TSC1/2 (210), and thereby 
prevents their ability to  turn off the GTPase, RHEB (211). The active GTP bound form 
of RHEB stimulates mTOR to facilitates the initialization of cap-dependent mRNA 
translation and to promote ribosomal elongation (212). Protein translation is required 
during the G1 phase of the cell cycle to produce the machinery to duplicate the genome. 
Consequently, defects in this process block cell growth (11). 
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 Consistent with ArhGEF1 expression being required for translation, RPPA 
analysis of ArhGEF1 silenced MCF7 cells  finds that the core proteins that activate the 
initiation and elongation phases of translation are inhibited.  However, activating 
phosphorylation events of PI3K/AKT are increased (Figure 4-6A). Specifically,  the 
expression of the regulatory subunit of PI3K (p85) and the phosphorylation of threonine 
308 of AKT were significantly increased (Figure 4-6A). This may be explained by the 
increases in NRAS levels and in the phosphorylation of ERRB3, an RTK that 
preferentially activates PI3K (213) (Figure 4-6A). Furthermore, a significant increase in 
AKT phosphorylation at serine 473, which is mediated by the mTORC2 complex, was 
also observed (Figure 4-6A). Dual phosphorylation of AKT maximizes its kinase activity 
(209). While surrogate events for the activation of the PI3K-Akt  pathway was observed,  
downstream  translation appears to be inhibited (Figure 4-6A) (211). For instance, there 
is a significant decrease in protein expression of RHEB in ArhGEF1 silenced MCF7 cells 
(Figure 4-6A). This inhibition of translation is also likely due to the observed increased 
levels of total AMPK as well as increased levels of its activated threonine phosphorylated 
form in ArhGEF1 silenced cells (Figure 4-6A).  AMPK is activated by AMP to 
phosphorylate TSC1 and TSC2 which results in the inhibition of mTORC1 and 
consequently the initiation of protein translation (214). Overall ArhGEF1 in MCF7 cells 
is predicted to activate the mTORC1 complex and consequently mRNA translation. 
 Protein translation is a multi-step process involving an initiating step, elongation 
of the protein product and termination. For translation of an mRNA to be initiated, eIF4E 
must bind the 5’ mRNA cap to allow engagement of the 60S ribosome . Subsequent 
elongation is then promoted by eIF2 (215). RPPA comparison of ArhGEF1 silenced 
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MCF7 cells to control cells shows  significantly elevated levels of total and serine 209 
phosphorylated eIF4E (Figure 4-6A). This suggests that ArhGEF1 may inhibit initiation. 
However, levels of the negative regulator of eIF4E, 4EBP1, are also significantly 
increased. Inhibitory activity induced by 4EBP1 is largely a product of stoichiometric 
interactions with eIF4E, so it’s hard to determine if functional inhibition of translation 
initiation is achieved. However, Proteins involved in ribosomal elongation are almost 
uniformly significantly decreased in ArhGEF1 knockdown MCF7 cells in comparison to 
control cells. This includes p70S6K1, the negative regulator of eukaryotic elongation 
factor 2 kinase (eEF2K), and eukaryotic translation elongation factor 2 (eEF2) (Figure 4-
6A). eEF2 promotes the GTP-dependent translocation of the ribosome and is inhibited 
through phosphorylation by eEF2K (Figure 4-6A). Together these data suggest that the 
initiation and elongation of translational may be perturbed in ArhGEF1 silenced MCF7 
cells. However, the overall effects on translation and the molecular underpinnings of how 
prolonged serum signaling can contribute to such effects are unknown. 
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Figure 4-4: ArhGEF1 is Intricately Involved in Global Cell Cycle Activity.  
A. CT value of Cyclin D1 mRNA transcript was measured by qRT-PCR in MCF7 cells silenced 
for expression of ArhGEF1 (ARG1) after serum starvation for 24 hours, followed with a 10 % 
FBS treatment for 30 minutes. Relative level of CTGF mRNA fold change (ΔΔCT) was then 
calculated for each sample compared to MCF7 transduced with the shRNA control and serum 
starved for 24 hours.  (Top Graph). Total ArhGEF1 (AG1) and GAPDH endogenous protein 
levels were detected by immunoblot (Bottom Panel). B. CT value of Cyclin D1 mRNA transcript 
was measured in MCF7 cells with complete, high and moderate stable silencing of ArhGEF1 
(AG1) were starved of serum before being treated for 30 min with media alone or media with 
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10% serum. Relative level of CTGF mRNA fold change (ΔΔCT) was then calculated for each 
sample compared to MCF7 transduced with the shRNA control and serum starved for 24 hours.  
C. CT value of Cyclin D1 mRNA transcript was measured by qRT-PCR in MCF7 cells 
expressing 3x-Flag Gα13WT or Gα13QL. Relative level of CTGF mRNA fold change (ΔΔCT) 
was then calculated for each sample compared to MCF7 expressing 3x-Flag control. (Top Graph). 
Detection of 3x-Flag Gα13WT and 3x-Flag Gα13QL using M2 antibody (Bottom Panel). D. CT 
value of cJUN mRNA transcript was measured by qRT-PCR in MCF7 cells silenced for 
expression of ArhGEF1 (ARG1) following serum starvation and then incubation with media 
containing or lacking 10 % FBS for 30 minutes. Relative level of CTGF mRNA fold change 
(ΔΔCT) was then calculated for each sample compared to MCF7 transduced with the shRNA 
control and serum starved for 24 hours.  E. CT value of cFOS mRNA transcript was measured by 
qRT-PCR in MCF7 cells silenced for expression of ArhGEF1 (ARG1) following serum 
starvation and then incubation with media containing or lacking 10 % FBS for 30 minutes. 
Relative level of CTGF mRNA fold change (ΔΔCT) was then calculated for each sample 
compared to MCF7 transduced with the shRNA control and serum starved for 24 hours.  F. 
Relative changes in protein expression between MCF7 control cells and MCF7 genetically 
inactivated for shArhGEF1 as measured by Reverse Phase Protein Array (RPPA). Samples were 
serum starved for 24 hours and treated for 30 minutes with serum. Colors: Black indicates protein 
was not present in array, Purple indicates no significance between shARG1 and control, Red 
indicates significant decrease (P <. 05) in expression, and Green indicates significant increase (P 
< .05) in expression. G. Immunoblot of endogenous total protein levels of PCNA, ARG1, and 
GAPDH in MCF7 cells knocked down for ARG1, using lentiviral transduction, compared to 
control upon a 24 hours serum starvation followed by a 30 minute serum add back. 
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Figure 4-5: ArhGEF11 and ArhGEF12 Contribute to Cell Cycle Activity.  
A. CT value of Cyclin D1 mRNA transcript was measured by qRT-PCR in MCF7 cells silenced 
for expression of ArhGEF11 (ARG11) or ArhGEF12 (ARG12) after serum starvation for 24 
hours, followed with a 10 % FBS treatment for 30 minutes. Relative level of CTGF mRNA fold 
change (ΔΔCT) was then calculated for each sample compared to MCF7 transduced with the 
shRNA control and serum starved for 24 hours.  (Top Graph). Total ArhGEF1 (AG1) and 
GAPDH endogenous protein levels were detected by immunoblot (Bottom Panel). B. CT value of 
cJUN mRNA transcript was measured by qRT-PCR in MCF7 cells silenced for expression of 
ArhGEF11 (ARG11) or ArhGGEF12 (ARG12) after serum starvation for 24 hours, followed with 
a 10 % FBS treatment for 30 minutes. Relative level of CTGF mRNA fold change (ΔΔCT) was 
then calculated for each sample compared to MCF7 transduced with the shRNA control and 
serum starved for 24 hours.  (Top Graph). Total ArhGEF1 (AG1) and GAPDH endogenous 
protein levels were detected by immunoblot (Bottom Panel). C. CT value of cFOS mRNA 
transcript was measured by qRT-PCR in MCF7 cells silenced for expression of ArhGEF11 
(ARG11) or ArhGEF12 (ARG12) after serum starvation for 24 hours, followed with a 10 % FBS 
treatment for 30 minutes. Relative level of CTGF mRNA fold change (ΔΔCT) was then 
calculated for each sample compared to MCF7 transduced with the shRNA control and serum 
starved for 24 hours.  (Top Graph). Total ArhGEF1 (AG1) and GAPDH endogenous protein 
levels were detected by immunoblot (Bottom Panel). D. Immunoblot of endogenous total protein 
levels of PCNA, ArhGEF1 (ARG1), ArhGEF11 (ARG11), ArhGEF12 (ARG12) and GAPDH in 
cells knocked down for either ArhGEF1, ArhGEF11, or ArhGEF12 under serum starvation and 
30 minute serum add back conditions. 
 112 
 
 
 
Figure 4-6: ArhGEF1 is Required for Translation Elongation.  
A. Relative changes in protein expression between MCF7 control cells and MCF7 genetically 
inactivated for shArhGEF1 as measured by Reverse Phase Protein Array (RPPA). Samples were 
serum starved for 24 hours and treated for 30 minutes with serum. Colors: Black indicates protein 
was not present in array, Purple indicates no significance between shARG1 and control, Red 
indicates significant decrease (P <. 05) in expression, and Green indicates significant increase (P 
< .05) in expression. 
 
 
 
 
  
 113 
4.2.4 Loss of ArhGEF1 Induces Aggregated Actin that Promotes Cellular Senescence  
The loss of ArhGEF1 in MCF7 cells results in a hyper-actin stress fiber 
phenotype as visualized by phalloidin staining (Figure 4-7A). This likely explains the 
extreme flattening of these cells. The stable expression of Gα13QL in MCF7 cells 
similarly induces a flattening phenotype, suggesting that the effects of ArhGEF1 
knockdown on actin occur from the  prolonged activation of Gα13 (Figure 4-7B).  Further 
analysis of RPPA, suggest that cells stably knocked down for ArhGEF1 elevates RhoA 
activity, as ROCK1 protein expression is significantly increased. ROCK1 is a 
serine/threonine kinase that upon being activated by RhoA, it phosphorylates downstream 
effectors including Myosin Light Chain Kinase (MLC) (216,217), Lim domain kinase 1 
(LIMK) (218), and mammalian Diaphanous-related formin-1 (mDia) (219). This  
typically results in  promoting cell migration . This is due to the activation of Myosin IIa 
(MYOIIA), the heavy chain of the non-muscle myosin complex, that in conjunction with 
MLC, mediates contraction of the actinomyosin network. However, in ArhGEF1 
knockdown MCF7 cells, the phosphorylation of serine 1943 of MYOIIA, when compared 
to control MCF7 cells, is significantly reduced, suggesting these cells lack migratory 
capacity (Figure 4-7C). Functional validation of a net reduction of cell migration is 
displayed by ArhGEF1 stably silenced MCF7 cells that only showed a 22% wound 
closure in a scratch wound assay compared to 66% wound closure by control cells over 
24 hours (Figure 4-7D). Again, stable overexpression of Gα13QL recapitulated this 
ArhGEF1 phenotype, where MCF7 cells expressing Gα13QL showed less wound closure, 
24% versus 52% for control cells (Figure 4-7D). These results highlight that ArhGEF1 in 
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MCF7 cells prevents the hyper-activation of Gα13, and thereby the formation of excessive 
stress fibers that results in migration defects. 
The increase in levels of actin stress fibers, the loss of migration, and an inability 
to grow, suggests that ArhGEF1 silenced cells may undergo senescence. Propidium 
iodide staining of cells allowed them to be sorted by flow cytometry on DNA content.  
This revealed that the ratio of G1/0/G2 for ArhGEF1 silenced cells was 2.8 versus control 
cells whose ratio was  1.8 (Figure 4-8A). These significant increases in G1/0/G2 for 
ArhGEF1 silenced MCF7 cells, suggest  that they are aberrantly arresting in G1/0. This 
aligns with their loss of Cyclin D1 transcription, as it is required for transition out of G0. 
These same cells also exhibit a ~3-fold increase in nuclear staining of 53-binding protein 
1 (53BP1), a marker for sustained double stranded breaks that is used as an indicator for 
cellular senescence (Figure 4-8B). Interestingly, knockdown of ArhGEF12 in MCF7 cells 
also locks cells in the G1/0  phase, as the ratio of cells in G1/0/G2 is 4.8 compared to a ratio 
of 2.0 for control cells (Figure 4-8C). Overall, the hyperactivation of Gα13 upon 
ArhGEF1 silencing is overwhelmingly and suggested to result in cellular senescence 
even though core pro-growth pathways are being activated. This suggests the existence of 
inherent fail-safe mechanisms to prevent cells from growing even under high levels of 
growth signaling in situations where ArhGEF1 fails to adequately dampen such signaling.  
 
 115 
 
 
Figure 4-7: Actin Dynamics are Disrupted in ArhGEF1 Knockout Cells. 
A. MCF7 cells infected with shArhGEF1 (shARG1) or shRNA and then fixed and 
immunostained for phalloidin (top panel) and Hoechst die (bottom panel). B. Brightfield imaging 
of live cells stably expressing 3x-Flag Gα13QL (Top Panel). Immunoblot of 3x-Flag Gα13QL 
using M2 antibody (Bottom Panel). C. Relative changes in protein expression between MCF7 
control cells and MCF7 genetically inactivated for shArhGEF1 as measured by Reverse Phase 
Protein Array (RPPA). Samples were serum starved for 24 hours and treated for 30 minutes with 
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serum. Colors: Black indicates protein was not present in array, Purple indicates no significance 
between shARG1 and control, Red indicates significant decrease (P <. 05) in expression, and 
Green indicates significant increase (P < .05) in expression. D. MCF7 cells infected with either 
an shScramble or shArhGEF1 (shARG1) were plated to density and scratched 24 hours later. 
Brightfield images were taken at initial scratch and 24 hours later. Average area closed represents 
4 individual experiments. (**P < .01). E. MCF7 cells stably expressing 3x-Flag Gα13QL were 
plated to density and scratched 24 hours later. Brightfield images were taken at initial scratch and 
24 hours later. Average area closed represents 4 individual experiments. (**P < .01). 
 
 
 
 
 
 117 
 
 
Figure 4-8: ArhGEF1 and ArhGEF12 Knockout Result in G1/0 Stacking.  
A. MCF7 cells were stably silenced for ArhGEF1 using lentiviral transduction, fixed, stained with 
propidium iodide and analyzed for DNA content. The first peak corresponds to G1/0 phase and the 
second smaller peak corresponds to G2 phase of the cell cycle. Control cells (Left Panel) and 
shArhGEF1 cells (Middle Panel). Ratio of G1/0 to G2 (Right Panel). B. MCF7 cells stably silenced 
for ArhGEF1 using lentiviral transduction were fixed and stained with 53BP1, Phalloidin, and 
Hoechst Dye (merged images) (Left two panels). The right panel is the average 53BP1 spots per 
nuclei C. MCF7 cells were stably silenced for ArhGEF12 using lentiviral transduction, fixed, 
stained with propidium iodide and analyzed for DNA content. The first peak corresponds to G1/0 
phase and the second smaller peak corresponds to G2 phase of the cell cycle. Control cells (Left 
Panel), shArhGEF12 cells (Middle Panel). Ratio of G1/0 to G2 (Right Panel). 
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4.2.5 YAP1 Protects ArhGEF1 Senescent Cells from Apoptosis 
YAP1 has been found to promote cell growth by both stimulating proliferation 
and by  increasing the ability of cells to evade apoptosis (201). For instance, epithelial 
cells that detach from the basement membrane undergo cytoskeleton reorganization 
inducing anoikis. However, exogenous overexpression of YAP1 prevents anoikis in this 
context. Considering the strong activation of YAP1 that occurs with concomitant growth 
arrest upon ArhGEF1 silencing, the role of YAP1 in promoting survival mechanisms in 
senescent cells was investigated.  
 As seen by bright field microscopy, MCF7 cells stably silenced for ArhGEF1 
exhibit a flattened morphology in comparison to control cells that exhibit a cuboidal 
epithelial phenotype (Figure 4-9A). The knockdown of YAP1 in MCF7 cells expressing 
shScramble produces no discernable affects on cellular morphology (Figure 4-9A). 
However, the silencing of YAP1 in cells that are already stably silenced for ArhGEF1, 
results in cell rounding and blebbing, indicative of apoptosis (Figure 4-9A). Tandem 
knockout of ArhGEF1 and YAP1 in MCF7 cells also significantly decreased cell viability 
when compared to YAP1 or ArhGEF1 individual knockouts, as measured by MTT assay 
following 60 hours of seeding (Figure 4-9B). Furthermore, 12 % of cells in which YAP1 
or ArhGEF1 was silenced in isolation in isolation underwent death after 48 hours as 
measured by cell counting following Trypan blue staining (Figure 4-9C). However, 35% 
of MCF7 cells that were silenced for both ArhGEF1 and YAP1 were not viable after 48 
hours (Figure 4-9C). These data suggest that YAP1 expression protects ArhGEF1 
silenced cells from switching from a senescence to an apoptotic program. 
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Figure 4-9: Tandem Knockout of ArhGEF1 and YAP1 is Synthetically Lethal.  
A. Brightfield imaging of live MCF7 cells stably silenced for YAP1, ArhGEF1, or a combination 
YAP1 and ArhGEF1 by lentiviral transduction. B. MCF7 cells stably silenced for YAP1, 
ArhGEF1, or a combination YAP1 and ArhGEF1 through lentiviral transduction were allowed to 
grow for 3 Days in a 96-well plate. On Day 3 15 uL of 5mg/mL of MTT was added for 4 hours, 
followed by the addition of 100 uL of MTT solvent for 1 hour. Cells were resuspended and 
absorbance at 570 nm was recorded and normalized to control. C. MCF7 cells stably silenced for 
YAP1, ArhGEF1, or a combination YAP1 and ArhGEF1 through lentiviral transduction, were 
allowed to grow for 3 Days and stained with 1:1 dilution of Trypan blue. 
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4.3 DISCUSSION 
4.3.1 Gα13 Role in Growth and the Excessive Growth Signaling “fail-safe” Switch  
The work in this chapter suggests that ArhGEF1 dictates a narrow range of Gα13 
activity that may stimulate cell growth. Loss of ARHGEF1 results in the hyper activation 
of Gα13 that stimulates a broad activation of growth-signaling including YAP1, ERK1/2, 
JNK1/2 and PI3K/AKT pathways. However, cell cycle and cell migration are impaired 
likely from an inhibition of mRNA translation.  
Chronic growth signaling in many contexts is linked to cellular senescence. For 
instance the overexpression of constitutive active RAS in NIH3T3 mouse fibroblast 
activates senescence pathways in the presence of wild type p53 (198). In more recent 
studies this was determined to require AKT, as cells that were deficient in AKT were 
resistant to replicative, oxidative, and oncogenic RAS induced senescence (220). Here, 
the aberrant activation of Gα13 through the loss of ArhGEF1, a key GTPase activating 
protein for Gα13, results in chronic growth signaling events that induce cellular 
senescence. This is accompanied by high levels of stress fibers that appear to aggregate 
and to lack a normal level of turnover. This may explain the reduced migratory capacity 
of ArhGEF1 silenced MCF7 cells. This suggests that if the actin dynamics of the cell are 
deregulated, then growth signaling is re-directed to promote a senescent phase. This work 
may also explain why senescent cells typically are observed to have a flattened 
morphology. This is proposed to be due to a structural “fail-safe” mechanism increased 
actin stress-fibers eventually physically limit the cell from proliferating, by uncoupling 
cell cycle activation from protein translation (221). Overall this “fail-safe mechanism 
appears to  supersede all other signaling that also controls cell fate 
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4.3.2 The Role of YAP1 in Maintaining Cell Survival under JNK1/2 Activation  
The chronic activation of JNK1/2 is associated with a variety of stresses, most 
notably DNA damage induced by UV irradiation (113). Cells that are UV-irradiated 
characteristically exhibit extreme flattening, increased actin stress fibers, the activation of 
JNK1/2 as measured by its phosphorylation, and senescence. Because MCF7 cells 
silenced for ArhGEF1 exhibit all of these characteristics, it is proposed that ARhGEF1 
silencing induces senescence. Further, the synthetically lethal phenotype observed upon 
the combination of ArhGEF1 and YAP1 knockdown suggests that YAP1 mainly 
functions to maintain cell survival in senescent cells. 
The ability of JNK1/2 to phosphorylate YAP1 presents a possible mechanism by 
which YAP1 may switch from acting as a pro-growth transcriptional co-activator to a 
manager of cell survival. Consistently, the JNK1/2 activator, anisomyocin, as well as 
UV-irradiation has been shown to induce the phosphorylation of YAP1 in a variety of 
cell types, including MCF7 breast cancer cells (222). Stimulation of JNK1/2 promotes 
YAP1 stabilization and association with Δp63α, as measured by IP, in HaCat and H357 
cells. This prevents the E3 ubiquitin ligase, ITCH, from binding PPxY motifs of Δp63α 
and promoting its degradation. Furthermore in this study, the knockdown of YAP1 
switched UV-irradiated cells from a Δp63α survival state to a p73 induced apoptotic state 
(222) (Figure 4-10A). Preliminary results in MCF7 breast cancer cells suggest the dual 
knockdown of YAP1 and ArhGEF1, increases the p73 dependent transcription of p53 
upregulated modulator of apoptosis (PUMA), but not when either are independently 
knocked down (Figure 4-10B).  More striking evidence that supports the idea that YAP1 
promotes the survival of stressed or senescent cells is the observation that  both p53 and 
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p63 pathways are predicted to be activated in cells silenced only for ArhGEF1 (Z score 
>2) by Ingenuity Pathway Analysis, whereas p73 is not (Figure 4-10C). These results in 
MCF7 cells mirror those found in this previous study and suggest in breast cancer cells 
that YAP1 may mediate cell survival under stressful conditions by toggling between 
stabilizing or contributing to the degradation of Δp63α in breast cancer cells. Overall, this 
suggests that the ability of YAP1 to protect stressed cells from engaging apoptotic 
pathways could contribute to the resistance of cancer cells to radiation or 
chemotherapeutic treatments. 
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Figure 4-10: YAP1 Protects ArhGEF1 Knockout Cells from Engaging Cell Death.  
A. Model of JNK1 phosphorylation and stabilization of YAP1/Δp63α to maintain cell survival 
under stress. Green indicates those proteins or post-translational modifications that are 
significantly increased in ArhGEF1 silenced MCF7 cells compared to control per RPPA. B. CT 
value of PUMA mRNA transcript was measured by qRT-PCR in MCF7 silenced for ArhGEF1 
(shARG1) compared to control (shScram), with a knockout of YAP1 (shYAP1) in each condition 
as well, all delivered by lentiviral transduction. C. Ingenuity Pathway Analysis upon total 
transcriptome sequencing by Illumina HiSeq following a comparison of transcripts differences 
among MCF7 cells silenced for ArhGEF1 and control. A Z-score >2 indicate activation. 
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CHAPTER 5. CONCLUDING REMARKS ON THE INTEGRATIN OF THE 
SERUM RESPONSE NETWORK, MAPK CASCADES, AND HIPPO IN 
CELLULAR HOMEOSTASIS 
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5.1 INTRODUCTION 
 The work presented in this dissertation elucidates intracellular roles of the RGS-
RhoGEFs in mediating serum mitogen signaling onto regulating RhoA induced YAP1-
TEAD dependent transcription. More specifically it defines how alterations in their 
regulation and function dictate YAP1 dependent cell fate decisions. The activity of the 
RGS-RhoGEFs mainly takes place at the plasma membrane, however they are known 
regulators of RhoA activity at focal adhesions (223). These variations in spatial activation 
of the RGS-RhoGEFs may have functionally different consequences in regards to YAP1 
regulation. The functionality of the RGS-RhoGEFs is regulated by biophysical and 
biochemical stimuli as highlighted by data in Chapters 3 and 4. ArhGEF1 can switch 
from a GEF, in low serum, to a GAP when stimulated by serum. This binary switch is 
likely regulated by post-translational modifications. Furthermore, both ArhGEF11 and 
ArhGEF12 increase their proclivity to induce nucleotide exchange on RhoA upon 
tyrosine phosphorylation by focal adhesion kinase (FAK) (224). It is therefore imperative 
for future studies to identify spatial and temporal regulation of post-translational 
modifications of the RGS-RhoGEFs, in order to fully elucidate the mechanisms by which 
they regulate YAP1 activity. Understanding these modifications could be key in 
understanding how cancer cells circumvent “fail-safe” signaling mechanisms, like 
oncogene induced senescence, to continue to proliferate in times of unwarranted growth.  
Also highlighted in this study is the requirement of the RGS-RhoGEFs for the 
integration of three prominent cell growth-signaling pathways: the Serum Response 
Network, Mitogen Activated Protein Kinase Cascades, and the HIPPO pathway. Cancer 
cells often utilize these pathways to propagate growth, and therefore further 
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understanding of how the RGS-RhoGEFs integrate these pathways is essential. In the 
data presented, we have physiologically identified a mechanism by which prolonged 
activation of the Serum response Network with concurrent activation of the MAPK 
cascades leads to growth retardation. The evidence suggest this rampant activation leads 
to cellular senescence, by inducing a hyper-actin stress fiber phenotype and by 
uncoupling the activation of growth signaling pathways from cell cycle progression. Also 
during this period of prolonged activation, and subsequent induction of cellular 
senescence, YAP1 is implicated in promoting cell survival. This function is essential, as 
the loss of YAP1 promotes a synthetically lethal phenotype. How exactly YAP1 
maintains its survival functionality independent of its growth activating potential is 
unknown. Recent studies indicate YAP1 is subject to a variety of post-translational 
modifications via phosphorylation, sumoylation, ubiquitination, and acetylation in times 
of stress (120, 222, 225, 226). This study leaves open an area of future exploration into 
understanding how YAP1 functionality is switched under different types of stress, and 
when combined with hyper-activation of the Serum Response Network this may point to  
potential therapeutics targeting resistance to chemo and radiation therapies for cancers.  
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5.2 Determination of Cell Fate by Signaling Flux and Actin Dynamics 
5.2.1 Role of Signaling Flux in Cell Growth and Cancer 
Under normal physiological conditions, cells have numerous mechanisms that act 
as “fail-safes” to prevent unwarranted cellular growth. Mechanisms that typically 
facilitate growth control are core to cell cycle progression and also monitoring the 
integrity of the duplicating genome. The rapid proliferation of cancer cells often by-pass 
key cell cycle checkpoints and have genomic integrity issues, such a mutations in 
essential genes or double-stranded breaks. The introduction of double stranded breaks 
activates the tumor suppressive protein p53 that functions to limit cell cycle activity in 
order to repair the damage (227, 228). P53 can activate for a limited time cellular 
senescence, if the damage is manageable, or it can engage apoptotic pathways if the stress 
cannot be overcome (229, 230). The dominant role p53 plays in managing genomic 
integrity is primarily why many cancers harbor mutations (231) that disrupt its tumor 
suppressive function. This allows cancer cells to facilitate unregulated cellular growth 
that cannot be inhibited by faults in duplicating the genome.  
 Past studies identified the role p53 plays in facilitating oncogene-induced 
senescence. RAS is often altered in cancers by mutations that make it constitutively 
active (232). This is a prominent feature of a variety of pancreatic and breast cancers. 
However, in cell model systems, the introduction of constitutive active RAS in mouse 
fibroblast, that maintain wild type p53, initiates oncogene-induced senescence (198). This 
is also the case for constitutive active and RAF (233). The two cell lines in this study that 
characterize the prolonged activation of the serum response network and MAPK cascade, 
by knockdown of ArhGEF1, resulting in cellular senescence, one MCF7, has wild-type 
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p53 (234), and the other MDA-MB-231 (235), has a gain of function mutant p53. This 
suggests that the “fail-safe” mechanism instigated by prolonged activation of the serum 
response network, concurrent MAPK signaling, and YAP1 hyper transcriptional activity 
is p53 independent (Figure 5-1A). This therefore suggests a universal mechanism for 
inhibiting growth in a variety of tumors that maintain high levels of MAPK signaling and 
mutated p53, many of which are inherently resistant or develop resistance to current 
treatments.  
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5.2.2 Role of Actin in Determining Cell Fate 
 Actin fibers form major structural components of cells that that are subject to 
drastic reorganization in response to microenvironmental conditions. These changes are 
core to relaying outward-inward signaling to mediate cell fate decisions. The ability of a 
cell to adapt to its environment is critical for survival, and conversely if it cannot adapt, 
the cell may engage cell death signaling pathways. Core to these cell fate decisions is the 
ability of actin cytoskeletal structures to be dynamic (236). Under these transitions, cells 
break down cortical actin structures, and repurpose that actin into stress fibers and 
adhesive structures (236). As this occurs, genes tied to the activation of the cell cycle are 
activated to propagate cell growth (172, 237, 238). However if the cell experiences 
extreme stress, actin structures become aggregated and then static. This stasis of actin 
fibers initiates cellular senescence and under extreme stresses apoptosis (236).  Because 
the mechanism(s) by which this stabilized, aggregated actin induces senescence is not 
known, I will speculate how this may occur based on the data in this dissertation. 
 The loss of ArhGEF1 promotes a dominant stress fiber phenotype. This 
phenotype is thought to exceed the normal physiological range of actin polymerization 
for a couple of reasons. First, actin polymerization typically elicits growth signaling, 
however in MCF7 cells with ArhGEF1 knockdown, actin polymerization is uncoupled 
from promoting cell proliferation. Second, the dominant actin phenotype in ArhGEF1 
knockdown MCF7 cells, also restricts cells from migrating correctly, which is supported 
by the loss of MYOIIA serine 1943 phosphorylation (Appendix C). These data suggest 
that ArhGEF1 is critical for maintaining actin turnover, and that too much signaling flux 
through the GTPase, Gα13, locks actin into a static form, leading to cellular senescence. 
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However, the mechanistic details of how actin dictates cellular senescence in this 
scenario are unknown. 
 Secondly, actin is a major source of ATP consumption. Actin filament formation 
involves the addition of ATP-G-actin monomers to the barbed (+) end of an active 
filament. Conversely, the breakdown of filaments involves the release of ADP-F-actin-
monomers from the pointed (-) end. The release of ADP from the pointed end is then 
converted back into ATP and the cycle continues if necessary. This cycle of addition and 
subtraction is known as actin tread-milling and is the dynamic mechanism for motility 
(236). Changes in environmental cues or the subjection of a cell to a stress, causes actin 
to be repurposed to stress fibers, which inherently alters the transcriptional programming 
and cellular ATP/ADP levels to change to respond to that stress. However if actin is 
static, it is hypothesized that ADP would be trapped in the filaments, creating a structural, 
“actin sink” for ATP. Recent work suggest the depletion of ATP in neurons is reduced by 
nearly 50% by slowing down actin turnover using drugs targeted toward filament 
turnover, jasplakinolide (targets disassembly) or latrunculin A (prevents assembly) (239). 
When these two drugs are applied together they prevent ATP loss in a background where 
ATP synthesis is inhibited. This study implies that actin filaments are major reservoirs for 
ATP/ADP in the cell and actin aggregates that are no longer dynamic reduce the levels of 
ADP available. This essentially starves the cell of energy, preventing basic cellular 
functions such as transcription, translation, protein synthesis, etc. Mechanistically this 
could explain how cells become senescent as they show a flattened phenotype with high 
levels of actin filaments, suggesting a structural “fail-safe” mechanism for unwarranted 
prolonged signaling.  
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 The mechanism by which ArhGEF1 knockdown contributes to the loss of cell 
growth is not known. However, knockdown of ArhGEF1 contributes to global losses in 
cell cycle progression and translation even in the presence of activated growth pathways 
such as the MAPK cascades and YAP1 transcriptional activity. These global cellular 
programs require a great deal of energy, from both ATP and GTP. The enhanced actin 
phenotype in ArhGEF1 knockdown cells, facilitated by activated Gα13-RhoA-Rock 
signaling, may suggest that actin is being aggregated and serves as an “actin sink” for 
cellular ATP, reducing energy reserves. This “actin sink” hypothesis is supported by the 
notion that MYOIIA serine 1943 phosphorylation is significantly decreased, consistent 
with actin turnover being reduced as migration is inhibited. Further, the activation of the 
nutrient sensor AMPK, via its phosphorylation at tyrosine 172, indicates that there is 
disproportional amount of AMP compared to ATP in the cell. Studies are needed to 
further prove that the loss of actin turnover is detrimental to maintaining a proper balance 
of cellular AMP, ADP, and ATP levels. Rescue experiments to show the liberation of 
ADP from the actin in ArhGEF1 knockdown MCF7 cells, for example by expressing a 
constitutive active cofillin that can potentially rescue the loss of cell growth, may help 
test this hypothesis. Such data might further indicate that actin dynamics supersedes the 
activity of even the most potent oncogenes like YAP1 or MAPK cascades.  
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Figure 5-1: Interdependence of Ras and Rho Signaling on Cell Fate; “Actin-sink” Model.  
 
A. Schematic of the dependence of Ras and Rho Signaling in response to mitogens. Maintained 
mitogenic signaling leads to regulated growth, whereas prolonged or unregulated mitogenic 
signaling results in cellular senescence. 
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5.2.3 RGS-RhoGEFs Regulate YAP1 Stability Through Actin Dynamics 
The nuclear translocation of YAP1 is essential for it to bind and co-activate 
transcription factors to influence transcriptional programs that control cell fate. The 
regulation of YAP1 nuclear translocation is completely dependent on the cells having a 
certain level of biomechanical loading. Canonical sequestration of YAP1 from the 
nucleus involves its phosphorylation at serine 127 by the upstream kinase LATS1/2 in 
response to cell-to-cell contact (120). 14-3-3 then binds this phosphorylation motif and 
YAP1 is retained in the cytosol. Furthermore, a LATS1/2-independent event was 
discovered that involves YAP1 mediated stabilization and nuclear translocation by 
filamentous actin fiber formation, the disruption of which caused YAP1 degradation and 
nuclear exclusion (142). However controversy still exists on to whether the dominant 
regulation of YAP1 nuclear translocation and stability is LATS1/2 dependent or 
independent.  
 Previous studies from the Wells laboratory delineated a role for Angiomotin 
members in YAP1 protein stabilization (Figure 5-2A). In response to serum deprivation, 
Angiomotin is phosphorylated at serine 175 by LATS1/2 (125). This phosphorylation site 
lies in the middle of an actin-binding domain (240). Phosphorylation dislodges 
Angiomotin from the actin cytoskeleton, freeing the N-terminal PPxY motifs to interact 
with YAP1. Subsequently, 14-3-3 can bind Angiomotin and sequester the Amot-YAP1 
complex in the cytosol or it can recruit an Amot-AIP4 complex. The dimerization of the 
Angiomotin complexes brings YAP1 into the proximity of AIP4, leading to YAP1 
ubiquitination and degradation (124). Conversely, in situation where there are high levels 
of actin stress fibers, which is indicative of low intercellular contact, LATS1/2 is 
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inactivated and Angiomotin binds to the actin cytoskeleton. This prevents the association 
of Amot with AIP4 and therefore YAP1 is not subject to ubiquitination and subsequent 
degradation. The RGS-RhoGEFs are key mediators of actin dynamics and therefore they 
are likely  able to alter YAP1 stability, nuclear translocation, and activity by altering 
actin-Angiomotin complex dynamics.  
The knockdown of ArhGEF12 and ArhGEF1 in MCF7 cells show appreciable 
changes in the overall actin structure and consequently cell morphology. Concurrent, 
with changes in actin dynamics, there is also an associative change in YAP1 protein 
stability and function. In MCF7 cells silenced for ArhGEF12, cells morphologically 
round, and their actin structures are reduced. Concurrently, there is a loss of YAP1 
protein transcriptional activity. Conversely, when ArhGEF1 is knocked down, cells 
flatten and acquire prominent stress fibers. YAP1 phosphorylation is also reduced, 
whereas YAP1 nuclear translocation and transcriptional activity are enhanced. In cells 
inactivated for ArhGEF1, it is proposed that the flattened, aggregated actin increases 
Angiomotin binding to the filament to inhibit the interaction of Angiomotin-AIP4 and 
Angiomotin-YAP1 complexes, allowing nuclear translocation of YAP1 (Figure 5-2B). 
The loss in YAP1 protein in ArhGEF12 knockdown MCF7 cells is hypothesized to result 
from the formation of Angiomotin/YAP1-Angiomotin/AIP4 complexes (Figure 5-2C). 
The formation of these complexes in ArhGEF12 knockdown MCF7 cells is expected to 
be dominant, as the cells have reduced levels of actin, therefore promoting the release of 
Angiomotin from actin fibers and consequently its coupling of ubiquitin mediated 
degradation to YAP1. This complete restriction of YAP1 from the nucleus may suggest 
why cells silenced for ArhGEF12, when compared to ArhGEF1 and ArhGEF11 silenced 
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MCF7 cells, have lower proliferation rates, and higher cell death. If these hypotheses are 
true it would suggest a dominant role for the actin cytoskeleton, and its regulators, to the 
regulation of LATS1/2 interactions with YAP1 to control its stability and functionality.  
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Figure 5-2: Angiomotin’s Potential Role in Regulating YAP1 in Cells Silenced for ArhGEF1 
or ArhGEF12. 
A. Schematic of known role Angiomotin plays in adapting YAP1 to AIP4 for ubiquitin mediated 
degradation. (Figure Adopted from Adler 2013). B. A model of the potential role Angiomotin 
plays in facilitating YAP1 nuclear translocation in shArhGEF1 cells. C. A model of the potential 
role Angiomotin plays in facilitating YAP1 nuclear exclusion in shArhGEF1 cells. Red dots are 
G-actin, Red fibers are f-actin. 
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5.3 Regulation of RGS-RhoGEFs and YAP1 by Localization and Post-Translational 
Modifications 
5.3.1. Role of RGS-RhoGEFs Localization Implications on Regulating YAP1 
This work identified the requirement of the RGS-RhoGEFs in regulating YAP1-
TEAD dependent transcription in response to biochemical signals at the plasma 
membrane, however the RhoGEFs also contribute to baso-lateral biomechanical 
signaling. How this baso-lateral signaling regulates YAP1 activity is still an area for 
future exploration. Biomechanical regulation of YAP1 is product of the cells asymmetric 
interactions with both the basement membrane and sites of cell-to-cell cohesion. 
Intercellular interactions are cadherin based and supported by the underlying cortical 
actin structures. The cell facilitates interaction with the basement membrane through 
integrin linked stress fibers at focal adhesion complex. The underlying regulation of 
actin/focal adhesion complexes involves the cyclic activity of RhoA mediated by the 
RGS-RhoGEFs, independently of their function at the plasma membrane (223, 224). The 
contradictory regulation of YAP1 by RhoA induced stress fibers and RhoA induced 
cortical actin; suggest that the localized activity of the RGS-RhoGEFs may contribute 
differentially to YAP1 localization and functionality. 
Focal adhesions independently regulate YAP1 activity and therefore 
understanding how the RGS-RhoGEFs contribute to the regulation of stress fiber/focal 
adhesion complexes together may explain what ultimately influences YAP1 functionality. 
Focal adhesion dynamics play a major role in the motility of the cell, and alter 
transcriptional growth propagating programs. The small GTPases, RhoA and Rac1, each 
are required and work in a temporal manner to regulate cell adhesion (223). Initially, 
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during early stage adhesion, Rac1-dependent activity drives lamellapodia formation and 
cell flattening (241). Conversely, during this time, RhoA activity is retarded in a GAP-
dependent manner, mainly through p190RhoGAP (242). During the late stage maturation 
of focal adhesion complexes, Rac1 activity is diminished and RhoA facilitates stress fiber 
formation (241). The GEFs responsible for RhoA activity are ArhGEF1 and ArhGEF12 
(223). At the plasma membrane, upon serum stimulation, the GAP activity of ArhGEF1 
is elevated, while under these same conditions, at focal adhesions its GEF activity is 
enhanced. This evidence strongly supports the notion that ArhGEF1 function is 
dependent of its localization within the cell. These reciprocal functions of ArhGEF1 
could potentially have opposing roles in mediating YAP1 nuclear translocation and 
functionality. 
Further complicating matters, the RGS-RhoGEFs also contribute to the regulation 
of cortical actin at cellular junctions and this regulation could further affect YAP1 
activity in a cell density manner. Evidence for this is highlighted in MCF7 cells, as the 
knockdown of ArhGEF1 results in the loss of E-cadherin complexes at intercellular 
junctions, which is likely due to a loss in the cortical actin network (243). Gα12/13 are 
known to stimulate actin filamentation at cell junctions, ArhGEF1 would presumably act 
as a GEF for RhoA in this context if the GTPases were working through it. If ArhGEF1 is 
working independently of heterotrimeric proteins, this would define a new avenue for its 
regulation and function  and add another layer to our understanding of how actin network 
regulation is coupled to YAP1 localization. These data also support the notion that 
ArhGEF1 may have dual functions that are context dependent. Conversely, knockdown 
of ArhGEF11 drastically enhances E-cadherin attachments whereas the knockdown of 
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ArhGEF12 has no discernible effect (243). Again, ArhGEF11, like ArhGEF1, exhibits 
contradictory functionalities that are dependent on its localization within the cell. The 
RGS-RhoGEFs are also differentially required in response to serum to regulate YAP1 as 
highlighted by the differential activation of TEAD transcription under different cellular 
densities. These data suggest a rheostat role for the RGS-RhoGEFs, as they are uniquely 
capable of dialing “up” or “down” the actin cytoskeleton, which directly dictates YAP1 
nuclear translocation and activation. Further understanding of how these GEFs utilize 
their functional domains at each locale, and how the cell mediates the activation of these 
seemingly opposing domains will be important to understanding the intercalated crosstalk 
between cell density and the basement membrane attachments that facilitate epithelial 
cell fate decisions. 
The RGS-RhoGEFs also differentially localize between the cytosolic and nuclear 
compartments of the cell (Figure 5-3A & 3B). Nuclear fractionation data suggest that 
ArhGEF1 is found mainly in the cytosol fraction, ArhGEF11 is distributed among the 
cytosol and nuclear fraction, whereas ArhGEF12 is found mainly in the nuclear fraction. 
This complicates the notion that RGS-RhoGEFs function only at the plasma membrane, 
focal adhesions, and at sites of cell-to-cell contacts. The ability of ArhGEF11 and 
ArhGEF12 to distribute to the nucleus may be important in controlling subpopulations of 
RhoA that directly impinge on YAP1 nuclear activity. Consistently, RhoA is required for 
cellular division, and recently actin has been shown to integrate into the RNA Polymerase 
II complex to facilitate transcription (221). Understanding how ArhGEF11 and 
ArhGEF12 contribute to RhoA nuclear activity may provide insight into how they 
regulate cell fate decisions.  
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Figure 5-3: Cytosolic vs. Nuclear Localization of the RGS-RhoGEFs.  
 
A. Immunoblot of endogenous ArhGEF1 (ARG1), ArhGEF11 (ARG11), ArhGEF12 (ARG12), 
snRNP70, and GAPDH in MCF7 cells. Cells were lysed in Nuclear Fractionation Buffer and 
fractionated, into nuclear and cytosolic fractions based on method 2.6. B. Immunoblot of 
endogenous ArhGEF1 (ARG1), ArhGEF11 (ARG11), ArhGEF12 (ARG12), and snRNP70 in 
MCF7 infected with shScramble (shScram) or shArhGEF1 (shARG1) following a 24 hours serum 
starvation and 30 minute treatment with 10% FBS. Cells were lysed in Nuclear Fractionation 
Buffer and fractionated, into nuclear and cytosolic fractions based on method 2.6. 
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5.3.2 Regulation of RGS-RhoGEFs Function by Post-translational Modifications 
Post-translational modifications alter functionality, localization and stabilization 
of many proteins. All three members of the RGS-RhoGEF family can be post-
translationally modified by phosphorylation at serine/threonine residues as well as 
tyrosine residues by a variety of kinases. These events typically lead to the activation of 
their GEF function independent of Gα12/13. How these manipulations regulate YAP1 
activity is largely unknown, and thus  they are an area for further study.  
Besides the direct activation of the exchange activity of ArhGEF1 by Gα12/13, 
ArhGEF1 is independently activated by tyrosine and serine phosphorylation. In 
hematopoietic cells the angiostensin II receptor type-I (AT-1) Janus Kinase2 (JAK2) 
phosphorylates ArhGEF1 at tyrosine 738 to positively regulate its GEF activity (244). 
Positive regulation of GEF activity also occurs through tyrosine phosphorylation on an 
unknown residue by proline rich tyrosine kinase2 (Pyk2) following PAR-1 activation 
(197). It is not known if this increases GEF activity independently of Gα12/13 activation. 
Serine phosphorylation at residue 330 promotes the unhinging of the inhibitory linker 
region from the DH/PH domain, freeing it, and empowering its functionality (197) 
(Figure 5-4A). These post-translational modifications activate RhoA and therefore it is 
hypothesized that they would facilitate YAP1 nuclear localization. 
While post-translational modifications that activate exchange activity are known, 
an analysis of the ArhGEF1 sequence finds canonical LATS1/2 phosphorylation sites that 
are predicted to inhibit GEF activity. Of the three potential canonical LATS1/2 
phosphorylation sequence motifs, HxRxxS/T, the ones located at serine 631 and tyrosine 
695 in ArhGEF1 (Figure 5-4A) fall within the DH and PH domains,. It is predicted that 
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phosphorylation of these sites  negatively regulate GEF function because they are not 
present in ArhGEF11 and ArhGEF12, which exclusively transmit activated Gα12/13 
signaling to RhoA. Specifically, the tyrosine residue of ArhGEF1 that is part of the 
LATS1/2 phosphorylation motif is a nonpolar valine and alanine in ArhGEF11 and 
ArhGEF12, respectively. Furthermore, this tyrosine phosphorylation site in ArhGEF1 
may explain how ArhGEF1 flips its GEF activity under serum starved and serum add 
back conditions which strongly influences LATS1/2 activity. Previous work from our lab 
identified that serum deprivation activates LATS1/2 to phosphorylate the adaptor protein 
Angiomotin to facilitate YAP1 degradation. The negative regulation of ArhGEF1 GEF 
activity by LATS1/2  may therefore be a complimentary mechanism to inhibit YAP1 
activity. The concurrent loss of RhoA activity would effectively eliminate the formation 
of stress fibers necessary for YAP1 nuclear translocation. Furthermore, activation of 
LATS1/2 by cell-to-cell contacts explain the differentially effects of ArhGEF1 silencing 
observed in cells at different densities. If the phosphorylation of ArhGEF1  by LATS1/2 
is  density dependent, it may also define how the GEF/GAP activity of ArhGEF1 could 
be fine-tuned to regulate the migratory capacity of individual’s cells in a population 
(Figure 5-4B). This is important because it suggests that in non-pathological conditions, 
such as wound healing, ArhGEF1 is a key driver of cellular differentiation through its 
ability to manipulate the actin cytoskeleton. If this is true, ArhGEF1 is a critical rheostat 
to integrate biochemical signals released by platelets that induce migratory and 
proliferative events required to close a wound and to turn off those functions upon wound 
closure, even in the presence of excess biochemical stimuli. LATS1/2 activity is therefore 
hypothesized to control the impact of RGS-RhoGEFs on YAP1 activity. 
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While post-translational modifications of ArhGEF11 and ArhGEF12 have been 
extensively characterized, they encode only one canonical LATS1/2 phosphorylation site. 
However, focal Adhesion Kinase phosphorylates both ArhGEF11 and ArhGEF12 upon 
PAR-1 activation on a tyrosine residue in the c-terminus of each protein (224). This 
phosphorylation enhances GEF activity independently of Gα12/13. The prevailing thought 
on why this increases GEF activity is the phosphorylation event promotes the dissociation 
of inhibitory homo- and hetero-dimers of the RGS-RhoGEFs (245). This suggests the 
localized activation of ArhGEF11 and ArhGEF12 at focal adhesions could activate RhoA 
independent of Gα12/13, to facilitate YAP1-TEAD dependent transcription. Located in the 
N-terminus of ArhGEF11 is a canonical LATS1/2 phosphorylation site, however it’s not 
located within a known functional domain and thus it is likely to play a role in altering 
localization. The N-terminal domain is required for recruitment of ArhGEF11 to the 
plasma membrane upon activation of GPCR through Gα12/13. Speculation would arise at 
the idea that phosphorylation at this LATS1/2 canonical site, in a growth inhibitory 
environment, may interrupt the Gα12/13-ArhGEF11 interaction and further inhibit its 
recruitment to the plasma membrane. This would decisively limit the activation of RhoA 
by Gα12/13. Understanding how these post-translational modifications contribute to the 
functionality of the RGS-RhoGEFs and further how those contribute to YAP1 activity 
may provide key insights into our  understanding of actin mediated cell fate decision. 
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Figure 5-4: Post-Translational Modifications that Alter ArhGEF1 Functionality in 
Biochemical and Biophysical Stimuli.  
A. Schematic of ArhGEF1 domains as well as sites of known phosphorylation events (S330) and 
predicted LATS1/2 phosphorylation sites (S631 & T695). B. Model of how ArhGEF1 may 
respond to cell density among a population of cells to alter the activity of its functional domains 
to mediate cell fate decisions.  
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5.3.3 Nuclear YAP1 Post-Translational Modifications And Cell Fate 
YAP1, being a transcriptional co-activator facilitates most of its growth activating 
potential through the TEAD family of transcription factors. YAP1 has also been shown to 
promote cell survival by resisting anoikis (201) as well as inducing an apoptotic response 
through binding the p73 family of transcription factors (246). The data in this dissertation 
suggest that nuclear YAP1 is  required for cell survival and not growth activation in 
response to chronic serum signaling. Also in this work the loss of ArhGEF1 activates 
cellular senescence whereas the tandem knockout with YAP1 activates cell death. The 
mechanisms by which YAP1 oscillates among these opposing roles for mediating cellular 
fate is still an area under investigation, but recent work implicates post-translational 
modifications.  
In times of stress, YAP1 is preferentially post-translational modified. For 
instance, when cells are exposed to biochemical energy stress, the activation of AMPK 
facilitates phosphorylation of serine 94 of YAP1 (247). The phosphorylation of serine 94 
disrupts the interaction of YAP1 with its transcriptional co-activator TEAD, preventing 
oncogenic transformation of LATS1/2 null cells (247). Furthermore when cells are 
exposed to SN2 alkylating agent, YAP1 is acetylated by the CREB binding protein and 
p300 (225). This acetylation event is specific to stress induced by alkylating agents, not 
DNA damage, and can be reversed by SIRT1 deacetylation. In response to DNA damage, 
YAP1 is sumoylated and stabilized by promyelocytic leukemia (PML), enhancing its 
association with p73 to induce an apoptotic response (226). Understanding the role post-
translational modifications play in directing YAP1 dependent cell fate determination is 
critical to understanding growth control in cells. 
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As highlighted previously, biochemical stress can alter nuclear YAP1 post-
translational modifications, so it is hypothesized that biophysical stress, such as stress 
fibers can do the same. Previous studies highlight the necessity of stress fibers to mediate 
YAP1 nuclear translocation, independent of LATS1/2 regulation. A scenario has been 
described where YAP1 promotes cell survival in response to the biophysical stress of a 
cell detaching from its basement membrane. However, there is no evidence to date that 
suggest how stress fibers influence YAP1 induced cell fate decisions. Here we provide 
evidence that under high levels of stress fibers, YAP1 functionality is switched to 
promote survival, as its knockdown is synthetically lethal. Further studies are needed in 
high stress fiber environments to elucidate exactly how nuclear YAP1 promotes 
transcriptional programs that favor survival mechanisms rather than growth. It is likely 
that nuclear YAP1 is further post-transnationally modified. These alterations in post-
translational modifications likely dictate YAP1 transcriptional co-activator binding 
partners, which in turn preferentially activate genetic programs for survival, growth or 
apoptosis. Identifying how nuclear YAP1 post-translational modifications lead to 
corresponding cellular fate decisions could be critical to understanding why YAP1 is 
required for some cancers that have inherent or developed resistance to treatments.  
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5.4 Therapeutic Potential of the Serum Response Network 
5.4.1 ArhGEF1 and YAP1 Synthetic Lethality 
YAP1’s ability to mediate cellular survival under stress may be critical for the 
survival of cancers cells subject to low oxygen, low nutrient, or toxic treatment 
conditions. In cancer, traditional therapeutics involves invoking a cellular stress on 
rapidly proliferating cells or blocking key growth activating pathways that then engage 
cell death pathways. However, some cancers are inherently averse to treatment, or can 
develop resistance overtime as a result of mutational selection. The development of 
resistance typically involves the engagement of survival pathways until the cells can re-
integrate signaling networks to continue to grow. YAP1 is thought to be key factor in 
promoting survival-induced resistance, with which many cancers utilize (128, 248). 
 Recent work has highlighted YAP1’s role in promoting resistance to treatments in 
both pancreatic carcinomas as well as melanoma (128, 248). Roughly 95% pancreatic 
cancers harbor a mutation that promotes the translation of a constitutive active KRAS 
(147). This activation leads to the oncogenic addiction of pancreatic tumors to KRAS. 
The reliance of the tumors on the mutant KRAS signaling for initiation and maintenance 
is thus the basis of targeted MAPK therapies (248). However, many of these tumors 
develop resistance upon targeted treatments, and begin to grow in a KRAS-independent 
manner (248). These KRAS-independent tumors require YAP1 to facilitate growth 
through the transcription of cFOS or E2F (249), a component of the AP-1 progrowth 
transcription factor complex. However, knocking down YAP1 in cell lines that no longer 
depend on KRAS for growth was shown to inhibit their colony formation capacity and 
proliferation (248). This also holds true in melanoma cell lines that typically harbor an 
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activating mutant of BRAF. Using Vemurafenib, a RAF inhibitor, or Trametinib, a MEK 
inhibitor only garners cell from proliferation, it does not engage cell death in the presence 
of YAP1 (250). In this context, YAP1 activity facilitates the transcription of BCl-xL to 
prevent apoptosis. It is only when YAP1 is genetically inactivated with simultaneous 
treatment of MAPK inhibitors that causes BRAF mutant melanoma cell lines to engage 
cell death pathways (250). These studies suggest the requirement of YAP1 in cell 
survival and conversely, the need to co-target it in RAF-MEK-ERK driven cancers that 
utilize YAP1 to program survival genetic programs. 
 In this study we have also uncovered the dual requirement of YAP1 and the serum 
response pathway for cell survival. The knockdown of ArhGEF1 surrenders cells in a 
G1/G0 phase of the cell cycle. This is thought to occur due to the constitutive activation of 
Gα13, which produces a hyper-activated RhoA stress fiber phenotype, leading to 
prolonged/chronic MAPK signaling. The sensitization to growth signaling is a cellular 
stress, as the energy and macromolecule demands outweigh the capabilities of the cell, 
and in a reactionary measure the cell induces senescence. The induction of stress fibers, 
promotes YAP1 nuclear localization and evidence would suggest this is a survival signal, 
as ArhGEF1 knockout cells have limited growth capacity in both 2D and 3D. Further 
evidence that this is a survival signaling is that the tandem knockdown of ArhGEF1 and 
YAP1 induce a synthetic lethality in breast cancer cells. Therefore co-targeting the serum 
response pathway along with YAP1/TEAD interaction is potentially another therapeutic 
angle for tumors that are resistant to current treatments, such as MAPK inhibitors. 
 Developing compounds that inhibit the functionality of the RGS-RhoGEFs may 
prove effective in combination with YAP1/TEAD to limit cellular growth. ArhGEF1’s 
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ability to turn off Gα12/13 signaling and transmit activity to RhoA is based on its 
recruitment to the plasma membrane by activated Gα12/13. Therefore disrupting its ability 
to dominantly GAP, by targeting its known interaction domains with Gα13, is a potential 
mechanism to achieve prolonged activation of the serum sensitive heterotrimeric GTPase 
and induce cellular senescence. Hypothetically, as guided by these discoveries, 
compounds that target disruption in localization or the functionality of the RGS domain, 
combined with a molecule that would disrupt YAP1/TEAD interactions would produce a 
synthetically lethal phenotype. Of potentially more significant interest, targeting the 
DH/PH domain of ArhGEF12 could be more critical for preventing YAP1 mediated cell 
survival. ArhGEF12 seems to be dominantly required for YAP1 stability and stress fiber 
formation. The requirement of stress fibers for YAP1 nuclear translocation has already 
been well established. Therefore, by inhibiting the ability of ArhGEF12 to activate RhoA, 
YAP1 would remain cytosolic and negate its ability to activate any genetic program 
whether it is for survival or growth. Targeting the serum response pathway in tandem 
with YAP1/TEAD interactions may provide a new avenue for therapeutics, especially in 
cancers that are inherently resistant or develop resistance to MAPK inhibitors. 
Albeit the synthetic lethal effects were witnessed in 2D tissue culture, these hard 
tensile surfaces are not typical of 3D physiological environments. These environments 
are rich in an array of nutrients and ECM interactions that may contribute to alternative 
reactionary mechanisms when targeting the GEFs or YAP1/TEAD interactions. For 
instance, promoting stress fibers, such as eliminating the GAP activity of ArhGEF1, to 
initiate cellular stress in 2D, potentially, could backfire under physiological conditions, as 
these structures are needed for cell motility and migration. These are mechanisms and 
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structures that are utilized by cancers cells to disseminate throughout the body, and 
therefore validation in relevant 3D model systems will be critical for evaluating the 
effectiveness of targeting the RGS-RhoGEFs. 
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5.4.2 Targeting Triple Negative Breast Cancer Subtypes 
Triple negative breast cancers represent 10-20% of all diagnosed breast cancers, 
and tend to have a higher rate of recurrence that results in increased dissemination 
throughout the body (151). This phenotype is resistant to anti-estrogen treatments, such 
as Tamoxifen, and anti-HER2 monoclonal antibodies, like Trastuzumab, as they do not 
express the receptors to antagonize. This results in poor prognosis with a relative 5 year 
survival rate of an abysmal 22%, according to the American Cancer Society. Therefore a 
need for identifying new molecular targets for therapeutic treatment is needed.  
Recent work has identified the correlation between elevated ROCK1 and RhoA 
and poor patient prognosis for women with breast cancer (251-253). Work by the Bissel 
group further characterized that the inhibition of ROCK using a small molecule inhibitor 
could revert the metastatic phenotype of the highly invasive MDA-MB-231 cancer cell 
line in 3D tissue culture environments (254). Not only could ROCK inhibition revert the 
metastatic phenotype but it could also sensitize aggressive breast to apoptosis with 
concurrent overexpression of E-cadherin (254). Analysis of aberrant signal transduction 
pathways found in many breast cancers revealed the inhibition of ROCK suppressed the 
activation of AKT, MAPK, FAK, and the expression of GLUT3 and LDHA (254). These 
data suggest that intricate network of cell-cell contacts and cell to ECM contacts, which 
are mediated by changes in the actin cytoskeleton, are important for cell fate decisions 
through the regulation of signal transduction cascades. 
MCF7 breast cancer cells are estrogen receptor and progesterone receptor 
positive, suggesting current antagonist for these receptors would be ideal candidates to 
administer to limit their growth potential. Interestingly, in this study we observed that 
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when ArhGEF1 is knocked down in relative comparison to control MCF7 cells, the 
expression of both these receptors, as analyzed by RPPA were statistically decreased 
(Appendix C). Under these same conditions ROCK1 protein expression as well as a 
majority of canonical MAPK and AKT proteins had elevated expression. It would be 
interesting to see if the inhibition of ROCK1 resulted in the down regulation of the 
MAPK and AKT protein expression, as the Bissel group discovered. This transition from 
an estrogen receptor and progesterone receptor positive breast cancer cell line to a more 
triple negative type cell line, as MCF7 are negative for HER2, suggest ArhGEF1 may be 
a critical component to establishing sensitivity to current treatments. This also suggest 
that the extreme actin phenotypes, that results in the uncoupling of cell growth from the 
hyper activation of MAPK and the serum response pathway, is likely important for this 
transition as well.  
A vast array of new treatments for cancer in general are targeting components of 
the MAPK pathway using RAS, RAF and ERK inhibitors (90). Unfortunately, if these 
pathways are not utilized to facilitate growth, as we have shown in this study, these 
treatment strategies for triple negative breast cancers may be futile. This study provides 
evidence that an affective treatment would be to inhibit YAP1 transcriptional activity in 
triple negative breast cancers, as the knockout in the more triple negative like MCF7 cells 
(ArhGEF1 knockdown with a decrease in estrogen and progesterone receptors) would 
engage cell death pathways. The complications with this strategy are the transcriptional 
programs driven by YAP1 are not defined in the ArhGEF1 knockout MCF7 cells, which 
mimics cells in an extreme tensile environment. It is likely that under progrowth 
situations YAP1 is binding the TEAD family of transcription factors to drive growth, 
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however the transcription factors and survival genetic programs YAP1 is driving when 
cells exert a hyper-actin, senescent phenotype are not known much beyond its interaction 
with p73. Therefore studies need to be conducted to identify the YAP1 interactome of 
stressed cells and the concurrent transcriptome. Upon this characterization, strategies can 
be guided to disrupt the relevant and specific YAP1 interactions, preventing the 
transcriptional activation of these survival programs. Furthermore, ROCK inhibition 
could potentially revert triple negative cancers back to a positive receptor status, which is 
suggestive of data in this study and from the Bissel team (254). This could potentially 
sensitize them to current receptor antagonist treatments. Utilizing this re-sensitization 
strategy along with defining the YAP1 interactome that is maintaining cell survival could 
become powerful future treatments in the fight against those breast cancers that have the 
poorest prognosis. 
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5.5 Conclusion 
 The entirety of this work contributes to the body of knowledge trying to 
understand how cells integrate biomechanical and biochemical stimuli to determine cell 
fate decisions. Central to these decisions, as highlighted here, is the manipulation of the 
cellular architecture, which has an underappreciated role in regulating transcriptional 
programs that determine cellular fate. YAP1 is a key transcription factor that is regulated 
by changes in RhoA dependent actin dynamics as previously shown (142). Here we have 
identified the relative physiological role for the RGS-RhoGEFs in contributing to Gα12/13-
RhoA actin mediated YAP1 activity. Members of the RGS-RhoGEFs, ArhGEF1, 
ArhGEF11, and ArhGEF12 function in opposing roles to maintain a delicate cycle of 
activation of the Gα12/13-RhoA signaling axis, that can be quickly tuned in response to 
mitogens and tensile interactions with the microenvironment. ArhGEF1 mainly functions, 
in a physiological role, as described in this work as, a GAP for Gα13 whereas ArhGEF11 
and ArhGEF12 function to transmit signaling from Gα12/13 to RhoA. Defining the roles of 
the individual RGS-RhoGEFs in facilitating signaling through the serum response 
network to activate YAP1, further provided insight into the functional crosstalk between 
the Rho and RAS signaling networks. The loss of ArhGEF1, disrupted cellular 
homeostasis, and contributed to prolonged Gα13 signaling. We have demonstrated this 
prolonged activation results in stress fiber aggregation leading to the shutdown of the cell 
cycle and global translation elongation machinery to enact cellular senescence. 
Furthermore, this aggregated actin dominantly directed YAP1 into the nucleus, enhancing 
its transcriptionally activity. However, nuclear YAP1 in this context did not facilitate 
cellular growth, and mainly functioned to protect cells from engaging cell death during 
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this oncogene induced senescence. The critical requirement of the RGS-RhoGEFs in 
temporally regulating the Gα12/13-RhoA signaling axis, in response to biochemical and 
biophysical stimuli, provides insight into how cells maintain signaling homeostasis under 
physiological conditions. This insight into how cellular signaling pathways integrate can 
further be utilized to understand how cancers re-wire themselves to circumvent these 
inherent “fail-safe” mechanisms to propagate unmitigated growth.   
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APPENDICES 
-APPENDIX A- 
PLASMIDS USED IN YAP1/TEAD SCREEN (ALPHABETICAL LISTING) 
 
Protein Human or 
Mouse 
Accession # V# 
ALS2 Human BC031479 V2681 
ARAP1 Human AB018325 V2713 
ARHGAP 1 Human BC018118 V2661 
ARHGAP 11A Human D87717 V2693 
Arhgap 17 Mouse BC003259 V2744 
ARHGAP 2 Human BC011393 V2649 
ARHGAP 20 Human AB037845 V159 
ARHGAP 25 Human D29642 V2694 
ARHGAP 26 Human AB014521 V2708 
ARHGAP 28 Human BC033668 V2687 
ARHGAP 31 Human AB033030 V2721 
ARHGAP 35 Human AB051509 V2732 
ARHGAP 4 Human D50921 V2695 
ARHGAP 9 Human BC006107 V2745 
Arhgap12 Mouse BC024633 V2667 
Arhgap15 Mouse BC034881 V2688 
Arhgap18 Mouse BC030858 V2678 
Arhgap24 Mouse BC027070 V2672 
ArhGAP29 Mouse BC040387 V2691 
ARHGAP39 Human AB051510 V2733 
Arhgap8 Mouse BC010306 V2647 
ARHGEF 1  Human BC034013 V2747 
ARHGEF 10 Human AB002292 V2699 
ARHGEF 10L Human AB046846 V2731 
ARHGEF 11 Human AB002378 V2703 
ARHGEF 12 Human AB002380 V2704 
ARHGEF 15 Human AB020722 V2716 
ARHGEF 16 Human BC002681 V2633 
ARHGEF 17 Human AB002335 V2701 
ARHGEF 2 Human AB014551 V2709 
ARHGEF 25 Human BC012860 V2655 
ARHGEF 4 Human AB029035 V2718 
ARHGEF 5 Human BC010046 V2645 
ARHGEF 6 Human D25304 V2692 
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ARHGEF 7 Human D63476 V2696 
ARHGEF 9 Human AB007884 V2706 
ARHGEF39 Human BC033666 V2686 
ARHGEF8 Human BC010285 V2646 
DNMBP Human AB023227 V2746 
DOCK 4 Human AB018259 V2710 
DOCK6 Human AB037816 V2727 
DOCK7 Human AB051558 V2734 
Ect2 Mouse BC025565 V2668 
Fam13b Mouse BC031465 V2680 
Farp1 Mouse BC030329 V2676 
FARP2 Human AB018336 V2714 
FGD1 Human BC034530 V290 
FGD2 Human BC023645 V2665 
FGD6 Human AB037783 V2725 
Fgd6 Mouse BC026860 V2671 
HMHA1 Human D86976 V2613 
Inpp5B Mouse BC028864 V2674 
INTERSECTIN 2  Human AB033082 V2722 
NGEF Human BC031573 V2682 
P-REX1 Human AB037836 V2728 
Plekhg6 Mouse BC026778 V2670 
RACGAP1 Human BC032754 V2685 
RALBP1 Human BC013126 V2656 
SH3BP1 Human BC008282 V2642 
SRGAP3 Human BC039300 V2705 
Stard13 Mouse BC027830 V2673 
STARD8 Human D80011 V2697 
SYDE1 Human BC029926 V2675 
TAGAP Human BC015859 V2659 
VAV1 Human BC013361 V2657 
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-APPENDIX B- 
Nucleotide Sequences for Primers 
 
Primers for Cloning CTGF Promoter 
 
 
qRTPCR Primers 
 
CTGF Sense: AGGAGTGGGTGTGTGACGA (142) 
CTGF Antisense: CCAGGCAGTTGGCTCTAATC (142) 
 
Cyr61 Sense: AAGGAGCTGGGATTCGATG  
Cyr61 Antisense: TCTGGCCTTGTAAAGGGTTG  
 
Cyclin D1 Sense: GCCTGTGATGCTGGGCACTTCATC 
Cyclin D1 Antisense: TTTGGTTCGGCAGCTTGCTAGGTG 
Prom
oter 
Mutatio
ns Sense Antisense gBlock 
Short WT X X   
Short 
TEAD 
Mut 
X X 
3x TEAD 
gblock 
Short 
TEAD/S
RF Mut 
CCTACCCAGGATGTATGT
CAGTGGACAGAACAGGG
CAAACTTATT 
CATCCTGGGTAGGAAGTAG
GTAGCTGAAAGAGGCAAAC
AGCAG 
3x TEAD 
gblock 
Short 
SRF 
Mutant 
CCTACCCAGGATGTATGT
CAGTGGACAGAACAGGG
CAAACTTATT 
CATCCTGGGTAGGAAGTAG
GTAGCTGAAAGAGGCAAAC
AGCAG 
  
Long WT       
Long 
1st SRF 
Mut 
      
Long 
1st & 
2nd SRF 
Mut 
CATACCTGGGATAGCTTG
GTAAACAGGACTCAGTG
GCCAGC 
GCTATCCCAGGTATGTGTGT
GTGTCTACTAGGGCATCATT
TGTACTGG 
  
Long 
1, 2, and 
3 SRF 
Mutant 
CCTACCCAGGATGTATGT
CAGTGGACAGAACAGGG
CAAACTTATT 
CATCCTGGGTAGGAAGTAG
GTAGCTGAAAGAGGCAAAC
AGCAG 
  
Long 
1, 2, and 
3 SRF 
and 
TEAD 
Mutant 
GAGGGCGGCGAGGGCGG
TCCCTGTTTGTGTAGGAC 
GGGACCGCCTCGCCGCCCTC
C 
3x TEAD 
gblock 
Long 
WT 
TEAD 
Mutants 
GAGGGCGGCGAGGGCGG
TCCCTGTTTGTGTAGGAC 
GGGACCGCCTCGCCGCCCTC
C 
3x TEAD 
gBlock 
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cMyc Sense: CTTCTCTCCGTCCTCGGATTCT 
cMyc Antisense: GAAGGTGATCCAGACTCTGACCTT 
 
FOS Sense: CACTCCAAGCGGAGACAGAC 
FOS Antisense: AGGTCATCAGGGATCTTGCAG 
 
cFOS Sense: CTGGCGTTGTGAAGACCAT 
cFOS Antisense: TCCCTTCGGATTCTCCTTTT  
 
cJUN Sense: ATCAAGGCGGAGAGGAAGCG 
cJUN Antisense: TGAGCATGTTGGCCGTGGAC 
 
GAPDH Sense: CTCCTGCACCACCAACTGCT (142) 
GAPDH Antisense: GGGCCATCCACAGTCTTCTG (142) 
 
shRNA Sequences 
 
ARHGEF1 shRNA:  
 Sequence #1: 
CCGGCCATCTCTACCGACGAAGAAACTCGAGTTTCTTCGTCGGTAGAGATGG
TTTTTG 
 in pLKO.1 (Sigma, TRCN0000033566) 
 Sequence #2: 
CCGGTCCCTGAAGCAGCTTCTGTTTCTCGAGAAACAGAAGCTGCTTCAGGGA
TTTTTG 
in pLKO.1 (Sigma, TRCN0000033568) 
 
ARHGEF11 shRNA:  
CCGGCCTGATCTTCTACCAGCGAATCTCGAGATTCGCTGGTAGAAGATCAGG
TTTTTG 
in pLKO.1 (Sigma, TRCN0000047465) 
 
ARHGEF12 shRNA: 
 Sequence #1: 
CCGGGCGAGTATCCAGAGAAGGAATCTCGAGATTCCTTCTCTGGATACTCGC
TTTTTG in pLKO.1 (Sigma, TRCN0000298941) 
 Sequence #2: 
CCGGGCGTTGCGTAATCATCCAGAACTCGAGTTCTGGATGATTACGCAACGC
TTTTTG 
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in pLKO.1 (Sigma, TRCN0000298942) 
 
YAP1 shRNA: 
 Sequence #1: 
CCGGCAGGTCATACTATCAACCAAATCGAGTTTGGTTGATAGTATCACCTGTT
TTTG 
in pLKO.1 (Sigma, TRCN0000107267) 
 
Scramble shRNA: shControl pLKO.1 plasmid #1864 (Addgene) 
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-APPENDIX C-  
COMPLETE RESULTS OF RPPA COMPARING CONTROL TO ARHGEF1 
KNOCKDOWN MCF7 CELLS UNDER SERUM ADD BACK CONDITIONS 
(Red=Negative Relative Change, Green=Positive Relative Change, Yellow=statistical 
significance p<.05) 
Antibody Name Gene Name Probabilities (QC Score) 
Change 
(shARG1-
shScramble) 
TTEST 
eEF2K EEF2K 0.924519781 -0.782621396 3.35703E-06 
EMA EMA 0.914941009 -1.105142864 1.59682E-05 
ER ESR1 0.929650338 -0.846927639 2.67886E-05 
AR AR 0.921837285 -0.241715676 7.7882E-05 
Notch1 NOTCH1 0.929029422 -0.313420198 0.000130004 
MSH6 MSH6 0.906915983 -0.338250909 0.000176417 
INPP4b INPP4B 0.934027466 0.250212379 0.000186785 
c-Myc MYC 0.915134137 -0.174266509 0.000211574 
GATA3 GATA3 0.919524235 -0.445368492 0.000217064 
PAR PAR 0.93363016 0.914029681 0.000244503 
Src_pY527 SRC 0.952998946 0.276528602 0.000250872 
C-Raf_pS338 RAF1 0.946611448 0.214033161 0.000410915 
PEA-15 PEA15 0.955663775 0.172199353 0.000460139 
c-Met MET 0.89813279 -0.13751199 0.00047324 
YB1_pS102 YBX1 0.960910762 0.18401262 0.00070258 
Bcl-xL BCL2L1 0.958356756 0.120570735 0.000712437 
Bcl2 BCL2 0.808674126 -0.538587251 0.000745317 
IGFRb IGF1R 0.935735234 -0.270319874 0.000839395 
Hexokinase-II HK2 0.891190246 0.168319917 0.000895323 
p90RSK_pT573 RPS6K 0.949836221 0.243232403 0.000906354 
Gys_pS641 GYS1 0.924796756 -0.372546612 0.001056583 
Connexin-43 CNST43 0.859682344 0.455075848 0.001148287 
eIF4E EIF4E 0.961295801 0.27433424 0.001196745 
AMPKa PRKAA1 0.959336434 0.181942408 0.00150417 
Gab2 GAB2 0.950630467 0.269791066 0.001566279 
Sox2 SOX2 0.913202868 -0.663688552 0.001608348 
Cyclin-E1 CCNE1 0.871957271 -0.140108497 0.001613403 
Myt1 MYT1 0.857764605 -0.289923126 0.001956314 
MEK1 MAP2K1 0.886200842 0.199482807 0.00203358 
HSP27_pS82 HSBP1 0.899115019 0.365067834 0.002301855 
 162 
XRCC1 XRCC1 0.857350386 -0.169676472 0.00257914 
Caspase-7-
cleaved 
CASP7 0.937727913 0.317513856 0.002628117 
N-Ras NRAS 0.863343194 0.233849693 0.002695515 
c-Jun_pS73 JUN 0.932273615 0.237057804 0.002892938 
TWIST TWIST1 0.902995015 -0.141273591 0.002958416 
eEF2 EEF2 0.948364345 -0.562100593 0.003148213 
Glutamate-D1-2 GLUD 0.89358631 0.094160607 0.003148498 
Pdcd4 PDCD4 0.96278045 -0.341885465 0.003275396 
p70-S6K1 RPS6KB1 0.895390777 -0.441223929 0.003612783 
Bcl2A1 BCL2A1 0.921555341 0.20540552 0.003926516 
Akt_pT308 AKT1 0.948259669 0.398833285 0.004084158 
GAPDH GAPDH 0.900778605 -0.501460948 0.004126068 
Histone-H3 HIST3H3 0.926741302 0.207552795 0.004329081 
Granzyme-B GZMB 0.901817951 -0.279645869 0.004418429 
VHL-EPPK1 EPPK1 0.832274939 -0.313052939 0.004445258 
Rock-1 ROCK1 0.918664058 0.188136496 0.004732761 
Shc_pY317 SHC1 0.936181355 -0.196832646 0.005708169 
PI3K-p85 PIK3R1 0.962347653 0.127388943 0.006148226 
UGT1A UGT1A 0.876595017 -0.1530747 0.006288289 
TFAM TFAM 0.948567989 -0.277189577 0.006302088 
PREX1 PREX1 0.92958986 0.503393676 0.00655734 
IR-b INSRB 0.943488106 0.278906242 0.006796991 
NDUFB4 NDUFB4 0.858149039 -0.232000177 0.006946234 
Merlin NF2 0.945224176 -0.261442211 0.007033182 
Rb RB1 0.883650129 -0.101731273 0.007074228 
NF-kB-
p65_pS536 
NFKB1 0.939374736 0.187314413 0.00744387 
p38_pT180_Y182 MAPK14 0.890124822 0.172153206 0.007494262 
WIPI2 WIPI2 0.918360838 -0.096231581 0.007630346 
VEGFR-2 KDR 0.950805083 0.333532908 0.007778599 
SHP-2_pY542 PTPN11 0.923015974 0.337762112 0.008014248 
Bad_pS112 BAD 0.940912945 0.100642852 0.00828807 
PAK1 PAK1 0.932634371 0.271228572 0.00832206 
Akt_pS473 AKT1 0.953916425 0.310225272 0.009247238 
Rheb RHEB 0.88538088 -0.291261079 0.009294377 
XBP-1 XBP1 0.843554622 -0.254647345 0.009308097 
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ERCC1 ERCC1 0.916758163 -0.207225395 0.009481168 
Vimentin VIM 0.834682978 -0.348780319 0.009854836 
SOD1 SOD1 0.898228044 0.102803733 0.010104901 
Bim BCL2L11 0.947598357 -0.180317834 0.010138904 
SF2 SRSF1 0.866495597 -0.149575816 0.010476214 
PLK1 PLK1 0.954160701 -0.274038184 0.010720303 
RSK RPS6KA1 0.958876303 -0.047131196 0.011508911 
Src SRC 0.917964385 0.192983015 0.011851271 
JNK_pT183_Y18
5 
MAPK8 0.942058938 0.253104874 0.011978805 
4E-BP1 EIF4EBP1 0.952266644 0.125927025 0.012848913 
Notch3 NOTCH3 0.934675677 0.246661931 0.013233998 
HER3_pY1289 ERBB3 0.949816823 0.064189238 0.013278873 
PR PGR 0.946083442 -0.15580807 0.014303927 
FoxM1 FOXM1 0.952676375 -0.150507069 0.014334351 
YAP YAP1 0.914399036 0.16538202 0.015051339 
Glutaminase GLS 0.8498355 0.183686896 0.015534934 
Cyclin-B1 CCNB1 0.951700371 0.099013621 0.015633424 
Rab25 RAB25 0.939933499 -0.136221419 0.016299154 
RPA32 RPA2 0.856768809 -0.233789701 0.016548547 
DUSP4 DUSP4 0.944212494 0.214034523 0.016727482 
Myosin-
IIa_pS1943 
MYO2A 0.952525218 -0.880903283 0.016893503 
Paxillin PXN 0.927748675 0.148363234 0.017594558 
GSK-3a-b 
GSK3A/GS
K3B 
0.906663031 -0.295144992 0.017907573 
eIF4E_pS209 EIF4E 0.868939199 0.125220692 0.018604887 
CDK1 CDK1 0.951631851 -0.322012811 0.018818812 
SDHA SDHA 0.892025112 -0.160590202 0.019598368 
PCNA PCNA 0.842402773 -0.343000615 0.019704058 
Smad3 SMAD3 0.94453799 -0.168654923 0.02077896 
cdc25C CDC25C 0.919016188 -0.195843504 0.020988399 
Tyro3 TYRO3 0.941358517 -0.137863265 0.022191518 
UBAC1 UBAC1 0.94114427 0.237706027 0.02318527 
eIF4G EIF4G1 0.952669274 -0.353566321 0.023289049 
MAPK_pT202_Y
204 
MAPK3 0.928607995 0.184030645 0.025817529 
MIF MIF 0.82208949 -0.232734761 0.027198972 
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NDRG1_pT346 NDRG1 0.951074961 0.289844423 0.027366161 
DJ1 PARK7 0.950115095 0.161094411 0.028159697 
YAP_pS127 YAP1 0.946591374 0.15888396 0.029974363 
Creb CREB1 0.875291335 0.083641547 0.029997469 
XPF XPF 0.933202227 -0.115256815 0.030394708 
Jagged1 JAG1 0.831790996 0.081704815 0.031816515 
Mnk1 MKNK1 0.887836465 -0.200027256 0.032050539 
Rad50 RAD50 0.907297712 -0.214392988 0.032518741 
CD171 L1CAM 0.932042728 -0.195789821 0.032804193 
NAPSIN-A NAPSA 0.936579493 0.134452801 0.03335449 
TTF1 TTF1 0.813439498 -0.246792511 0.03639674 
ER-a_pS118 ESR1 0.912913145 -0.188051014 0.037890997 
Cdc2_pY15 CDK1 0.849876978 -0.088677843 0.037937422 
MIG6 ERRFI1 0.91816802 -0.17862004 0.04235988 
Bax BAX 0.942631041 -0.184153319 0.042765705 
p27_pT198 CDKN1B 0.932786303 0.10023564 0.04309231 
ATR_pS428 ATR 0.929656614 -0.063068585 0.043295185 
B-Raf_pS445 BRAF 0.954040186 0.107698233 0.043459997 
EGFR EGFR 0.919463542 -0.263588572 0.044431986 
Axl AXL 0.947576346 -0.230220886 0.044444839 
IGFBP2 IGFBP2 0.92540376 -0.16506233 0.048505241 
ENY2 ENY2 0.901109421 -0.231765819 0.048929918 
AMPKa_pT172 PRKAA1 0.952965502 0.184527599 0.049349929 
TSC1 TSC1 0.963610314 0.20330725 0.049815456 
Aurora-B AIM1 0.866944489 -0.105147554 0.052259317 
WIPI1 WIPI1 0.91578778 0.166329917 0.052327523 
DM-K9-Histone-
H3 
H3K9ME2 0.882757271 0.07355292 0.052963546 
PDGFR-b PDGFR 0.94195543 -0.171377826 0.055992339 
14-3-3-epsilon YWHAE 0.86868706 -0.084709291 0.059041118 
14-3-3-beta YWHAB 0.920483668 -0.150620842 0.059993357 
SCD SCD 0.878472238 -0.262215931 0.060430983 
PKM2 PKM2 0.904517888 0.152802392 0.060432321 
Stat5a STAT5A 0.956448437 -0.137054617 0.060884504 
PI3K-p110-b PIK3BC 0.905149746 -0.080582595 0.062736036 
ADAR1 ADAR 0.937891587 0.164095685 0.06274368 
53BP1 TP53BP1 0.959850837 0.202305759 0.063120814 
 165 
P-Cadherin CDH3 0.92082188 -0.203364647 0.066290214 
IRS1 IRS1 0.951272039 -0.154304637 0.066607342 
Beclin BECN1 0.85952359 -0.102981655 0.066936511 
CD31 PECAM1 0.818729862 0.114517446 0.067672546 
HER2 ERBB2 0.899754615 -0.113233302 0.068517136 
RBM15 RBM15 0.96366825 0.117453852 0.069223194 
Rictor_pT1135 RICTOR 0.959884739 0.152722955 0.072408382 
Ets-1 ETS1 0.800760225 -0.240927924 0.076692461 
N-Cadherin CDH2 0.890046222 0.071761586 0.077595229 
PARP1 PARP1 0.92900004 0.197575271 0.078465625 
PAK4 PAK4 0.911743213 0.091602625 0.079049907 
H2AX_pS140 H2AFX 0.88516782 0.181127134 0.079255777 
Chk1 CHEK1 0.895271108 -0.11542644 0.079517173 
G6PD G6PD 0.855824293 -0.232303075 0.081226646 
C-Raf RAF1 0.944673349 0.12802346 0.08513827 
c-
Met_pY1234_Y1
235 
MET 0.910119508 -0.097540817 0.086051782 
GSK-3a-
b_pS21_S9 
GSK3A 
GSK3B 
0.962506153 -0.159349906 0.088483228 
TAZ TAZ 0.940228008 -0.081285639 0.089788131 
LDHA LDHA 0.860015649 -0.15594994 0.091662805 
PI3K-p110-a PIK3C2A 0.936300542 0.085212101 0.092662683 
VASP VASP 0.894157385 0.135495612 0.093129859 
Wee1 WEE1 0.902240853 -0.108097973 0.093925575 
PDK1_pS241 PDK1 0.964036888 -0.079178356 0.095295107 
JNK2 MAPK9 0.861215193 -0.251178667 0.101728265 
ULK1_pS757 ULK1 0.940440661 0.131226996 0.10544179 
Rictor RICTOR 0.96480466 0.167691517 0.105989431 
SOD2 SOD2 0.826950876 0.055441929 0.105999049 
Bak BAK1 0.915375136 0.079488036 0.110441497 
S6 RPS6 0.878278211 0.26111214 0.110520108 
PDK1 PDK1 0.941446581 -0.061994401 0.116199395 
IRF-1 IRF1 0.9193 -0.166715084 0.116334889 
Wee1_pS642 WEE1 0.925881034 0.077561702 0.116585043 
FRA-1 FOSL1 0.928100641 -0.14678341 0.117982713 
SLC1A5 SLC1A5 0.948444961 0.083905567 0.119681717 
Cox2 CMC2 0.926941734 0.14674027 0.122245869 
 166 
TFRC TFRC 0.956537825 0.059570894 0.125733258 
Chk2 CHEK2 0.890084389 -0.168637941 0.126140028 
PKC-b-II_pS660 PRKCB 0.962128936 0.140796089 0.128146909 
CD44 CD44 0.869158542 0.090777669 0.128663756 
p70-S6K_pT389 RPS6KB1 0.904492601 0.16421419 0.134782616 
Annexin-VII ANXA7 0.845780423 -0.173776928 0.135151085 
Raptor RPTOR 0.96285984 -0.131030454 0.136520874 
HER3 ERBB3 0.948379117 -0.138336148 0.139704432 
LRP6_pS1490 LRP6 0.878015944 -0.071822475 0.141472281 
CD49b ITGA2 0.892866427 -0.08534928 0.142610639 
TRIM25 TRIM25 0.948126764 -0.191413818 0.143395563 
CD29 CD29 0.84550005 -0.133250143 0.146261011 
FoxO3a_pS318_S
321 
FOXO3 0.941110072 0.055713016 0.149162356 
E2F1 E2F1 0.876652917 -0.035569727 0.159680906 
RIP RIP 0.895510946 -0.095582261 0.161875739 
ATRX ATRX 0.879463378 0.132874702 0.16280821 
HSP70 HSPA1A 0.936139482 -0.068204694 0.164155807 
Syk SYK 0.923145899 0.091520742 0.169209623 
Jak2 JAK2 0.927379868 0.121786811 0.183152809 
Chk2_pT68 CHEK2 0.912454656 0.06564456 0.183172056 
Stat3_pY705 STAT3 0.947819279 0.073086942 0.183286675 
TUFM TUFM 0.867157233 -0.113544183 0.190918747 
Atg7 ATG7 0.92429845 0.069468196 0.19954523 
Src_pY416 SRC 0.927365842 0.084248858 0.20227887 
Cox-IV PTGS3 0.891645109 -0.075649151 0.202693438 
Chk1_pS296 CHEK1 0.901064164 0.053996826 0.203612968 
p21 CDKN1A 0.922240971 0.070909188 0.203793333 
Ubq-Histone-
H2B 
H2BFM 0.869110765 -0.165300796 0.217115153 
Tuberin_pT1462 TSC2 0.941491547 0.034403663 0.22001039 
DM-Histone-H3 HISTH3 0.907659435 0.071109227 0.220139584 
AMPK-a2_pS345 PRKAA2 0.883373786 0.03606149 0.221502406 
PEA-15_pS116 PEA15 0.862043142 0.070836236 0.231739731 
 167 
RPA32_pS4_S8 RPA2 0.93219595 0.15379532 0.238452935 
PDHK1 PDHK1 0.896612896 0.037463225 0.242201332 
PAX8 PAX8 0.93775019 -0.078990506 0.24683624 
4E-BP1_pS65 EIF4EBP1 0.955001119 0.050815246 0.254687284 
HSP27 HSBP1 0.865317061 -0.083318041 0.256383724 
MDM2_pS166 MDM2 0.962828399 -0.081818993 0.279129147 
B7-H4 VTCN1 0.879510237 0.047922452 0.283262844 
Fibronectin FN1 0.90112857 0.081143207 0.296132628 
Gys GYS1 0.930619549 -0.090914535 0.306914165 
PRAS40 AKT1S1 0.890769068 -0.085718459 0.30748265 
LC3A-B LC3AB 0.866665392 0.092702538 0.32385153 
Collagen-VI COL6A1 0.903121728 0.067763918 0.324036703 
PAICS PAICS 0.949686294 0.056134794 0.324076048 
ACC1 ACACA 0.96067722 -0.07038547 0.330557222 
TIGAR TIGAR 0.940998046 -0.061000471 0.331138269 
b-
Catenin_pT41_S4
5 
CTNNB1 0.921505538 -0.063245475 0.345073385 
HES1 HES1 0.948686722 -0.03557233 0.346115152 
MSI2 MSI2 0.878007368 0.031268456 0.346858054 
Heregulin NRG1 0.935422005 0.047776099 0.350299196 
Smad4 SMAD4 0.877720431 -0.050294471 0.355127746 
Myosin-11 MYH11 0.929613212 -0.063824105 0.359468708 
Pdcd-1L1 PDCD1 0.838939896 0.055163274 0.362122961 
Rab11 RAB11A 0.911237331 -0.043199324 0.373065664 
Snail SNAI2 0.88186091 0.050881088 0.375925091 
b-Catenin CTNNB1 0.945816291 0.044272554 0.387149585 
IGF1R_pY1135_
Y1136 
IGF1R 0.940709673 0.078640903 0.39548314 
b-Actin ACTB 0.826466747 -0.043202374 0.398360203 
mTOR MTOR 0.964167593 -0.031872844 0.400274648 
HER2_pY1248 ERBB2 0.940032967 0.074404441 0.401927975 
FASN FASN 0.954931529 0.097855572 0.405552788 
c-IAP2 BIRC3 0.895640062 -0.046504338 0.406474581 
GCLM GCLM 0.860156054 -0.025531823 0.417873877 
PTEN PTEN 0.950865773 -0.033696168 0.418400134 
 168 
PMS2 PMS2 0.895510682 -0.045718438 0.422351463 
Rb_pS807_S811 RB1 0.961853551 -0.048798626 0.447247241 
Rad51 RAD51 0.907398227 -0.026953154 0.451311288 
14-3-3-zeta YWHAZ 0.932699104 -0.046460678 0.455905364 
ZAP-70 ZAP70 0.898087037 -0.032301943 0.476534123 
PKC-delta_pS664 PRKCD 0.89969306 -0.039953166 0.477919093 
ACC_pS79 ACACA 0.956825154 0.060103487 0.483903042 
Bid BID 0.914385664 0.027587174 0.491554516 
FAK_pY397 PTK2 0.924612769 0.037384011 0.492452207 
Stathmin-1 STMN1 0.933044668 0.012666531 0.495780976 
Stat3 STAT3 0.957852539 0.052929938 0.496723404 
p38-MAPK MAPK14 0.962348377 0.057750032 0.497022718 
p16INK4a CDKN2A 0.897591442 0.063810701 0.505003302 
ARID1A ARID1A 0.965111926 -0.053831361 0.505985899 
Smad1 SMAD1 0.912781418 0.041021259 0.512729061 
Akt AKT1 0.906913806 0.050207676 0.51467867 
c-Abl ABL1 0.895417672 0.040017239 0.523156713 
GCN5L2 KAT2A 0.937620567 -0.059756601 0.533352324 
ATM ATM 0.958305597 0.024491231 0.537314206 
BiP-GRP78 HSPA5 0.825035489 0.042065791 0.546420097 
Caspase-3 CASP3 0.929047996 -0.036698153 0.547138959 
Oct-4 OCT4 0.906201348 0.027768839 0.551222257 
MCT4 SLC16A4 0.930072269 -0.150716267 0.563820403 
S6_pS240_S244 RPS6 0.955767997 -0.102079387 0.567999411 
COG3 COG3 0.956201463 -0.036456211 0.575623369 
PLC-
gamma2_pY759 
PLCG2 0.893114005 -0.028117768 0.578116216 
p27-Kip-1 CDKN1B 0.876353548 -0.048682106 0.580042357 
Cyclin-D3 CCND3 0.893231558 0.034238183 0.591909174 
PKA-a PRKAR1A 0.964364548 0.05082469 0.603484526 
CD26 DPP4 0.921168287 0.013316176 0.605314033 
FAK PTK2 0.895871854 -0.026334968 0.614446626 
PKCa PRKCA 0.959382438 0.02780146 0.62495743 
EGFR_pY1173 EGFR 0.946716206 -0.011448577 0.626387624 
MEK1_pS217_S2
21 
MAP2K1 0.926137202 0.034950157 0.62699941 
 169 
Caveolin-1 CAV1 0.945889174 -0.084582541 0.636178994 
BAP1 BAP1 0.90552614 -0.054427727 0.649145325 
A-Raf ARAF 0.957599003 0.057640456 0.652539135 
Atg3 ATG3 0.940925825 -0.017440376 0.659174592 
c-Kit KIT 0.915589662 -0.023933221 0.674046647 
Smac DIABLO 0.932136808 0.02024953 0.681584421 
D-a-Tubulin TUBA1A 0.908841788 -0.025107787 0.684235821 
ERCC5 ERCC5 0.965449096 -0.029318375 0.71054704 
Transglutaminase TGM2 0.922737728 -0.014435034 0.712842183 
MERIT40_pS29 BABAM1 0.930816455 -0.015964806 0.727602324 
PAI-1 SERPINE1 0.919700611 -0.015335085 0.731211036 
Cyclophilin-F PPIF 0.944362008 -0.051308613 0.775126281 
FoxO3a FOX3 0.885258515 0.010442903 0.775847866 
B-Raf BRAF 0.924694841 -0.010589111 0.781796069 
Caspase-8 CASP8 0.906354255 0.022215457 0.792627355 
mTOR_pS2448 MTOR 0.959819881 -0.012794421 0.793089893 
PD-L1 CD274 0.897957206 0.011099223 0.804683043 
E-Cadherin CDH1 0.938221099 -0.012375217 0.80502146 
S6_pS235_S236 RPS6 0.962743168 -0.029753045 0.820538846 
Mcl-1 MCL1 0.949925576 0.01198075 0.837527452 
Lck LCK 0.909992033 0.013076019 0.880510559 
Tuberin TSC2 0.942642367 -0.008287769 0.882289599 
Elk1_pS383 ELK1 0.93342207 -0.006031659 0.885403148 
Annexin-I ANXA1 0.850489364 0.022988764 0.887456953 
XPA XPA 0.913097595 -0.007662482 0.906198506 
Cyclin-D1 CCND1 0.942241131 -0.007475434 0.90639671 
PRAS40_pT246 AKT1S1 0.959921709 0.00660596 0.92077878 
Tau MAPT 0.872948242 0.008939546 0.944788388 
p44-42-MAPK MAPK3 0.954227863 -0.00490989 0.949928155 
Claudin-7 CLDN7 0.941950888 -0.00476762 0.969660842 
ATM_pS1981 ATM 0.855016859 0.001174199 0.970904381 
Hif-1-alpha HIF1A 0.863310684 0.001884145 0.972337185 
MMP2 MMP2 0.910304447 -0.001349593 0.983460951 
BRD4 BRD4 0.934794426 0.00252552 0.986316871 
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p53 TP53 0.856310474 0.001528984 0.987480401 
Porin VDAC1 0.913176636 0.00019121 0.996632734 
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